BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Baker SJ, Fearon ER, Nigro JM, Hamilton SR, Preisinger AC, Jessup JM, vanTuinen P, Ledbetter DH, Barker DF, Nakamura Y. Chromosome 17 deletions and p53 gene mutations in colorectal carcinomas. Science. 1989;244:217-221. [PMID: 2649981 DOI: 10.1126/science.2649981] [Cited by in Crossref: 1275] [Cited by in F6Publishing: 1291] [Article Influence: 39.8] [Reference Citation Analysis]
Number Citing Articles
1 Müller-Ladner U, Nishioka K. p53 in rheumatoid arthritis: friend or foe? Arthritis Res 2000;2:175-8. [PMID: 11094424 DOI: 10.1186/ar82] [Cited by in Crossref: 5] [Cited by in F6Publishing: 13] [Article Influence: 0.2] [Reference Citation Analysis]
2 Vaughan C, Pearsall I, Yeudall A, Deb SP, Deb S. p53: its mutations and their impact on transcription. Subcell Biochem 2014;85:71-90. [PMID: 25201189 DOI: 10.1007/978-94-017-9211-0_4] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 2.7] [Reference Citation Analysis]
3 Litofsky NS, Recht LD. The impact of p53 tumor suppressor gene on glioma biology. Neurosurg Focus 1997;3:e4. [PMID: 15104416 DOI: 10.3171/foc.1997.3.3.7] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
4 Potter JD, Sellers TA, Rich SS. Colorectal cancer. In: Ponder BAJ, Waring MJ, editors. The Genetics of Cancer. Dordrecht: Springer Netherlands; 1995. pp. 45-65. [DOI: 10.1007/978-94-011-0677-1_3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.0] [Reference Citation Analysis]
5 Smardová J, Smarda J, Koptíková J. Functional analysis of p53 tumor suppressor in yeast. Differentiation 2005;73:261-77. [PMID: 16138827 DOI: 10.1111/j.1432-0436.2005.00028.x] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 1.4] [Reference Citation Analysis]
6 Donehower LA, Bradley A. The tumor suppressor p53. Biochim Biophys Acta 1993;1155:181-205. [PMID: 8357826 DOI: 10.1016/0304-419x(93)90004-v] [Cited by in Crossref: 23] [Cited by in F6Publishing: 60] [Article Influence: 0.8] [Reference Citation Analysis]
7 Bell SM, Kelly SA, Hoyle JA, Lewis FA, Taylor GR, Thompson H, Dixon MF, Quirke P. c-Ki-ras gene mutations in dysplasia and carcinomas complicating ulcerative colitis. Br J Cancer 1991;64:174-8. [PMID: 1854618 DOI: 10.1038/bjc.1991.264] [Cited by in Crossref: 60] [Cited by in F6Publishing: 61] [Article Influence: 2.0] [Reference Citation Analysis]
8 Xue W, Kitzing T, Roessler S, Zuber J, Krasnitz A, Schultz N, Revill K, Weissmueller S, Rappaport AR, Simon J, Zhang J, Luo W, Hicks J, Zender L, Wang XW, Powers S, Wigler M, Lowe SW. A cluster of cooperating tumor-suppressor gene candidates in chromosomal deletions. Proc Natl Acad Sci U S A 2012;109:8212-7. [PMID: 22566646 DOI: 10.1073/pnas.1206062109] [Cited by in Crossref: 94] [Cited by in F6Publishing: 93] [Article Influence: 10.4] [Reference Citation Analysis]
9 Pricolo VE, Finkelstein SD, Bland KI. Topographic genotyping of colorectal carcinoma: From a molecular carcinogenesis model to clinical relevance. Annals of Surgical Oncology 1997;4:269-78. [DOI: 10.1007/bf02306621] [Cited by in Crossref: 1] [Article Influence: 0.0] [Reference Citation Analysis]
10 Rupnarain C, Dlamini Z, Naicker S, Bhoola K. Colon cancer: genomics and apoptotic events. Biol Chem. 2004;385:449-464. [PMID: 15255176 DOI: 10.1515/bc.2004.053] [Cited by in Crossref: 61] [Cited by in F6Publishing: 31] [Article Influence: 3.8] [Reference Citation Analysis]
11 Wang JY, Hsieh JS, Chang MY, Huang TJ, Chen FM, Cheng TL, Alexandersen K, Huang YS, Tzou WS, Lin SR. Molecular detection of APC, K- ras, and p53 mutations in the serum of colorectal cancer patients as circulating biomarkers. World J Surg. 2004;28:721-726. [PMID: 15185002 DOI: 10.1007/s00268-004-7366-8] [Cited by in Crossref: 77] [Cited by in F6Publishing: 95] [Article Influence: 4.5] [Reference Citation Analysis]
12 Joypaul BV, Newman EL, Hopwood D, Grant A, Qureshi S, Lane DP, Cuschieri A. Expression of p53 protein in normal, dysplastic, and malignant gastric mucosa: an immunohistochemical study. J Pathol. 1993;170:279-283. [PMID: 8133401 DOI: 10.1002/path.1711700310] [Cited by in Crossref: 58] [Cited by in F6Publishing: 57] [Article Influence: 2.1] [Reference Citation Analysis]
13 Miyoshi A, Kito K, Aramoto T, Abe Y, Kobayashi N, Ueda N. Identification of CGI-121, a novel PRPK (p53-related protein kinase)-binding protein. Biochem Biophys Res Commun 2003;303:399-405. [PMID: 12659830 DOI: 10.1016/s0006-291x(03)00333-4] [Cited by in Crossref: 12] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
14 Karjalainen JM, Kellokoski JK, Mannermaa AJ, Kujala HE, Moisio KI, Mitchell PJ, Eskelinen MJ, Alhava EM, Kosma VM. Failure in post-transcriptional processing is a possible inactivation mechanism of AP-2alpha in cutaneous melanoma. Br J Cancer 2000;82:2015-21. [PMID: 10864211 DOI: 10.1054/bjoc.2000.1145] [Cited by in Crossref: 9] [Cited by in F6Publishing: 13] [Article Influence: 0.4] [Reference Citation Analysis]
15 Curling M, Stenning S, Hudson CN, Watson JV. Multivariate analyses of DNA index, p62c-myc, and clinicopathological status of patients with ovarian cancer. J Clin Pathol 1998;51:455-61. [PMID: 9771445 DOI: 10.1136/jcp.51.6.455] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
16 Salahshor S, Kressner U, P�hlman L, Glimelius B, Lindmark G, Lindblom A. Colorectal cancer with and without microsatellite instability involves different genes. Genes Chromosom Cancer 1999;26:247-52. [DOI: 10.1002/(sici)1098-2264(199911)26:3<247::aid-gcc9>3.0.co;2-h] [Cited by in Crossref: 86] [Cited by in F6Publishing: 1] [Article Influence: 3.9] [Reference Citation Analysis]
17 Stegelmeier BL, Gillett NA, Rebar AH, Kelly G. The molecular progression of plutonium-239–induced rat lung carcinogenesis: Ki-ras expression and activation. Mol Carcinog 1991;4:43-51. [DOI: 10.1002/mc.2940040108] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 0.7] [Reference Citation Analysis]
18 Li D, Yan D, Tang H, Zhou C, Fan J, Li S, Wang X, Xia J, Huang F, Qiu G, Peng Z. IMP3 is a novel prognostic marker that correlates with colon cancer progression and pathogenesis. Ann Surg Oncol 2009;16:3499-506. [PMID: 19672661 DOI: 10.1245/s10434-009-0648-5] [Cited by in Crossref: 71] [Cited by in F6Publishing: 73] [Article Influence: 6.5] [Reference Citation Analysis]
19 Egan SE, Wright JA, Greenberg AH. Molecular determinants of metastatic transformation. Environ Health Perspect 1991;93:91-5. [PMID: 1773806 DOI: 10.1289/ehp.919391] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
20 Dong JT, Rinker-Schaeffer CW, Ichikawa T, Barrett JC, Isaacs JT. Prostate cancer--biology of metastasis and its clinical implications. World J Urol 1996;14:182-9. [PMID: 8806197 DOI: 10.1007/BF00186898] [Cited by in Crossref: 21] [Cited by in F6Publishing: 11] [Article Influence: 0.8] [Reference Citation Analysis]
21 Nathanson SD, Linden MD, Tender P, Zarbo RJ, Jacobsen G, Nelson LT. Relationship among p53, stage, and prognosis of large bowel cancer. Dis Colon Rectum 1994;37:527-34. [PMID: 8200229 DOI: 10.1007/BF02050985] [Cited by in Crossref: 26] [Cited by in F6Publishing: 14] [Article Influence: 1.0] [Reference Citation Analysis]
22 Selter H, Montenarh M. The emerging picture of p53. Int J Biochem 1994;26:145-54. [PMID: 8174748 DOI: 10.1016/0020-711x(94)90139-2] [Cited by in Crossref: 22] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
23 Vet JA, Bringuier PP, Poddighe PJ, Karthaus HF, Debruyne FM, Schalken JA. p53 mutations have no additional prognostic value over stage in bladder cancer. Br J Cancer 1994;70:496-500. [PMID: 8080737 DOI: 10.1038/bjc.1994.334] [Cited by in Crossref: 33] [Cited by in F6Publishing: 35] [Article Influence: 1.2] [Reference Citation Analysis]
24 Johnson I. Phytochemicals and cancer: an overview. Phytochemical Functional Foods. Elsevier; 2003. pp. 18-44. [DOI: 10.1533/9781855736986.1.18] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
25 Shaw PH. The Role of p53 in Cell Cycle Regulation. Pathology - Research and Practice 1996;192:669-75. [DOI: 10.1016/s0344-0338(96)80088-4] [Cited by in Crossref: 73] [Cited by in F6Publishing: 31] [Article Influence: 2.9] [Reference Citation Analysis]
26 Maletzki C, Gock M, Randow M, Klar E, Huehns M, Prall F, Linnebacher M. Establishment and characterization of cell lines from chromosomal instable colorectal cancer. World J Gastroenterol 2015; 21(1): 164-176 [PMID: 25574089 DOI: 10.3748/wjg.v21.i1.164] [Cited by in CrossRef: 16] [Cited by in F6Publishing: 15] [Article Influence: 2.7] [Reference Citation Analysis]
27 Kao CC, Yew PR, Berk AJ. Domains required for in vitro association between the cellular p53 and the adenovirus 2 E1B 55K proteins. Virology 1990;179:806-14. [PMID: 2146804 DOI: 10.1016/0042-6822(90)90148-k] [Cited by in Crossref: 145] [Cited by in F6Publishing: 58] [Article Influence: 4.7] [Reference Citation Analysis]
28 Frezza C, Martins CP. From tumor prevention to therapy: Empowering p53 to fight back. Drug Resistance Updates 2012;15:258-67. [DOI: 10.1016/j.drup.2012.10.001] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 2.0] [Reference Citation Analysis]
29 Chang SC, Lin JK, Lin TC, Liang WY. Loss of heterozygosity: An independent prognostic factor of colorectal cancer. World J Gastroenterol 2005; 11(6): 778-784 [PMID: 15682467 DOI: 10.3748/wjg.v11.i6.778] [Cited by in CrossRef: 26] [Cited by in F6Publishing: 22] [Article Influence: 1.6] [Reference Citation Analysis]
30 Levine AJ. Introduction: The Changing Directions of p53 Research. Genes Cancer. 2011;2:382-384. [PMID: 21785490 DOI: 10.1177/1947601911413463] [Cited by in Crossref: 14] [Cited by in F6Publishing: 17] [Article Influence: 1.4] [Reference Citation Analysis]
31 Lee JH, Hwang I, Kang YN, Choi IJ, Kim DK. Genetic characteristics of mitochondrial DNA was associated with colorectal carcinogenesis and its prognosis. PLoS One 2015;10:e0118612. [PMID: 25734426 DOI: 10.1371/journal.pone.0118612] [Cited by in Crossref: 21] [Cited by in F6Publishing: 23] [Article Influence: 3.5] [Reference Citation Analysis]
32 Zhou D, Yang L, Zheng L, Ge W, Li D, Zhang Y, Hu X, Gao Z, Xu J, Huang Y. Exome capture sequencing of adenoma reveals genetic alterations in multiple cellular pathways at the early stage of colorectal tumorigenesis. PLoS One. 2013;8:e53310. [PMID: 23301059 DOI: 10.1371/journal.pone.0053310] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 3.1] [Reference Citation Analysis]
33 Shibata Y, Kotanagi H, Andoh H, Koyama K, Itoh H, Kudo S. Detection of circulating anti-p53 antibodies in patients with colorectal carcinoma and the antibody's relation to clinical factors. Dis Colon Rectum. 1996;39:1269-1274. [PMID: 8918437 DOI: 10.1007/BF02055121] [Cited by in Crossref: 13] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
34 Alessandrino F, Shinagare AB, Bossé D, Choueiri TK, Krajewski KM. Radiogenomics in renal cell carcinoma. Abdom Radiol (NY) 2019;44:1990-8. [PMID: 29713740 DOI: 10.1007/s00261-018-1624-y] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 16.0] [Reference Citation Analysis]
35 Goyette MC, Cho K, Fasching CL, Levy DB, Kinzler KW, Paraskeva C, Vogelstein B, Stanbridge EJ. Progression of colorectal cancer is associated with multiple tumor suppressor gene defects but inhibition of tumorigenicity is accomplished by correction of any single defect via chromosome transfer. Mol Cell Biol 1992;12:1387-95. [PMID: 1347643 DOI: 10.1128/mcb.12.3.1387-1395.1992] [Cited by in Crossref: 162] [Article Influence: 5.6] [Reference Citation Analysis]
36 Li TJ, Browne RM, Prime SS, Paterson IC, Matthews JB. p53 expression in odontogenic keratocyst epithelium. J Oral Pathol Med 1996;25:249-55. [PMID: 8835823 DOI: 10.1111/j.1600-0714.1996.tb01380.x] [Cited by in Crossref: 54] [Cited by in F6Publishing: 58] [Article Influence: 2.2] [Reference Citation Analysis]
37 Moll UM, Riou G, Levine AJ. Two distinct mechanisms alter p53 in breast cancer: mutation and nuclear exclusion. Proc Natl Acad Sci U S A 1992;89:7262-6. [PMID: 1353891 DOI: 10.1073/pnas.89.15.7262] [Cited by in Crossref: 356] [Cited by in F6Publishing: 361] [Article Influence: 12.3] [Reference Citation Analysis]
38 Vidaurreta M, Maestro ML, Sanz-Casla MT, Rafael S, Veganzones S, de la Orden V, Cerdán J, Arroyo M, Torres A. Colorectal carcinoma prognosis can be predicted by alterations in gene p53 exons 5 and 8. Int J Colorectal Dis 2008;23:581-6. [PMID: 18322661 DOI: 10.1007/s00384-008-0454-8] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 1.2] [Reference Citation Analysis]
39 Keesee SK, Meneghini MD, Szaro RP, Wu YJ. Nuclear matrix proteins in human colon cancer. Proc Natl Acad Sci USA. 1994;91:1913-1916. [PMID: 8127905 DOI: 10.1073/pnas.91.5.1913] [Cited by in Crossref: 53] [Cited by in F6Publishing: 46] [Article Influence: 2.0] [Reference Citation Analysis]
40 Ahnen DJ. Lessons from the genetics of colon cancer. Scand J Gastroenterol Suppl 1990;175:166-76. [PMID: 2173130 DOI: 10.3109/00365529009093140] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.2] [Reference Citation Analysis]
41 Oren M. p53: not just a tumor suppressor. J Mol Cell Biol 2019;11:539-43. [PMID: 31291648 DOI: 10.1093/jmcb/mjz070] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
42 Kiga K, Fukuda-Yuzawa Y, Tanabe M, Tsuji S, Sasakawa C, Fukao T. Comprehensive silencing of target-sharing microRNAs is a mechanism for SIRT1 overexpression in cancer. RNA Biol 2014;11:1347-54. [PMID: 25483038 DOI: 10.4161/rna.32093] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.7] [Reference Citation Analysis]
43 Klingelhutz AJ, Wu S, Reznikoff CA. Nonrandom chromosome losses in tumorigenic revertants of hybrids between isogeneic immortal and neoplastic human uroepithelial cells. Somat Cell Mol Genet 1991;17:551-65. [DOI: 10.1007/bf01233620] [Cited by in Crossref: 7] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
44 Wright C, Mellon K, Johnston P, Lane DP, Harris AL, Horne CH, Neal DE. Expression of mutant p53, c-erbB-2 and the epidermal growth factor receptor in transitional cell carcinoma of the human urinary bladder. Br J Cancer 1991;63:967-70. [PMID: 1712624 DOI: 10.1038/bjc.1991.211] [Cited by in Crossref: 135] [Cited by in F6Publishing: 121] [Article Influence: 4.5] [Reference Citation Analysis]
45 Urano Y, Oura H, Sakaki A, Nagae H, Matsumoto K, Fukuhara K, Nagae T, Arase S, Ninomiya Y, Nakanishi H, Shigemi F, Takeda K. Immunohistological analysis of P53 expression in human skin tumors. Journal of Dermatological Science 1992;4:69-75. [DOI: 10.1016/0923-1811(92)90061-f] [Cited by in Crossref: 31] [Cited by in F6Publishing: 2] [Article Influence: 1.1] [Reference Citation Analysis]
46 Olive M, Untawale S, Coffey RJ, Siciliano MJ, Wildrick DM, Fritsche H, Pathak S, Cherry LM, Blick M, Lointier P, Roubein LD, Levin B, Boman BM. Characterization of the DiFi Rectal carcinoma cell line derived from a familial adenomatous polyposis patient. In Vitro Cell Dev Biol - Animal 1993;29:239-48. [DOI: 10.1007/bf02634191] [Cited by in Crossref: 25] [Cited by in F6Publishing: 12] [Article Influence: 0.9] [Reference Citation Analysis]
47 Longy M, Saura R, Dumas F, Leseve J, Taine L, Goussot J, Couzigou P. Chromosome analysis of adenomatous polyps of the colon. Cancer Genetics and Cytogenetics 1993;67:7-13. [DOI: 10.1016/0165-4608(93)90037-m] [Cited by in Crossref: 26] [Cited by in F6Publishing: 3] [Article Influence: 0.9] [Reference Citation Analysis]
48 Konishi K, Fujii T, Boku N, Kato S, Koba I, Ohtsu A, Tajiri H, Ochiai A, Yoshida S. Clinicopathological differences between colonic and rectal carcinomas: are they based on the same mechanism of carcinogenesis? Gut. 1999;45:818-821. [PMID: 10562578 DOI: 10.1136/gut.45.6.818] [Cited by in Crossref: 45] [Cited by in F6Publishing: 41] [Article Influence: 2.1] [Reference Citation Analysis]
49 Menter DG, Davis JS, Broom BM, Overman MJ, Morris J, Kopetz S. Back to the Colorectal Cancer Consensus Molecular Subtype Future. Curr Gastroenterol Rep 2019;21:5. [PMID: 30701321 DOI: 10.1007/s11894-019-0674-9] [Cited by in Crossref: 20] [Cited by in F6Publishing: 22] [Article Influence: 10.0] [Reference Citation Analysis]
50 Isomura M, Tanigami A, Saito H, Harada Y, Katagiri T, Inazawa J, Nakamura Y, Ledbetter DH. Detailed analysis of loss of heterozygosity on chromosome band 17p13 in breast carcinoma on the basis of a high-resolution physical map with 29 markers. Genes Chromosom Cancer 1994;9:173-9. [DOI: 10.1002/gcc.2870090305] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 0.7] [Reference Citation Analysis]
51 Kouvidou C, Kanavaros P, Papaioannou D, Stathopoulos E, Sotsiou F, Datseris G, Tzardi M, Kittas C, Delides G. Expression of bcl-2 and p53 proteins in nasopharyngeal carcinoma. Absence of correlation with the presence of EBV encoded EBER1-2 transcripts and latent membrane protein-1. Clin Mol Pathol 1995;48:M17-22. [PMID: 16695969 DOI: 10.1136/mp.48.1.m17] [Cited by in Crossref: 11] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
52 Rasool S, Rasool V, Naqvi T, Ganai BA, Shah BA. Genetic unraveling of colorectal cancer. Tumour Biol. 2014;35:5067-5082. [PMID: 24573608 DOI: 10.1007/s13277-014-1713-7] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
53 Potter JD. Nutrition and colorectal cancer. Cancer Causes Control. 1996;7:127-146. [PMID: 8850441 DOI: 10.1007/bf00115644] [Cited by in Crossref: 222] [Cited by in F6Publishing: 44] [Article Influence: 9.3] [Reference Citation Analysis]
54 Gallion H, Powell D, Morrow J, Pieretti M, Case E, Turker M, Depriest P, Hunter J, van Nagell J. Molecular genetic changes in human epithelial ovarian malignancies. Gynecologic Oncology 1992;47:137-42. [DOI: 10.1016/0090-8258(92)90096-2] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 0.9] [Reference Citation Analysis]
55 Müller H, Scott R. Hereditary conditions in which the loss of heterozygosity may be important. Mutation Research/Fundamental and Molecular Mechanisms of Mutagenesis 1992;284:15-24. [DOI: 10.1016/0027-5107(92)90021-s] [Cited by in Crossref: 18] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
56 Cohn KH, Ornstein DL, Wang F, Lapaix FD, Phipps K, Edelsberg C, Zuna R, Mott LA, Dunn JL. The significance of allelic deletions and aneuploidy in colorectal carcinoma: Results of a 5-year follow-up study. Cancer 1997;79:233-44. [DOI: 10.1002/(sici)1097-0142(19970115)79:2<233::aid-cncr6>3.0.co;2-l] [Cited by in Crossref: 37] [Article Influence: 1.5] [Reference Citation Analysis]
57 Pino MS, Chung DC. The chromosomal instability pathway in colon cancer. Gastroenterology. 2010;138:2059-2072. [PMID: 20420946 DOI: 10.1053/j.gastro.2009.12.065] [Cited by in Crossref: 398] [Cited by in F6Publishing: 373] [Article Influence: 36.2] [Reference Citation Analysis]
58 Ray FA. Simian Virus 40 Large T Antigen Induces Chromosome Damage that Precedes and Coincides with Complete Neoplastic Transformation. In: Barbanti-brodano G, Bendinelli M, Friedman H, editors. DNA Tumor Viruses. Boston: Springer US; 1995. pp. 15-26. [DOI: 10.1007/978-1-4899-1100-1_2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.1] [Reference Citation Analysis]
59 Wiśniewski JR, Duś-Szachniewicz K, Ostasiewicz P, Ziółkowski P, Rakus D, Mann M. Absolute Proteome Analysis of Colorectal Mucosa, Adenoma, and Cancer Reveals Drastic Changes in Fatty Acid Metabolism and Plasma Membrane Transporters. J Proteome Res 2015;14:4005-18. [PMID: 26245529 DOI: 10.1021/acs.jproteome.5b00523] [Cited by in Crossref: 55] [Cited by in F6Publishing: 51] [Article Influence: 9.2] [Reference Citation Analysis]
60 Ding-wei Y, Jia-fu Z, Song-xi Q, Young-jiang M. Expression of p53 product in Chinese human bladder carcinoma. Urol Res 1993;21:223-6. [DOI: 10.1007/bf00590040] [Cited by in Crossref: 17] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
61 Quesnel S, Verselis S, Portwine C, Garber J, White M, Feunteun J, Malkin D, Li FP. p53 compound heterozygosity in a severely affected child with Li-Fraumeni syndrome. Oncogene 1999;18:3970-8. [PMID: 10435620 DOI: 10.1038/sj.onc.1202783] [Cited by in Crossref: 20] [Cited by in F6Publishing: 24] [Article Influence: 0.9] [Reference Citation Analysis]
62 Ishioka C, Sato T, Gamoh M, Suzuki T, Shibata H, Kanamaru R, Wakui A, Yamazaki T. Mutations of the p53 gene, including an intronic point mutation, in colorectal tumors. Biochemical and Biophysical Research Communications 1991;177:901-6. [DOI: 10.1016/0006-291x(91)90623-f] [Cited by in Crossref: 10] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
63 Olivos DJ, Mayo LD. Emerging Non-Canonical Functions and Regulation by p53: p53 and Stemness. Int J Mol Sci 2016;17:E1982. [PMID: 27898034 DOI: 10.3390/ijms17121982] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 4.6] [Reference Citation Analysis]
64 Gaustadnes M, Ørntoft TF, Jensen JL, Torring N. Validation of the use of DNA pools and primer extension in association studies of sporadic colorectal cancer for selection of candidate SNPs. Hum Mutat 2006;27:187-94. [PMID: 16395669 DOI: 10.1002/humu.20248] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 1.1] [Reference Citation Analysis]
65 Soussi T, Béroud C. Assessing TP53 status in human tumours to evaluate clinical outcome. Nat Rev Cancer 2001;1:233-40. [PMID: 11902578 DOI: 10.1038/35106009] [Cited by in Crossref: 444] [Cited by in F6Publishing: 404] [Article Influence: 23.4] [Reference Citation Analysis]
66 Ciardiello F, Kim N, Saeki T, Dono R, Persico MG, Plowman GD, Garrigues J, Radke S, Todaro GJ, Salomon DS. Differential expression of epidermal growth factor-related proteins in human colorectal tumors. Proc Natl Acad Sci USA. 1991;88:7792-7796. [PMID: 1715580 DOI: 10.1073/pnas.88.17.7792] [Cited by in Crossref: 164] [Cited by in F6Publishing: 151] [Article Influence: 5.5] [Reference Citation Analysis]
67 Shastri S, Chatterjee B, Thakur SS. Achievements in Cancer Research and its Therapeutics in Hundred Years. Curr Top Med Chem 2019;19:1545-62. [PMID: 31362690 DOI: 10.2174/1568026619666190730093034] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
68 Macdonald GA. Pathogenesis of Hepatocellular Carcinoma. Clinics in Liver Disease 2001;5:69-85. [DOI: 10.1016/s1089-3261(05)70154-9] [Cited by in Crossref: 37] [Cited by in F6Publishing: 7] [Article Influence: 1.9] [Reference Citation Analysis]
69 Abood ME. Molecular Biology of Cannabinoid Receptors: Mutational Analyses of the CB Receptors. In: Reggio PH, editor. The Cannabinoid Receptors. Totowa: Humana Press; 2009. pp. 203-34. [DOI: 10.1007/978-1-59745-503-9_8] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
70 Rainwater R, Parks D, Anderson ME, Tegtmeyer P, Mann K. Role of cysteine residues in regulation of p53 function. Mol Cell Biol 1995;15:3892-903. [PMID: 7791795 DOI: 10.1128/MCB.15.7.3892] [Cited by in Crossref: 204] [Cited by in F6Publishing: 74] [Article Influence: 7.8] [Reference Citation Analysis]
71 Potter JD. Colorectal cancer: molecules and populations. J Natl Cancer Inst. 1999;91:916-932. [PMID: 10359544 DOI: 10.1093/jnci/91.11.916] [Cited by in Crossref: 550] [Cited by in F6Publishing: 455] [Article Influence: 25.0] [Reference Citation Analysis]
72 Clark CR, Starr TK. Mouse models for the discovery of colorectal cancer driver genes. World J Gastroenterol 2016; 22(2): 815-822 [PMID: 26811627 DOI: 10.3748/wjg.v22.i2.815] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
73 Soussi T, Legros Y, Lubin R, Ory K, Schlichtholz B. Multifactorial analysis ofp53 alteration in human cancer: A review. Int J Cancer 1994;57:1-9. [DOI: 10.1002/ijc.2910570102] [Cited by in Crossref: 230] [Cited by in F6Publishing: 214] [Article Influence: 8.5] [Reference Citation Analysis]
74 Nargi JL, Ratan RR, Griffin DE. p53-independent inhibition of proliferation and p21(WAF1/Cip1)-modulated induction of cell death by the antioxidants N-acetylcysteine and vitamin E. Neoplasia 1999;1:544-56. [PMID: 10935502 DOI: 10.1038/sj.neo.7900068] [Cited by in Crossref: 30] [Cited by in F6Publishing: 25] [Article Influence: 1.4] [Reference Citation Analysis]
75 Gelmann A, Desnoyers R, Cagir B, Weinberg D, Boman BM, Waldman SA. Colorectal cancer staging and adjuvant chemotherapy. Expert Opin Pharmacother 2000;1:737-55. [PMID: 11249513 DOI: 10.1517/14656566.1.4.737] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 0.7] [Reference Citation Analysis]
76 Feng X, Zhang S, Ichikawa T, Koga H, Washiyama K, Motoyama T, Kumanishi T. Intracranial germ cell tumors: detection of p53 gene mutations by single-strand conformation polymorphism analysis. Jpn J Cancer Res 1995;86:555-61. [PMID: 7622420 DOI: 10.1111/j.1349-7006.1995.tb02434.x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.2] [Reference Citation Analysis]
77 Sakakura C, Koide K, Ichikawa D, Wakasa T, Shirasu M, Kimura A, Taniguchi H, Hagiwara A, Yamaguchi T, Inazawa J, Abe T, Takahashi T, Otsuji E. Analysis of histological therapeutic effect, apoptosis rate and p53 status after combined treatment with radiation, hyperthermia and 5-fluorouracil suppositories for advanced rectal cancers. Br J Cancer 1998;77:159-66. [PMID: 9459162 DOI: 10.1038/bjc.1998.25] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 0.7] [Reference Citation Analysis]
78 Dolloff NG. Emerging Therapeutic Strategies for Overcoming Proteasome Inhibitor Resistance. Elsevier; 2015. pp. 191-226. [DOI: 10.1016/bs.acr.2015.03.002] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
79 Sugo H, Takamori S, Kojima K, Beppu T, Futagawa S. The significance of p53 mutations as an indicator of the biological behavior of recurrent hepatocellular carcinomas. Surg Today 1999;29:849-55. [PMID: 10489124 DOI: 10.1007/BF02482774] [Cited by in Crossref: 29] [Cited by in F6Publishing: 14] [Article Influence: 1.3] [Reference Citation Analysis]
80 Tiemann F, Deppert W. Stabilization of the tumor suppressor p53 during cellular transformation by simian virus 40: influence of viral and cellular factors and biological consequences. J Virol 1994;68:2869-78. [PMID: 8151757 DOI: 10.1128/JVI.68.5.2869-2878.1994] [Cited by in Crossref: 32] [Cited by in F6Publishing: 14] [Article Influence: 1.2] [Reference Citation Analysis]
81 Console-Bram L, Marcu J, Abood ME. Cannabinoid receptors: nomenclature and pharmacological principles. Prog Neuropsychopharmacol Biol Psychiatry 2012;38:4-15. [PMID: 22421596 DOI: 10.1016/j.pnpbp.2012.02.009] [Cited by in Crossref: 95] [Cited by in F6Publishing: 80] [Article Influence: 10.6] [Reference Citation Analysis]
82 Naka N, Tomita Y, Nakanishi H, Araki N, Hongyo T, Ochi T, Aozasa K. Mutations ofp53 tumor-suppressor gene in angiosarcoma. Int J Cancer 1997;71:952-5. [DOI: 10.1002/(sici)1097-0215(19970611)71:6<952::aid-ijc7>3.0.co;2-x] [Cited by in Crossref: 61] [Cited by in F6Publishing: 20] [Article Influence: 2.5] [Reference Citation Analysis]
83 Martens UM, Zijlmans JJ, Poon SS, Dragowska W, Yui J, Chavez EA, Ward RK, Lansdorp PM. Short telomeres on human chromosome 17p. Nat Genet 1998;18:76-80. [DOI: 10.1038/ng0198-76] [Cited by in Crossref: 156] [Cited by in F6Publishing: 103] [Article Influence: 6.8] [Reference Citation Analysis]
84 Jesnowski R, Muller P, Schareck W, Liebe S, Lohr M. Immortalized Pancreatic Duct Cells in vitro and in vivo. Annals NY Acad Sci 1999;880:50-65. [DOI: 10.1111/j.1749-6632.1999.tb09509.x] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 0.6] [Reference Citation Analysis]
85 Kuwabara A, Watanabe H, Ajioka Y, Yasuda K, Saito H, Matsuda K, Kijima H, Hatakeyama K. Alteration of p53 clonality accompanying colorectal cancer progression. Jpn J Cancer Res 1998;89:40-6. [PMID: 9510474 DOI: 10.1111/j.1349-7006.1998.tb00477.x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 0.4] [Reference Citation Analysis]
86 Goolsby CL, Steiner M, Nemeth J. Viral and cellular oncogene expression during progressive malignant transformation of SV40 transformed human fibroblasts. Cytometry 1991;12:748-56. [PMID: 1665408 DOI: 10.1002/cyto.990120809] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.2] [Reference Citation Analysis]
87 Marsigliante S, Leo G, Mottaghi A, Biscozzo L, Greco S, Storelli C. P53 associated with cathepsin D in primary breast cancer. Int J Clin Lab Res 1993;23:102-8. [DOI: 10.1007/bf02592291] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
88 Muleris M, Salmon R, Dutrillaux B. Cytogenetics of colorectal adenocarcinomas. Cancer Genetics and Cytogenetics 1990;46:143-56. [DOI: 10.1016/0165-4608(90)90100-o] [Cited by in Crossref: 97] [Cited by in F6Publishing: 17] [Article Influence: 3.1] [Reference Citation Analysis]
89 Chen J, Wang A, Chen Q. SirT3 and p53 Deacetylation in Aging and Cancer: SirT3 DEACETYLATE p53 IN AGING AND CANCER. J Cell Physiol 2017;232:2308-11. [DOI: 10.1002/jcp.25669] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 3.8] [Reference Citation Analysis]
90 Wang Y, Zhang W, Edelmann L, Kolodner RD, Kucherlapati R, Edelmann W. Cis lethal genetic interactions attenuate and alter p53 tumorigenesis. Proc Natl Acad Sci U S A 2010;107:5511-5. [PMID: 20212136 DOI: 10.1073/pnas.1001223107] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
91 Fenoglio-preiser CM. Selection of appropriate cellular and molecular biologic diagnostic tests in the evaluation of cancer. Cancer 1992;69:1607-32. [DOI: 10.1002/1097-0142(19920315)69:6+<1607::aid-cncr2820691317>3.0.co;2-c] [Cited by in Crossref: 23] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
92 Rabbani F, Cordon-Cardo C. Mutation of cell cycle regulators and their impact on superficial bladder cancer. Urol Clin North Am. 2000;27:83-102, ix. [PMID: 10696248 DOI: 10.1016/s0094-0143(05)70237-8] [Cited by in Crossref: 29] [Cited by in F6Publishing: 3] [Article Influence: 1.4] [Reference Citation Analysis]
93 Cappell MS, Waye JD, Farrar JT, Sleisenger MH. FIFTY LANDMARK DISCOVERIES IN GASTROENTEROLOGY DURING THE PAST 50 YEARS. Gastroenterology Clinics of North America 2000;29:513-50. [DOI: 10.1016/s0889-8553(05)70125-4] [Cited by in Crossref: 2] [Article Influence: 0.1] [Reference Citation Analysis]
94 Mao X, Hamoudi RA, Talbot IC, Baudis M. Allele-specific loss of heterozygosity in multiple colorectal adenomas: toward an integrated molecular cytogenetic map II. Cancer Genet Cytogenet. 2006;167:1-14. [PMID: 16682279 DOI: 10.1016/j.cancergencyto.2005.08.030] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 1.0] [Reference Citation Analysis]
95 Baumgartner M, Viegas-pequignot E, Hoffschir F, Ricoul M, Bravard A, Dutrillaux B. Detection of translocations of 10p by non-radioactive in situ hybridization of VIM gene in SV40-transformed human cell lines. Cancer Genetics and Cytogenetics 1991;56:23-9. [DOI: 10.1016/0165-4608(91)90358-2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
96 Lee CS, Pirdas A, Lee MW. p53 in cutaneous melanoma: Immunoreactivity and correlation with prognosis. Australas J Dermatol 1995;36:192-5. [DOI: 10.1111/j.1440-0960.1995.tb00971.x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 0.4] [Reference Citation Analysis]
97 Nakamura Y. DNA variations in human and medical genetics: 25 years of my experience. J Hum Genet 2009;54:1-8. [PMID: 19158818 DOI: 10.1038/jhg.2008.6] [Cited by in Crossref: 44] [Cited by in F6Publishing: 30] [Article Influence: 3.7] [Reference Citation Analysis]
98 Bottema CD, Koeberl DD, Sommer SS. Direct carrier testing in 14 families with haemophilia B. Lancet 1989;2:526-9. [PMID: 2570235 DOI: 10.1016/s0140-6736(89)90653-3] [Cited by in Crossref: 19] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
99 Gullick WJ. Growth factors and oncogenes in breast cancer. Prog Growth Factor Res 1990;2:1-13. [PMID: 1966556 DOI: 10.1016/0955-2235(90)90006-6] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 0.6] [Reference Citation Analysis]
100 Cousin P, Billotte J, Chaubert P, Shaw P. Physical Map of 17p13 and the Genes Adjacent to p53. Genomics 2000;63:60-8. [DOI: 10.1006/geno.1999.6062] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.4] [Reference Citation Analysis]
101 Sun T, Liu S, Zhou Y, Yao Z, Zhang D, Cao S, Wei Z, Tan B, Li Y, Lian Z, Wang S. Evolutionary biologic changes of gut microbiota in an 'adenoma-carcinoma sequence' mouse colorectal cancer model induced by 1, 2-Dimethylhydrazine. Oncotarget 2017;8:444-57. [PMID: 27880935 DOI: 10.18632/oncotarget.13443] [Cited by in Crossref: 27] [Cited by in F6Publishing: 25] [Article Influence: 9.0] [Reference Citation Analysis]
102 Shoemaker AR, Gould KA, Luongo C, Moser AR, Dove WF. Studies of neoplasia in the Min mouse. Biochim Biophys Acta. 1997;1332:F25-F48. [PMID: 9141462 DOI: 10.1016/s0304-419x(96)00041-8] [Cited by in Crossref: 15] [Cited by in F6Publishing: 47] [Article Influence: 0.6] [Reference Citation Analysis]
103 Mcgregor J, Yu C, Dublin E, Levison D, Macdonald D. Aberrant expression of p53 tumour-suppressor protein in non-melanoma skin cancer. Br J Dermatol 1992;127:463-9. [DOI: 10.1111/j.1365-2133.1992.tb14841.x] [Cited by in Crossref: 68] [Cited by in F6Publishing: 65] [Article Influence: 2.3] [Reference Citation Analysis]
104 Qiao GB, Han CL, Jiang RC, Sun CS, Wang Y, Wang YJ. Overexpression of P53 and its risk factors in esophageal cancer in urban areas of Xi’an. World J Gastroenterol 1998; 4(1): 57-60 [PMID: 11819233 DOI: 10.3748/wjg.v4.i1.57] [Cited by in CrossRef: 15] [Cited by in F6Publishing: 18] [Article Influence: 0.7] [Reference Citation Analysis]
105 Szedlak A, Paternostro G, Piermarocchi C. Control of asymmetric Hopfield networks and application to cancer attractors. PLoS One 2014;9:e105842. [PMID: 25170874 DOI: 10.1371/journal.pone.0105842] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 1.9] [Reference Citation Analysis]
106 Venter DJ, Thomas DG. Multiple sequential molecular abnormalities in the evolution of human gliomas. Br J Cancer 1991;63:753-7. [PMID: 1674878 DOI: 10.1038/bjc.1991.168] [Cited by in Crossref: 42] [Cited by in F6Publishing: 39] [Article Influence: 1.4] [Reference Citation Analysis]
107 Warnakulasuriya KAAS, Johnson NW. Expression of p53 mutant nuclear phosphoprotein in oral carcinoma and potentially malignant oral lesions. J Oral Pathol Med 1992;21:404-8. [DOI: 10.1111/j.1600-0714.1992.tb01028.x] [Cited by in Crossref: 78] [Cited by in F6Publishing: 73] [Article Influence: 2.7] [Reference Citation Analysis]
108 Hammond DW, Goepel JR, Aitken M, Hancock BW, Potter AM, Goyns MH. Cytogenetic analysis of a United Kingdom series of non-Hodgkins lymphomas. Cancer Genetics and Cytogenetics 1992;61:31-8. [DOI: 10.1016/0165-4608(92)90366-g] [Cited by in Crossref: 27] [Cited by in F6Publishing: 1] [Article Influence: 0.9] [Reference Citation Analysis]
109 Whitehead RE Jr, Sugawara O, Maronpot RR, Gladen BC, Barrett JC. Detection of multiple tumor suppressor genes for Syrian hamster fibrosarcomas by somatic cell hybridization. Somat Cell Mol Genet 1992;18:131-42. [PMID: 1574739 DOI: 10.1007/BF01233160] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
110 Tomlinson IP, Bodmer WF. Chromosome 11q in sporadic colorectal carcinoma: patterns of allele loss and their significance for tumorigenesis. J Clin Pathol 1996;49:386-90. [PMID: 8707952 DOI: 10.1136/jcp.49.5.386] [Cited by in Crossref: 8] [Cited by in F6Publishing: 12] [Article Influence: 0.3] [Reference Citation Analysis]
111 Jones S, Chen WD, Parmigiani G, Diehl F, Beerenwinkel N, Antal T, Traulsen A, Nowak MA, Siegel C, Velculescu VE. Comparative lesion sequencing provides insights into tumor evolution. Proc Natl Acad Sci USA. 2008;105:4283-4288. [PMID: 18337506 DOI: 10.1073/pnas.0712345105] [Cited by in Crossref: 561] [Cited by in F6Publishing: 502] [Article Influence: 43.2] [Reference Citation Analysis]
112 Hasegawa H, Ueda M, Furukawa K, Watanabe M, Teramoto T, Mukai M, Kitajima M. p53 gene mutations in early colorectal carcinoma. De novo vs. adenoma-carcinoma sequence. Int J Cancer 1995;64:47-51. [PMID: 7665248 DOI: 10.1002/ijc.2910640110] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 1.0] [Reference Citation Analysis]
113 Smith DR, Myint T, Goh HS. Over-expression of the c-myc proto-oncogene in colorectal carcinoma. Br J Cancer 1993;68:407-13. [PMID: 8347498 DOI: 10.1038/bjc.1993.350] [Cited by in Crossref: 54] [Cited by in F6Publishing: 53] [Article Influence: 1.9] [Reference Citation Analysis]
114 Inoue K, Kurabayashi A, Shuin T, Ohtsuki Y, Furihata M. Overexpression of p53 protein in human tumors. Med Mol Morphol. 2012;45:115-123. [PMID: 23001293 DOI: 10.1007/s00795-012-0575-6] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 1.8] [Reference Citation Analysis]
115 Fagin JA, Matsuo K, Karmakar A, Chen DL, Tang SH, Koeffler HP. High prevalence of mutations of the p53 gene in poorly differentiated human thyroid carcinomas. J Clin Invest 1993;91:179-84. [PMID: 8423216 DOI: 10.1172/JCI116168] [Cited by in Crossref: 441] [Cited by in F6Publishing: 118] [Article Influence: 15.8] [Reference Citation Analysis]
116 Talamonti MS, Roh MS, Curley SA, Gallick GE. Increase in activity and level of pp60c-src in progressive stages of human colorectal cancer. J Clin Invest. 1993;91:53-60. [PMID: 7678609 DOI: 10.1172/jci116200] [Cited by in Crossref: 291] [Cited by in F6Publishing: 107] [Article Influence: 10.4] [Reference Citation Analysis]
117 Toschi E, Rota R, Antonini A, Melillo G, Capogrossi MC. Wild-type p53 gene transfer inhibits invasion and reduces matrix metalloproteinase-2 levels in p53-mutated human melanoma cells. J Invest Dermatol. 2000;114:1188-1194. [PMID: 10844565 DOI: 10.1046/j.1523-1747.2000.00000.x] [Cited by in Crossref: 33] [Cited by in F6Publishing: 32] [Article Influence: 1.6] [Reference Citation Analysis]
118 Bibi N, Hupp T, Kamal MA, Rashid S. Elucidation of PLK1 Linked Biomarkers in Oesophageal Cancer Cell Lines: A Step Towards Novel Signaling Pathways by p53 and PLK1-Linked Functions Crosstalk. Protein Pept Lett 2021;28:340-58. [PMID: 32875973 DOI: 10.2174/0929866527999200901201837] [Reference Citation Analysis]
119 Millau JF, Bastien N, Drouin R. P53 transcriptional activities: a general overview and some thoughts. Mutat Res 2009;681:118-33. [PMID: 18639648 DOI: 10.1016/j.mrrev.2008.06.002] [Cited by in Crossref: 35] [Cited by in F6Publishing: 33] [Article Influence: 2.7] [Reference Citation Analysis]
120 Schmidt V, Nagar R, Martinez LA. Control of Nucleotide Metabolism Enables Mutant p53's Oncogenic Gain-of-Function Activity. Int J Mol Sci 2017;18:E2759. [PMID: 29257071 DOI: 10.3390/ijms18122759] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
121 Collins VP, Kunimi K, Bergerheim U, Ekman P. Molecular Genetics and Human Prostatic Carcinoma. Acta Oncologica 2009;30:181-5. [DOI: 10.3109/02841869109092347] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 1.3] [Reference Citation Analysis]
122 Chen S, Wang DL, Liu Y, Zhao L, Sun FL. RAD6 regulates the dosage of p53 by a combination of transcriptional and posttranscriptional mechanisms. Mol Cell Biol 2012;32:576-87. [PMID: 22083959 DOI: 10.1128/MCB.05966-11] [Cited by in Crossref: 19] [Cited by in F6Publishing: 14] [Article Influence: 1.9] [Reference Citation Analysis]
123 Duan W, Gao L, Wu X, Hade EM, Gao JX, Ding H, Barsky SH, Otterson GA, Villalona-Calero MA. Expression of a mutant p53 results in an age-related demographic shift in spontaneous lung tumor formation in transgenic mice. PLoS One 2009;4:e5563. [PMID: 19440353 DOI: 10.1371/journal.pone.0005563] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
124 Ueba T, Nosaka T, Takahashi JA, Shibata F, Florkiewicz RZ, Vogelstein B, Oda Y, Kikuchi H, Hatanaka M. Transcriptional regulation of basic fibroblast growth factor gene by p53 in human glioblastoma and hepatocellular carcinoma cells. Proc Natl Acad Sci U S A 1994;91:9009-13. [PMID: 8090761 DOI: 10.1073/pnas.91.19.9009] [Cited by in Crossref: 91] [Cited by in F6Publishing: 92] [Article Influence: 3.4] [Reference Citation Analysis]
125 Aragane H, Sakakura C, Nakanishi M, Yasuoka R, Fujita Y, Taniguchi H, Hagiwara A, Yamaguchi T, Abe T, Inazawa J. Chromosomal aberrations in colorectal cancers and liver metastases analyzed by comparative genomic hybridization. Int J Cancer. 2001;94:623-629. [PMID: 11745455 DOI: 10.1002/ijc.1522] [Cited by in Crossref: 59] [Cited by in F6Publishing: 53] [Article Influence: 3.1] [Reference Citation Analysis]
126 Sun X, Suo J, Yan J. Immunotherapy in human colorectal cancer: Challenges and prospective. World J Gastroenterol 2016; 22(28): 6362-6372 [PMID: 27605872 DOI: 10.3748/wjg.v22.i28.6362] [Cited by in CrossRef: 27] [Cited by in F6Publishing: 28] [Article Influence: 5.4] [Reference Citation Analysis]
127 Tagawa Y, Sawai T, Nakagoe T, Morinaga M, Yasutake T, Ayabe H, Tomita M. Numerical aberrations of chromosomes 11 and 17 in colorectal adenocarcinomas. Surg Today 1996;26:869-74. [PMID: 8931216 DOI: 10.1007/BF00311787] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
128 Temin HM. Safety considerations in somatic gene therapy of human disease with retrovirus vectors. Hum Gene Ther 1990;1:111-23. [PMID: 2078575 DOI: 10.1089/hum.1990.1.2-111] [Cited by in Crossref: 112] [Cited by in F6Publishing: 104] [Article Influence: 3.7] [Reference Citation Analysis]
129 Zarbl H, Kho CJ, Boylan MO, Van Amsterdam J, Sullivan RC, Hoemann CD, Afshani VL. Functional in vitro assays for the isolation of cell transformation effector and suppressor genes. Environ Health Perspect 1991;93:83-9. [PMID: 1685446 DOI: 10.1289/ehp.919383] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.1] [Reference Citation Analysis]
130 Zhu JY, Abate M, Rice PW, Cole CN. The ability of simian virus 40 large T antigen to immortalize primary mouse embryo fibroblasts cosegregates with its ability to bind to p53. J Virol 1991;65:6872-80. [PMID: 1658380 DOI: 10.1128/JVI.65.12.6872-6880.1991] [Cited by in Crossref: 91] [Cited by in F6Publishing: 47] [Article Influence: 3.0] [Reference Citation Analysis]
131 Brett MC, Pickard M, Green B, Howel-Evans A, Smith D, Kinsella A, Poston G. p53 protein overexpression and response to biomodulated 5-fluorouracil chemotherapy in patients with advanced colorectal cancer. Eur J Surg Oncol 1996;22:182-5. [PMID: 8608838 DOI: 10.1016/s0748-7983(96)90827-6] [Cited by in Crossref: 25] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
132 Ito T, Seyama T, Mizuno T, Tsuyama N, Hayashi Y, Dohi K, Nakamura N, Akiyama M. Genetic alterations in thyroid tumor progression: association with p53 gene mutations. Jpn J Cancer Res 1993;84:526-31. [PMID: 8100564 DOI: 10.1111/j.1349-7006.1993.tb00171.x] [Cited by in Crossref: 66] [Cited by in F6Publishing: 57] [Article Influence: 2.4] [Reference Citation Analysis]
133 Reiter JG, Bozic I, Allen B, Chatterjee K, Nowak MA. The effect of one additional driver mutation on tumor progression. Evol Appl 2013;6:34-45. [PMID: 23396615 DOI: 10.1111/eva.12020] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 2.9] [Reference Citation Analysis]
134 Nakamura T, Pichel JG, Williams-Simons L, Westphal H. An apoptotic defect in lens differentiation caused by human p53 is rescued by a mutant allele. Proc Natl Acad Sci U S A 1995;92:6142-6. [PMID: 7597093 DOI: 10.1073/pnas.92.13.6142] [Cited by in Crossref: 45] [Cited by in F6Publishing: 38] [Article Influence: 1.7] [Reference Citation Analysis]
135 Simic MG. Urinary biomarkers and the rate of DNA damage in carcinogenesis and anticarcinogenesis. Mutation Research/Fundamental and Molecular Mechanisms of Mutagenesis 1992;267:277-90. [DOI: 10.1016/0027-5107(92)90072-a] [Cited by in Crossref: 44] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
136 Pricolo VE, Finkelstein SD, Wu T, Keller G, Bakker A, Swalsky PA, Bland KI. Prognostic value of TP53 and K-ras-2 mutational analysis in stage III carcinoma of the colon. The American Journal of Surgery 1996;171:41-6. [DOI: 10.1016/s0002-9610(99)80071-3] [Cited by in Crossref: 56] [Cited by in F6Publishing: 15] [Article Influence: 2.2] [Reference Citation Analysis]
137 Ranzani GN, Renault B, Pellegata NS, Fattorini P, Magni E, Bacci F, Amadori D. Loss of heterozygosity and K-ras gene mutations in gastric cancer. Hum Genet. 1993;92:244-249. [PMID: 8406432 DOI: 10.1007/bf00244466] [Cited by in Crossref: 30] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
138 Ahuja H, Bar-Eli M, Arlin Z, Advani S, Allen SL, Goldman J, Snyder D, Foti A, Cline M. The spectrum of molecular alterations in the evolution of chronic myelocytic leukemia. J Clin Invest 1991;87:2042-7. [PMID: 2040694 DOI: 10.1172/JCI115234] [Cited by in Crossref: 115] [Cited by in F6Publishing: 5] [Article Influence: 3.8] [Reference Citation Analysis]
139 Grundmann E, Ueda Y, Schneider-stock R, Roessner A. New Aspects of Cell Biology in Osteosarcoma. Pathology - Research and Practice 1995;191:563-70. [DOI: 10.1016/s0344-0338(11)80877-0] [Cited by in Crossref: 16] [Cited by in F6Publishing: 1] [Article Influence: 0.6] [Reference Citation Analysis]
140 Yeargin J, Cheng J, Yu AL, Gjerset R, Bogart M, Haas M. P53 mutation in acute T cell lymphoblastic leukemia is of somatic origin and is stable during establishment of T cell acute lymphoblastic leukemia cell lines. J Clin Invest 1993;91:2111-7. [PMID: 8486778 DOI: 10.1172/JCI116435] [Cited by in Crossref: 17] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
141 Haslem DS, Ji HP, Ford JM, Nadauld LD. Precision Oncology Strategy in Trastuzumab-Resistant Human Epidermal Growth Factor Receptor 2-Positive Colon Cancer: Case Report of Durable Response to Ado-Trastuzumab Emtansine. JCO Precis Oncol 2017;1:PO. [PMID: 32913966 DOI: 10.1200/PO.16.00055] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
142 Scheffner M, Werness BA, Huibregtse JM, Levine AJ, Howley PM. The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell. 1990;63:1129-1136. [PMID: 2175676 DOI: 10.1016/0092-8674(90)90409-8] [Cited by in Crossref: 2683] [Cited by in F6Publishing: 2609] [Article Influence: 89.4] [Reference Citation Analysis]
143 Hamilton SR. Molecular genetic alterations as potential prognostic indicators in colorectal carcinoma. Cancer 1992;69:1589-91. [DOI: 10.1002/1097-0142(19920315)69:6+<1589::aid-cncr2820691314>3.0.co;2-a] [Cited by in Crossref: 21] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
144 Vagner-capodano AM, Gentet JC, Gambarelli D, Pellissier JF, Gouzien M, Lena G, Genitori L, Choux M, Raybaud C. Cytogenetic Studies in 45 Pediatric Brain Tumors. Pediatric Hematology and Oncology 2009;9:223-35. [DOI: 10.3109/08880019209016590] [Cited by in Crossref: 45] [Cited by in F6Publishing: 38] [Article Influence: 3.8] [Reference Citation Analysis]
145 Nelson E. Laboratory Probing of Oncogenes from Human Liquid and Solid Specimens as Markers of Exposure to Toxicants. Critical Reviews in Toxicology 2008;26:483-549. [DOI: 10.3109/10408449609037476] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
146 Malkhosyan S, Yasuda J, Soto JL, Sekiya T, Yokota J, Perucho M. Molecular karyotype (amplotype) of metastatic colorectal cancer by unbiased arbitrarily primed PCR DNA fingerprinting. Proc Natl Acad Sci U S A 1998;95:10170-5. [PMID: 9707619 DOI: 10.1073/pnas.95.17.10170] [Cited by in Crossref: 39] [Cited by in F6Publishing: 39] [Article Influence: 1.7] [Reference Citation Analysis]
147 Chen LC, Dollbaum C, Smith HS. Loss of heterozygosity on chromosome 1q in human breast cancer. Proc Natl Acad Sci U S A 1989;86:7204-7. [PMID: 2550934 DOI: 10.1073/pnas.86.18.7204] [Cited by in Crossref: 73] [Cited by in F6Publishing: 73] [Article Influence: 2.3] [Reference Citation Analysis]
148 Knowles DM. Biology of Non-Hodgkin’s Lymphoma. In: Sparano JA, editor. HIV & HTLV-I Associated Malignancies. Boston: Springer US; 2001. pp. 149-200. [DOI: 10.1007/978-1-4615-1601-9_6] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
149 Garitaonandia I, Amir H, Boscolo FS, Wambua GK, Schultheisz HL, Sabatini K, Morey R, Waltz S, Wang YC, Tran H, Leonardo TR, Nazor K, Slavin I, Lynch C, Li Y, Coleman R, Gallego Romero I, Altun G, Reynolds D, Dalton S, Parast M, Loring JF, Laurent LC. Increased risk of genetic and epigenetic instability in human embryonic stem cells associated with specific culture conditions. PLoS One. 2015;10:e0118307. [PMID: 25714340 DOI: 10.1371/journal.pone.0118307] [Cited by in Crossref: 85] [Cited by in F6Publishing: 76] [Article Influence: 14.2] [Reference Citation Analysis]
150 Sakata K. Alterations of tumor suppressor genes and the H-ras oncogene in oral squamous cell carcinoma. J Oral Pathol Med 1996;25:302-7. [DOI: 10.1111/j.1600-0714.1996.tb00266.x] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 1.1] [Reference Citation Analysis]
151 Murata T, Nagasaka T, Kamiya J, Nimura Y, Wakai K, Yoshida K, Nakashima N. p53 labeling index in cholangioscopic biopsies is useful for determining spread of bile duct carcinomas. Gastrointestinal Endoscopy 2002;56:688-95. [DOI: 10.1016/s0016-5107(02)70118-1] [Cited by in Crossref: 8] [Article Influence: 0.4] [Reference Citation Analysis]
152 Fujimori T, Satonaka K, Yamamura-Idei Y, Nagasako K, Maeda S. Non-involvement of ras mutations in flat colorectal adenomas and carcinomas. Int J Cancer. 1994;57:51-55. [PMID: 8150541 DOI: 10.1002/ijc.2910570110] [Cited by in Crossref: 88] [Cited by in F6Publishing: 79] [Article Influence: 3.3] [Reference Citation Analysis]
153 Takayama T, Miyanishi K, Hayashi T, Sato Y, Niitsu Y. Colorectal cancer: genetics of development and metastasis. J Gastroenterol. 2006;41:185-192. [PMID: 16699851 DOI: 10.1007/s00535-006-1801-6] [Cited by in Crossref: 130] [Cited by in F6Publishing: 128] [Article Influence: 8.7] [Reference Citation Analysis]
154 Gandhi N, Das GM. Metabolic Reprogramming in Breast Cancer and Its Therapeutic Implications. Cells 2019;8:E89. [PMID: 30691108 DOI: 10.3390/cells8020089] [Cited by in Crossref: 57] [Cited by in F6Publishing: 54] [Article Influence: 28.5] [Reference Citation Analysis]
155 Almazov VP, Kochetkov DV, Chumakov PM. Use of p53 for therapy of human cancer. Mol Biol 2007;41:863-77. [DOI: 10.1134/s0026893307060015] [Cited by in Crossref: 21] [Article Influence: 1.5] [Reference Citation Analysis]
156 Froggatt NJ, Leveson SH, Garner RC. Low frequency and late occurrence ofp53 anddcc aberrations in colorectal tumours. J Cancer Res Clin Oncol 1995;121:7-15. [DOI: 10.1007/bf01202723] [Cited by in Crossref: 13] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
157 Inoue A, Robinson FS, Minelli R, Tomihara H, Rizi BS, Rose JL, Kodama T, Srinivasan S, Harris AL, Zuniga AM, Mullinax RA, Ma X, Seth S, Daniele JR, Peoples MD, Loponte S, Akdemir KC, Khor TO, Feng N, Roszik J, Sobieski MM, Brunell D, Stephan C, Giuliani V, Deem AK, Shingu T, Deribe YL, Menter DG, Heffernan TP, Viale A, Bristow CA, Kopetz S, Draetta GF, Genovese G, Carugo A. Sequential Administration of XPO1 and ATR Inhibitors Enhances Therapeutic Response in TP53-mutated Colorectal Cancer. Gastroenterology 2021;161:196-210. [PMID: 33745946 DOI: 10.1053/j.gastro.2021.03.022] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
158 Marks JR, Davidoff AM, Iglehart JD. p53 in Human Cancer. In: Garrett CT, Sell S, editors. Cellular Cancer Markers. Totowa: Humana Press; 1995. pp. 77-110. [DOI: 10.1007/978-1-4757-2381-6_4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.0] [Reference Citation Analysis]
159 Howell GM, Sun L, Ziober BL, Wu SP, Brattain MG. The role of growth regulatory aberrations in progression of human colon carcinoma. Cancer Metast Rev 1993;12:275-86. [DOI: 10.1007/bf00665958] [Cited by in Crossref: 12] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
160 Olschwang S, Hamelin R, Laurent-Puig P, Thuille B, De Rycke Y, Li YJ, Muzeau F, Girodet J, Salmon RJ, Thomas G. Alternative genetic pathways in colorectal carcinogenesis. Proc Natl Acad Sci U S A 1997;94:12122-7. [PMID: 9342373 DOI: 10.1073/pnas.94.22.12122] [Cited by in Crossref: 154] [Cited by in F6Publishing: 155] [Article Influence: 6.4] [Reference Citation Analysis]
161 Blagih J, Buck MD, Vousden KH. p53, cancer and the immune response. J Cell Sci 2020;133:jcs237453. [PMID: 32144194 DOI: 10.1242/jcs.237453] [Cited by in Crossref: 51] [Cited by in F6Publishing: 46] [Article Influence: 51.0] [Reference Citation Analysis]
162 Zhou CZ, Peng ZH, Zhang F, Qiu GQ, He L. Loss of heterozygosity on long arm of chromosome 22 in sporadic colorectal carcinoma. World J Gastroenterol 2002; 8(4): 668-673 [PMID: 12174376 DOI: 10.3748/wjg.v8.i4.668] [Cited by in CrossRef: 24] [Cited by in F6Publishing: 27] [Article Influence: 1.3] [Reference Citation Analysis]
163 Foo JB, Saiful Yazan L, Tor YS, Wibowo A, Ismail N, Armania N, Cheah YK, Abdullah R. Dillenia suffruticosa dichloromethane root extract induced apoptosis towards MDA-MB-231 triple-negative breast cancer cells. Journal of Ethnopharmacology 2016;187:195-204. [DOI: 10.1016/j.jep.2016.04.048] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
164 Lin D, Fiscella M, O'Connor PM, Jackman J, Chen M, Luo LL, Sala A, Travali S, Appella E, Mercer WE. Constitutive expression of B-myb can bypass p53-induced Waf1/Cip1-mediated G1 arrest. Proc Natl Acad Sci U S A 1994;91:10079-83. [PMID: 7937841 DOI: 10.1073/pnas.91.21.10079] [Cited by in Crossref: 75] [Cited by in F6Publishing: 81] [Article Influence: 2.8] [Reference Citation Analysis]
165 Finlay GJ. Genetics, molecular biology and colorectal cancer. Mutation Research/Fundamental and Molecular Mechanisms of Mutagenesis 1993;290:3-12. [DOI: 10.1016/0027-5107(93)90027-d] [Cited by in Crossref: 16] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
166 Dolcetti R, Doglioni C, Maestro R, Gasparotto D, Barzan L, Pastore A, Romanelli M, Boiocchi M. p53 over-expression is an early event in the development of human squamous-cell carcinoma of the larynx: Genetic and prognostic implications. Int J Cancer 1992;52:178-82. [DOI: 10.1002/ijc.2910520204] [Cited by in Crossref: 94] [Cited by in F6Publishing: 92] [Article Influence: 3.2] [Reference Citation Analysis]
167 Wachter F, Morgan AM, Godes M, Mourtada R, Bird GH, Walensky LD. Mechanistic validation of a clinical lead stapled peptide that reactivates p53 by dual HDM2 and HDMX targeting. Oncogene 2017;36:2184-90. [PMID: 27721413 DOI: 10.1038/onc.2016.361] [Cited by in Crossref: 24] [Cited by in F6Publishing: 21] [Article Influence: 4.8] [Reference Citation Analysis]
168 Duffy M. Cellular oncogenes and suppressor genes as prognostic markers in cancer. Clinical Biochemistry 1993;26:439-47. [DOI: 10.1016/0009-9120(93)80007-h] [Cited by in Crossref: 28] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
169 Siddiqui SS, Rahman S, Rupasinghe HPV, Vazhappilly CG. Dietary Flavonoids in p53-Mediated Immune Dysfunctions Linking to Cancer Prevention. Biomedicines 2020;8:E286. [PMID: 32823757 DOI: 10.3390/biomedicines8080286] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
170 Turker MS. Somatic cell mutations: can they provide a link between aging and cancer? Mechanisms of Ageing and Development 2000;117:1-19. [DOI: 10.1016/s0047-6374(00)00133-0] [Cited by in Crossref: 27] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
171 Donehower LA, Soussi T, Korkut A, Liu Y, Schultz A, Cardenas M, Li X, Babur O, Hsu TK, Lichtarge O, Weinstein JN, Akbani R, Wheeler DA. Integrated Analysis of TP53 Gene and Pathway Alterations in The Cancer Genome Atlas. Cell Rep 2019;28:1370-1384.e5. [PMID: 31365877 DOI: 10.1016/j.celrep.2019.07.001] [Cited by in Crossref: 111] [Cited by in F6Publishing: 89] [Article Influence: 111.0] [Reference Citation Analysis]
172 Kay NE, Ranheim EA, Peterson LC. Tumor Suppressor Genes and Clonal Evolution in B-CLL. Leukemia & Lymphoma 2009;18:41-9. [DOI: 10.3109/10428199509064921] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
173 Karczmarski J, Goryca K, Pachlewski J, Dabrowska M, Pysniak K, Paziewska A, Kulecka M, Lenarcik M, Mroz A, Mikula M, Ostrowski J. Mutation Profiling of Premalignant Colorectal Neoplasia. Gastroenterol Res Pract 2019;2019:2542640. [PMID: 31781186 DOI: 10.1155/2019/2542640] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
174 Field J. Prognostic Implications of ras Oncogene Expression in Head and Neck Squamous Cell Carcinoma. In: Spandidos DA, editor. The Superfamily of ras-Related Genes. Boston: Springer US; 1992. pp. 213-26. [DOI: 10.1007/978-1-4684-6018-6_24] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
175 Regezi JA, Zarbo RJ, Regev E, Pisanty S, Silverman S, Gazit D. p53 protein expression in sequential biopsies of oral dysplasias and in situ carcinomas. J Oral Pathol Med 1995;24:18-22. [DOI: 10.1111/j.1600-0714.1995.tb01124.x] [Cited by in Crossref: 54] [Cited by in F6Publishing: 50] [Article Influence: 2.1] [Reference Citation Analysis]
176 Johnson P, Gray D, Mowat M, Benchimol S. Expression of wild-type p53 is not compatible with continued growth of p53-negative tumor cells. Mol Cell Biol 1991;11:1-11. [PMID: 1986214 DOI: 10.1128/mcb.11.1.1-11.1991] [Cited by in F6Publishing: 26] [Reference Citation Analysis]
177 O'brian CA, Ward NE, loannides CG. Altered Signal Transduction in Carcinogenesis1. Biology of the Cancer Cell. Elsevier; 1993. pp. 61-88. [DOI: 10.1016/s1569-2558(08)60235-0] [Cited by in Crossref: 3] [Article Influence: 0.1] [Reference Citation Analysis]
178 Presnell SC, Thompson MT, Strom SC. Investigation of the cooperative effects of transforming growth factor α and c-myc overexpression in rat liver epithelial cells. Mol Carcinog 1995;13:233-44. [DOI: 10.1002/mc.2940130406] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 0.4] [Reference Citation Analysis]
179 Fagin JA. Tumor suppressor genes in human thyroid neoplasms: p53 mutations are associated undifferentiated thyroid cancers. J Endocrinol Invest 1995;18:140-2. [PMID: 7629382 DOI: 10.1007/BF03349723] [Cited by in Crossref: 30] [Cited by in F6Publishing: 8] [Article Influence: 1.2] [Reference Citation Analysis]
180 Barnetson R, Eckstein R, Robinson B, Schnitzler M. There is no increase in frequency of somatic mutations in metastases compared with primary colorectal carcinomas with microsatellite instability. Genes Chromosom Cancer 2003;38:149-56. [DOI: 10.1002/gcc.10262] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.3] [Reference Citation Analysis]
181 Fujiwara T, Mukhopadhyay T, Cai DW, Morris DK, Roth JA, Grimm EA. Retroviral-mediated transduction of p53 gene increases TGF-beta expression in a human glioblastoma cell line. Int J Cancer 1994;56:834-9. [PMID: 8119773 DOI: 10.1002/ijc.2910560614] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 0.7] [Reference Citation Analysis]
182 Felley-Bosco E, Pourzand C, Zijlstra J, Amstad P, Cerutti P. A genotypic mutation system measuring mutations in restriction recognition sequences. Nucleic Acids Res 1991;19:2913-9. [PMID: 1676153 DOI: 10.1093/nar/19.11.2913] [Cited by in Crossref: 41] [Cited by in F6Publishing: 39] [Article Influence: 1.4] [Reference Citation Analysis]
183 Miki Y, Nishisho I, Nakamura Y, Miyoshi Y, Utsunomiya J. Interstitial loss of the same region of 5q in multiple adenomas and a carcinoma derived from an adenomatous polyposis coli (apc) patient. Genes Chromosom Cancer 1992;4:81-3. [DOI: 10.1002/gcc.2870040112] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.3] [Reference Citation Analysis]
184 Sadot E, Geiger B, Oren M, Ben-Ze'ev A. Down-regulation of beta-catenin by activated p53. Mol Cell Biol. 2001;21:6768-6781. [PMID: 11564862 DOI: 10.1128/MCB.21.20.6768-6781.2001] [Cited by in Crossref: 149] [Cited by in F6Publishing: 72] [Article Influence: 7.5] [Reference Citation Analysis]
185 Solomon E. Colorectal cancer genes. Nature 1990;343:412-3. [DOI: 10.1038/343412a0] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 0.9] [Reference Citation Analysis]
186 Monti P, Menichini P, Speciale A, Cutrona G, Fais F, Taiana E, Neri A, Bomben R, Gentile M, Gattei V, Ferrarini M, Morabito F, Fronza G. Heterogeneity of TP53 Mutations and P53 Protein Residual Function in Cancer: Does It Matter? Front Oncol 2020;10:593383. [PMID: 33194757 DOI: 10.3389/fonc.2020.593383] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
187 Frank JL, Bur ME, Garb JL, Kay S, Ware JL, Sismanis A, Neifeld JP. p53 tumor suppressor oncogene expression in squamous cell carcinoma of the hypopharynx. Cancer 1994;73:181-6. [PMID: 8275422 DOI: 10.1002/1097-0142(19940101)73:1<181::aid-cncr2820730131>3.0.co;2-3] [Cited by in Crossref: 39] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
188 Wazer DE, Chu Q, Liu XL, Gao Q, Safaii H, Band V. Loss of p53 protein during radiation transformation of primary human mammary epithelial cells. Mol Cell Biol 1994;14:2468-78. [PMID: 7511207 DOI: 10.1128/mcb.14.4.2468-2478.1994] [Cited by in Crossref: 52] [Cited by in F6Publishing: 1] [Article Influence: 1.9] [Reference Citation Analysis]
189 Thompson AM, Steel CM, Chetty U, Hawkins RA, Miller WR, Carter DC, Forrest AP, Evans HJ. p53 gene mRNA expression and chromosome 17p allele loss in breast cancer. Br J Cancer 1990;61:74-8. [PMID: 2137009 DOI: 10.1038/bjc.1990.17] [Cited by in Crossref: 80] [Cited by in F6Publishing: 90] [Article Influence: 2.6] [Reference Citation Analysis]
190 Weiss J, Heine M, Arden KC, Körner B, Pilch H, Herbst RA, Jung EG. Mutation and Expression of TP53 in Malignant Melanomas. In: Garbe C, Schmitz S, Orfanos CE, editors. Skin Cancer: Basic Science, Clinical Research and Treatment. Berlin: Springer Berlin Heidelberg; 1995. pp. 137-54. [DOI: 10.1007/978-3-642-78771-3_10] [Cited by in Crossref: 29] [Cited by in F6Publishing: 27] [Article Influence: 1.1] [Reference Citation Analysis]
191 Węsierska-gądek J. Targeting p53 as a promising therapeutic option for cancer by re-activating the wt or mutant p53’s tumor suppression. Future Medicinal Chemistry 2018;10:755-77. [DOI: 10.4155/fmc-2017-0175] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
192 Kern SE, Kinzler KW, Bruskin A, Jarosz D, Friedman P, Prives C, Vogelstein B. Identification of p53 as a sequence-specific DNA-binding protein. Science. 1991;252:1708-1711. [PMID: 2047879 DOI: 10.1126/science.2047879] [Cited by in Crossref: 674] [Cited by in F6Publishing: 699] [Article Influence: 22.5] [Reference Citation Analysis]
193 Della Ragione F, Oliva A, Palumbo R, Russo GL, Zappia V. Enzyme Deficiency and Tumor Suppressor Genes: Absence of 5’-Deoxy-5’-Methylthioadenosine Phosphorylase in Human Tumors. In: Zappia V, Salvatore M, Della Ragione F, editors. Advances in Nutrition and Cancer. Boston: Springer US; 1993. pp. 31-43. [DOI: 10.1007/978-1-4615-2942-2_3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.1] [Reference Citation Analysis]
194 Baker SJ, Vogelstein B. p53: a tumor suppressor hiding in plain sight. J Mol Cell Biol 2019;11:536-8. [PMID: 31276589 DOI: 10.1093/jmcb/mjz068] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
195 Shaulsky G, Goldfinger N, Ben-Ze'ev A, Rotter V. Nuclear accumulation of p53 protein is mediated by several nuclear localization signals and plays a role in tumorigenesis. Mol Cell Biol 1990;10:6565-77. [PMID: 2247074 DOI: 10.1128/mcb.10.12.6565-6577.1990] [Cited by in Crossref: 4] [Cited by in F6Publishing: 93] [Article Influence: 0.1] [Reference Citation Analysis]
196 Bois FY, Compton-Quintana PJ. Sensitivity analysis of a new model of carcinogenesis. J Theor Biol 1992;159:361-75. [PMID: 1296096 DOI: 10.1016/s0022-5193(05)80730-1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
197 Mitchell C. Multistage carcinogenesis in paediatric and adult cancers. European Journal of Cancer 1992;28:296-8. [DOI: 10.1016/0959-8049(92)90438-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
198 Cristobal A, van den Toorn HWP, van de Wetering M, Clevers H, Heck AJR, Mohammed S. Personalized Proteome Profiles of Healthy and Tumor Human Colon Organoids Reveal Both Individual Diversity and Basic Features of Colorectal Cancer. Cell Rep 2017;18:263-74. [PMID: 28052255 DOI: 10.1016/j.celrep.2016.12.016] [Cited by in Crossref: 80] [Cited by in F6Publishing: 75] [Article Influence: 20.0] [Reference Citation Analysis]
199 Kawasaki T, Tomita Y, Watanabe R, Tanikawa T, Kumanishi T, Sato S. mRNA and protein expression of p53 mutations in human bladder cancer cell lines. Cancer Letters 1994;82:113-21. [DOI: 10.1016/0304-3835(94)90154-6] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 0.7] [Reference Citation Analysis]
200 Bischoff JR, Casso D, Beach D. Human p53 inhibits growth in Schizosaccharomyces pombe. Mol Cell Biol 1992;12:1405-11. [PMID: 1549103 DOI: 10.1128/mcb.12.4.1405-1411.1992] [Cited by in F6Publishing: 27] [Reference Citation Analysis]
201 Braun P, Gingras A. History of protein-protein interactions: From egg-white to complex networks. Proteomics 2012;12:1478-98. [DOI: 10.1002/pmic.201100563] [Cited by in Crossref: 124] [Cited by in F6Publishing: 102] [Article Influence: 13.8] [Reference Citation Analysis]
202 Knowles MA, Eydmann ME. Loss of a tumor suppressor function during neoplastic progression of epithelial cells in vitro. Int J Cancer 1991;47:726-31. [PMID: 2004853 DOI: 10.1002/ijc.2910470517] [Reference Citation Analysis]
203 Martens UM, Zijlmans JJ, Poon SS, Dragowska W, Yui J, Chavez EA, Ward RK, Lansdorp PM. Short telomeres on human chromosome 17p. Nat Genet 1998;18:76-80. [DOI: 10.1038/ng0198-018] [Cited by in Crossref: 106] [Cited by in F6Publishing: 139] [Article Influence: 4.6] [Reference Citation Analysis]
204 Weston A, Godbold JH. Polymorphisms of H-ras-1 and p53 in breast cancer and lung cancer: a meta-analysis. Environ Health Perspect 1997;105 Suppl 4:919-26. [PMID: 9255581 DOI: 10.1289/ehp.97105s4919] [Cited by in Crossref: 43] [Cited by in F6Publishing: 42] [Article Influence: 1.8] [Reference Citation Analysis]
205 Wen JG, van Steenbrugge GJ, Egeler RM, Nijman RM. Progress of fundamental research in Wilms' tumor. Urol Res 1997;25:223-30. [DOI: 10.1007/bf00942090] [Cited by in Crossref: 15] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
206 Finlay CA. Normal and malignant growth control by p53. In: Benz CC, Liu ET, editors. Oncogenes and Tumor Suppressor Genes in Human Malignancies. Boston: Springer US; 1993. pp. 327-44. [DOI: 10.1007/978-1-4615-3088-6_17] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.3] [Reference Citation Analysis]
207 Carroll SL, Roth KA, Gordon JI. Liver fatty acid-binding protein: a marker for studying cellular differentiation in gut epithelial neoplasms. Gastroenterology 1990;99:1727-35. [PMID: 1699834 DOI: 10.1016/0016-5085(90)90480-o] [Cited by in Crossref: 14] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
208 Weisz L, Oren M, Rotter V. Transcription regulation by mutant p53. Oncogene. 2007;26:2202-2211. [PMID: 17401429 DOI: 10.1038/sj.onc.1210294] [Cited by in Crossref: 135] [Cited by in F6Publishing: 133] [Article Influence: 9.6] [Reference Citation Analysis]
209 Hann BC, Lane DP. The dominating effect of mutant p53. Nat Genet 1995;9:221-2. [DOI: 10.1038/ng0395-221] [Cited by in Crossref: 35] [Cited by in F6Publishing: 34] [Article Influence: 1.3] [Reference Citation Analysis]
210 Subler MA, Martin DW, Deb S. Inhibition of viral and cellular promoters by human wild-type p53. J Virol 1992;66:4757-62. [PMID: 1352831 DOI: 10.1128/JVI.66.8.4757-4762.1992] [Cited by in Crossref: 119] [Cited by in F6Publishing: 51] [Article Influence: 4.1] [Reference Citation Analysis]
211 Wright E, Goldgar D, Fain P, Barker D, Skolnick M. A genetic map of human chromosome 17p. Genomics 1990;7:103-9. [DOI: 10.1016/0888-7543(90)90524-x] [Cited by in Crossref: 46] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
212 Gao XQ, Han JX, Xu ZF, Zhang WD, Zhang HN, Huang HY. Identification of the differential expressive tumor associated genes in rectal cancers by cDNA microarray. World J Gastroenterol 2007; 13(3): 341-348 [PMID: 17230600 DOI: 10.3748/wjg.v13.i3.341] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
213 Cartwright CA, Coad CA, Egbert BM. Elevated c-Src tyrosine kinase activity in premalignant epithelia of ulcerative colitis. J Clin Invest 1994;93:509-15. [PMID: 7509341 DOI: 10.1172/JCI117000] [Cited by in Crossref: 99] [Cited by in F6Publishing: 24] [Article Influence: 3.7] [Reference Citation Analysis]
214 Goyette MC, Cho K, Fasching CL, Levy DB, Kinzler KW, Paraskeva C, Vogelstein B, Stanbridge EJ. Progression of colorectal cancer is associated with multiple tumor suppressor gene defects but inhibition of tumorigenicity is accomplished by correction of any single defect via chromosome transfer. Mol Cell Biol 1992;12:1387-95. [PMID: 1347643 DOI: 10.1128/mcb.12.3.1387-1395.1992] [Cited by in F6Publishing: 39] [Reference Citation Analysis]
215 Spruck CH, Rideout WM, Jones PA. DNA Methylation and cancer. In: Jost J, Saluz H, editors. DNA Methylation. Basel: Birkhäuser; 1993. pp. 487-509. [DOI: 10.1007/978-3-0348-9118-9_22] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 0.3] [Reference Citation Analysis]
216 Leone G, Maybaum L, Lee PW. The reovirus cell attachment protein possesses two independently active trimerization domains: Basis of dominant negative effects. Cell 1992;71:479-88. [DOI: 10.1016/0092-8674(92)90516-f] [Cited by in Crossref: 31] [Cited by in F6Publishing: 11] [Article Influence: 1.1] [Reference Citation Analysis]
217 Carducci MA, Simons JW. Renal, bladder, and prostate cancers: gene therapy. In: Pienta KJ, editor. Diagnosis and Treatment of Genitourinary Malignancies. Boston: Springer US; 1997. pp. 219-34. [DOI: 10.1007/978-1-4615-6343-3_14] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
218 Greenstein R, Ybanez M, Zhang R, Bauman W. Is aging preprogrammed? Observations from the brain/gut axis. Mechanisms of Ageing and Development 1991;61:113-21. [DOI: 10.1016/0047-6374(91)90010-w] [Cited by in Crossref: 7] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
219 Klemi PJ, Pylkkänen L, Kiilholma P, Kurvinen K, Joensuu H. p53 protein detected by immunohistochemistry as a prognostic factor in patients with epithelial ovarian carcinoma. Cancer 1995;76:1201-8. [PMID: 8630898 DOI: 10.1002/1097-0142(19951001)76:7<1201::aid-cncr2820760716>3.0.co;2-l] [Cited by in Crossref: 82] [Cited by in F6Publishing: 17] [Article Influence: 3.3] [Reference Citation Analysis]
220 Ro Y, Cooper P, Lee J, Quinn A, Harrison D, Lane D, Hornh C, Rees J, Angus B. p53 protein expression in benign and malignant skin tumours. Br J Dermatol 1993;128:237-41. [DOI: 10.1111/j.1365-2133.1993.tb00164.x] [Cited by in Crossref: 72] [Cited by in F6Publishing: 70] [Article Influence: 2.6] [Reference Citation Analysis]
221 Lazo de la Vega L, Bick N, Hu K, Rahrig SE, Silva CD, Matayoshi S, Picciarelli P, Wang X, Sugar A, Soong HK, Mian SI, Robinson DR, Chinnaiyan AM, Demirci H, Daniels AB, Worden F, Eberhart CG, Tomlins SA, Rao RC, Harms PW. Invasive squamous cell carcinomas and precursor lesions on UV-exposed epithelia demonstrate concordant genomic complexity in driver genes. Mod Pathol 2020;33:2280-94. [PMID: 32461624 DOI: 10.1038/s41379-020-0571-7] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
222 Chen S, Wei HM, Lv WW, Wang DL, Sun FL. E2 ligase dRad6 regulates DMP53 turnover in Drosophila. J Biol Chem 2011;286:9020-30. [PMID: 21205821 DOI: 10.1074/jbc.M110.190314] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 1.3] [Reference Citation Analysis]
223 Kehoe J, Khatri VP. Staging and prognosis of colon cancer. Surg Oncol Clin N Am. 2006;15:129-146. [PMID: 16389154 DOI: 10.1016/j.soc.2005.08.006] [Cited by in Crossref: 35] [Cited by in F6Publishing: 30] [Article Influence: 2.3] [Reference Citation Analysis]
224 Levine AJ, Hu W, Feng Z. Tumor Suppressor Genes. The Molecular Basis of Cancer. Elsevier; 2008. pp. 31-8. [DOI: 10.1016/b978-141603703-3.10003-2] [Cited by in Crossref: 4] [Article Influence: 0.3] [Reference Citation Analysis]
225 Rhyu M, Park W, Jung Y, Choi S, Meltzer SJ. Allelic deletions of MCC/APC and p53 are frequent late events in human gastric carcinogenesis. Gastroenterology 1994;106:1584-8. [DOI: 10.1016/0016-5085(94)90414-6] [Cited by in Crossref: 65] [Cited by in F6Publishing: 55] [Article Influence: 2.4] [Reference Citation Analysis]
226 Merino D, Malkin D. p53 and Hereditary Cancer. In: Deb SP, Deb S, editors. Mutant p53 and MDM2 in Cancer. Dordrecht: Springer Netherlands; 2014. pp. 1-16. [DOI: 10.1007/978-94-017-9211-0_1] [Cited by in Crossref: 26] [Cited by in F6Publishing: 20] [Article Influence: 3.7] [Reference Citation Analysis]
227 Cizdziel PE, Hosoi J, Montgomery JC, Wiseman RW, Barrett JC. Loss of a tumor suppressor gene function is correlated with downregulation of chondrocyte-specific collagen expression in syrian hamster embryo cells. Mol Carcinog 1991;4:14-24. [DOI: 10.1002/mc.2940040105] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 0.5] [Reference Citation Analysis]
228 Kurtkaya-yapıcıer Ö, Scheithauer BW, Hebrink D, James CD. p53 in Nonneoplastic Central Nervous System Lesions: An Immunohistochemical and Genetic Sequencing Study. Neurosurgery 2002;51:1246-55. [DOI: 10.1097/00006123-200211000-00021] [Cited by in Crossref: 26] [Cited by in F6Publishing: 22] [Article Influence: 1.4] [Reference Citation Analysis]
229 Wu CE, Pan YR, Yeh CN, Lunec J. Targeting P53 as a Future Strategy to Overcome Gemcitabine Resistance in Biliary Tract Cancers. Biomolecules 2020;10:E1474. [PMID: 33113997 DOI: 10.3390/biom10111474] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
230 Kadioglu O, Saeed M, Mahmoud N, Azawi S, Mrasek K, Liehr T, Efferth T. Identification of potential novel drug resistance mechanisms by genomic and transcriptomic profiling of colon cancer cells with p53 deletion. Arch Toxicol 2021;95:959-74. [PMID: 33515271 DOI: 10.1007/s00204-021-02979-4] [Reference Citation Analysis]
231 Biyani DK, Skordilis K, Watson AJ. Mixed hyperplastic/adenomatous polyps--a collision. Colorectal Dis 2008;10:96-8. [PMID: 17441967 DOI: 10.1111/j.1463-1318.2007.01272.x] [Reference Citation Analysis]
232 Unger T, Mietz JA, Scheffner M, Yee CL, Howley PM. Functional domains of wild-type and mutant p53 proteins involved in transcriptional regulation, transdominant inhibition, and transformation suppression. Mol Cell Biol 1993;13:5186-94. [PMID: 8355677 DOI: 10.1128/mcb.13.9.5186-5194.1993] [Cited by in Crossref: 65] [Article Influence: 2.3] [Reference Citation Analysis]
233 Bennett MA, Kay EW, Mulcahy H, O'flaherty L, O'donoghue DP, Leader M, Croke DT. ras and p53 in the prediction of survival in Dukes' stage B colorectal carcinoma. Clin Mol Pathol 1995;48:M310-5. [PMID: 16696029 DOI: 10.1136/mp.48.6.m310] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
234 Raycroft L, Schmidt JR, Yoas K, Hao MM, Lozano G. Analysis of p53 mutants for transcriptional activity. Mol Cell Biol 1991;11:6067-74. [PMID: 1944276 DOI: 10.1128/mcb.11.12.6067-6074.1991] [Cited by in Crossref: 45] [Article Influence: 1.5] [Reference Citation Analysis]
235 Shimaya K, Shiozaki H, Inoue M, Tahara H, Monden T, Shimano T, Mori T. Significance of p53 expression as a prognostic factor in oesophageal squamous cell carcinoma. Vichows Archiv A Pathol Anat 1993;422:271-6. [DOI: 10.1007/bf01608335] [Cited by in Crossref: 61] [Cited by in F6Publishing: 12] [Article Influence: 2.2] [Reference Citation Analysis]
236 Høyheim B, Nakamura Y, White R. A BamHI-polymorphism is detected by a genomic p53-clone (pBHP53). Nucleic Acids Res 1989;17:8898. [PMID: 2573883 DOI: 10.1093/nar/17.21.8898] [Cited by in Crossref: 15] [Cited by in F6Publishing: 20] [Article Influence: 0.5] [Reference Citation Analysis]
237 Suzuki T, Takano Y. Comparative immunohistochemical studies of p53 and proliferating cell nuclear antigen expression and argyrophilic nucleolar organizer regions in pancreatic duct cell carcinomas. Jpn J Cancer Res 1993;84:1072-7. [PMID: 7901190 DOI: 10.1111/j.1349-7006.1993.tb02803.x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 0.5] [Reference Citation Analysis]
238 Nakamori S, Ota DM, Cleary KR, Shirotani K, Irimura T. MUC1 mucin expression as a marker of progression and metastasis of human colorectal carcinoma. Gastroenterology. 1994;106:353-361. [PMID: 7905449 DOI: 10.1016/0016-5085(94)90592-4] [Cited by in Crossref: 179] [Cited by in F6Publishing: 192] [Article Influence: 6.6] [Reference Citation Analysis]
239 Bergel M, Hochman J, Siwarski D, Huppi K, Bhatia K, Gutierrez M. Association of tumorigenic and nontumorigenic (immunogenic) variants in a mouse t-cell lymphoma with two distinctp53 mutations. Mol Carcinog 1993;8:221-7. [DOI: 10.1002/mc.2940080404] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.1] [Reference Citation Analysis]
240 Francis JM, Zhang CZ, Maire CL, Jung J, Manzo VE, Adalsteinsson VA, Homer H, Haidar S, Blumenstiel B, Pedamallu CS. EGFR variant heterogeneity in glioblastoma resolved through single-nucleus sequencing. Cancer Discov. 2014;4:956-971. [PMID: 24893890 DOI: 10.1158/2159-8290.cd-13-0879] [Cited by in Crossref: 172] [Cited by in F6Publishing: 114] [Article Influence: 24.6] [Reference Citation Analysis]
241 Younes M, Riley S, Genta RM, Mosharaf M, Mody DR. p53 protein accumulation in tumors of the ampulla of Vater. Cancer 1995;76:1150-4. [DOI: 10.1002/1097-0142(19951001)76:7<1150::aid-cncr2820760709>3.0.co;2-e] [Cited by in Crossref: 26] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
242 Ried T, Heselmeyer-Haddad K, Blegen H, Schröck E, Auer G. Genomic changes defining the genesis, progression, and malignancy potential in solid human tumors: a phenotype/genotype correlation. Genes Chromosomes Cancer 1999;25:195-204. [PMID: 10379865 DOI: 10.1002/(sici)1098-2264(199907)25:3<195::aid-gcc1>3.0.co;2-8] [Cited by in Crossref: 179] [Cited by in F6Publishing: 73] [Article Influence: 8.1] [Reference Citation Analysis]
243 Lozano G. The Enigma of p53. Cold Spring Harb Symp Quant Biol 2016;81:37-40. [PMID: 27932563 DOI: 10.1101/sqb.2016.81.031062] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
244 Imamura T, Arima T, Kato H, Miyamoto S, Sasazuki T, Wake N. Chromosomal deletions and K-ras gene mutations in human endometrial carcinomas. Int J Cancer 1992;51:47-52. [DOI: 10.1002/ijc.2910510110] [Cited by in Crossref: 53] [Cited by in F6Publishing: 52] [Article Influence: 1.8] [Reference Citation Analysis]
245 Augenlicht LH, Heerdt BG. Colonic Carcinoma: A Common Tumor with Multiple Genomic Abnormalities. Biochemical and Molecular Aspects of Selected Cancers. Elsevier; 1994. pp. 47-91. [DOI: 10.1016/b978-0-12-564499-0.50007-9] [Cited by in Crossref: 3] [Article Influence: 0.1] [Reference Citation Analysis]
246 Isermann T, Şener ÖÇ, Stender A, Klemke L, Winkler N, Neesse A, Li J, Wegwitz F, Moll UM, Schulz-Heddergott R. Suppression of HSF1 activity by wildtype p53 creates a driving force for p53 loss-of-heterozygosity. Nat Commun 2021;12:4019. [PMID: 34188043 DOI: 10.1038/s41467-021-24064-1] [Reference Citation Analysis]
247 Sengstag C. The Role of Mitotic Recombination in Carcinogenesis. Critical Reviews in Toxicology 2008;24:323-53. [DOI: 10.3109/10408449409017922] [Cited by in Crossref: 59] [Cited by in F6Publishing: 56] [Article Influence: 4.5] [Reference Citation Analysis]
248 Kuroyanagi N, Machida J, Sakuma H, Miyabe S, Hashimoto O, Yokoi M, Warnakulasuriya S, Nagao T, Shimozato K. p53 mutations in keratocystic odontogenic tumour. Oral Surgery 2009;2:64-70. [DOI: 10.1111/j.1752-248x.2009.01048.x] [Cited by in Crossref: 2] [Article Influence: 0.2] [Reference Citation Analysis]
249 Sullivan KD, Gallant-Behm CL, Henry RE, Fraikin JL, Espinosa JM. The p53 circuit board. Biochim Biophys Acta 2012;1825:229-44. [PMID: 22333261 DOI: 10.1016/j.bbcan.2012.01.004] [Cited by in Crossref: 14] [Cited by in F6Publishing: 49] [Article Influence: 1.6] [Reference Citation Analysis]
250 Sato Y, Tsurumi T. Genome guardian p53 and viral infections. Rev Med Virol 2013;23:213-20. [PMID: 23255396 DOI: 10.1002/rmv.1738] [Cited by in Crossref: 50] [Cited by in F6Publishing: 48] [Article Influence: 5.6] [Reference Citation Analysis]
251 Offerhaus GA, De Feyter EP, Cornelisse CJ, Tersmette KW, Floyd J, Kern SE, Vogelstein B, Hamilton SR. The relationship of DNA aneuploidy to molecular genetic alterations in colorectal carcinoma. Gastroenterology 1992;102:1612-9. [DOI: 10.1016/0016-5085(92)91721-f] [Cited by in Crossref: 76] [Cited by in F6Publishing: 11] [Article Influence: 2.6] [Reference Citation Analysis]
252 Nakamura T, Yana I, Kobayashi T, Shin E, Karakawa K, Fujita S, Miya A, Mori T, Nishisho I, Takai S. p53 gene mutations associated with anaplastic transformation of human thyroid carcinomas. Jpn J Cancer Res 1992;83:1293-8. [PMID: 1483945 DOI: 10.1111/j.1349-7006.1992.tb02761.x] [Cited by in Crossref: 93] [Cited by in F6Publishing: 80] [Article Influence: 3.3] [Reference Citation Analysis]
253 Wazer DE, Chu Q, Liu XL, Gao Q, Safaii H, Band V. Loss of p53 protein during radiation transformation of primary human mammary epithelial cells. Mol Cell Biol 1994;14:2468-78. [PMID: 7511207 DOI: 10.1128/mcb.14.4.2468-2478.1994] [Cited by in F6Publishing: 14] [Reference Citation Analysis]
254 Cerda SR, Mustafi R, Little H, Cohen G, Khare S, Moore C, Majumder P, Bissonnette M. Protein kinase C delta inhibits Caco-2 cell proliferation by selective changes in cell cycle and cell death regulators. Oncogene 2006;25:3123-38. [PMID: 16434969 DOI: 10.1038/sj.onc.1209360] [Cited by in Crossref: 40] [Cited by in F6Publishing: 35] [Article Influence: 2.7] [Reference Citation Analysis]
255 Fujiwara Y, Ohata H, Emi M, Okui K, Koyama K, Tsuchiya E, Nakajima T, Monden M, Mori T, Kurimasa A. A 3-Mb physical map of the chromosome region 8p21.3-p22, including a 600-kb region commonly deleted in human hepatocellular carcinoma, colorectal cancer, and non-small cell lung cancer. Genes Chromosomes Cancer. 1994;10:7-14. [PMID: 7519877 DOI: 10.1002/gcc.2870100103] [Cited by in Crossref: 55] [Cited by in F6Publishing: 55] [Article Influence: 2.0] [Reference Citation Analysis]
256 Kemp CJ, Donehower LA, Bradley A, Balmain A. Reduction of p53 gene dosage does not increase initiation or promotion but enhances malignant progression of chemically induced skin tumors. Cell 1993;74:813-22. [PMID: 8374952 DOI: 10.1016/0092-8674(93)90461-x] [Cited by in Crossref: 318] [Cited by in F6Publishing: 119] [Article Influence: 11.4] [Reference Citation Analysis]
257 Wang L, Li L, Zhou HY, Gao XK, Li SJ. t(13q;17p) and del(5q): Possibly specific changes in Chinese patients with colorectal cancers. Cancer Genetics and Cytogenetics 1992;62:191-6. [DOI: 10.1016/0165-4608(92)90261-6] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.2] [Reference Citation Analysis]
258 Hisamuddin IM, Yang VW. Molecular Genetics of Colorectal Cancer: An Overview. Curr Colorectal Cancer Rep 2006;2:53-9. [PMID: 19079560 DOI: 10.1007/s11888-006-0002-2] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 1.1] [Reference Citation Analysis]
259 Nakopoulou L, Constantinides C, Papandropoulos J, Theodoropoulos G, Tzonou A, Giannopoulos A, Zervas A, Dimopoulos C. Evaluation of overexpression of p53 tumor suppressor protein in superficial and invasive transitional cell bladder cancer: Comparison with dna ploidy. Urology 1995;46:334-40. [DOI: 10.1016/s0090-4295(99)80216-7] [Cited by in Crossref: 30] [Cited by in F6Publishing: 1] [Article Influence: 1.2] [Reference Citation Analysis]
260 Quirke P. The molecular revolution--coming your way soon. Gut 1992;33:1-3. [PMID: 1740263 DOI: 10.1136/gut.33.1.1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.0] [Reference Citation Analysis]
261 D'Emilia JC, Rodriguez-Bigas MA, Petrelli NJ. The clinical and genetic manifestations of hereditary nonpolyposis colorectal carcinoma. Am J Surg. 1995;169:368-372. [PMID: 7879846 DOI: 10.1016/s0002-9610(99)80178-0] [Cited by in Crossref: 14] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
262 Neuman WL, Wasylyshyn ML, Jacoby R, Erroi F, Angriman I, Montag A, Brasitus T, Michelassi F, Westbrook CA. Evidence for a common molecular pathogenesis in colorectal, gastric, and pancreatic cancer. Genes Chromosomes Cancer. 1991;3:468-473. [PMID: 1663781 DOI: 10.1002/gcc.2870030609] [Cited by in Crossref: 32] [Cited by in F6Publishing: 33] [Article Influence: 1.1] [Reference Citation Analysis]
263 Tahara E. Growth factors and oncogenes in human gastrointestinal carcinomas. J Cancer Res Clin Oncol 1990;116:121-31. [DOI: 10.1007/bf01612665] [Cited by in Crossref: 127] [Cited by in F6Publishing: 39] [Article Influence: 4.1] [Reference Citation Analysis]
264 Crook T, Wrede D, Tidy J, Vousden K, Wrede D, Tidy J, Mason W, Evans D. Clonal p53 mutation in primary cervical cancer: association with human-papillomavirus-negative tumours. The Lancet 1992;339:1070-3. [DOI: 10.1016/0140-6736(92)90662-m] [Cited by in Crossref: 210] [Cited by in F6Publishing: 50] [Article Influence: 7.2] [Reference Citation Analysis]
265 Pierceall WE, Mukhopadhyay T, Goldberg LH, Ananthaswamy HN. Mutations in the p53 tumor suppressor gene in human cutaneous squamous cell carcinomas. Mol Carcinog 1991;4:445-9. [PMID: 1793482 DOI: 10.1002/mc.2940040606] [Cited by in Crossref: 87] [Cited by in F6Publishing: 80] [Article Influence: 3.0] [Reference Citation Analysis]
266 Effert P, McCoy R, Abdel-Hamid M, Flynn K, Zhang Q, Busson P, Tursz T, Liu E, Raab-Traub N. Alterations of the p53 gene in nasopharyngeal carcinoma. J Virol 1992;66:3768-75. [PMID: 1349927 DOI: 10.1128/JVI.66.6.3768-3775.1992] [Cited by in Crossref: 99] [Cited by in F6Publishing: 21] [Article Influence: 3.4] [Reference Citation Analysis]
267 Park S, Kang Y, Kim B, Lee S, Lee E, Lee K, Park K, Lee J. Loss of heterozygosity on the short arm of chromosome 17 in uterine cervical carcinomas. Cancer Genetics and Cytogenetics 1995;79:74-8. [DOI: 10.1016/0165-4608(94)00103-i] [Cited by in Crossref: 16] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
268 U HS, Banaie A, Rigby L, Chen J, Meltzer H. Alteration in p53 modulates glial proteins in human glial tumour cells. J Neurooncol 2000;48:191-206. [PMID: 11100817 DOI: 10.1023/a:1006453316656] [Cited by in Crossref: 2] [Article Influence: 0.1] [Reference Citation Analysis]
269 Smith DR, Ji CY, Goh HS. Prognostic significance of p53 overexpression and mutation in colorectal adenocarcinomas. Br J Cancer 1996;74:216-23. [PMID: 8688324 DOI: 10.1038/bjc.1996.340] [Cited by in Crossref: 58] [Cited by in F6Publishing: 57] [Article Influence: 2.3] [Reference Citation Analysis]
270 Zhuang XQ, Yuan SZ, Wang XH, Lai RQ, Luo ZQ. Oncoprotein expression and inhibition of apoptosis during colorectal tumorigenesis. World J Gastroenterol 1996; 2(1): 3-5 [DOI: 10.3748/wjg.v2.i1.3] [Reference Citation Analysis]
271 Lilleberg SL, Cabonce MA, Raju NR, Wagner LM, Kier LD. Alterations in the structural gene and the expression ofp53 in rat liver tumors induced by aflatoxin B1. Mol Carcinog 1992;6:159-72. [DOI: 10.1002/mc.2940060211] [Cited by in Crossref: 26] [Cited by in F6Publishing: 21] [Article Influence: 0.9] [Reference Citation Analysis]
272 Sun S, Klebaner F, Tian T. A new model of time scheme for progression of colorectal cancer. BMC Syst Biol 2014;8 Suppl 3:S2. [PMID: 25350788 DOI: 10.1186/1752-0509-8-S3-S2] [Cited by in Crossref: 15] [Cited by in F6Publishing: 8] [Article Influence: 2.1] [Reference Citation Analysis]
273 Klaus A, Birchmeier W. Wnt signalling and its impact on development and cancer. Nat Rev Cancer. 2008;8:387-398. [PMID: 18432252 DOI: 10.1038/nrc2389] [Cited by in Crossref: 1052] [Cited by in F6Publishing: 1015] [Article Influence: 80.9] [Reference Citation Analysis]
274 Nishida T, Nakao K, Hamaji M, Nakahara MA, Tsujimoto M. Overexpression of p53 protein and DNA content are important biologic prognostic factors for thyroid cancer. Surgery 1996;119:568-75. [PMID: 8619214 DOI: 10.1016/s0039-6060(96)80269-8] [Cited by in Crossref: 23] [Cited by in F6Publishing: 3] [Article Influence: 0.9] [Reference Citation Analysis]
275 Iggo R, Gatter K, Bartek J, Lane D, Harris AL. Increased expression of mutant forms of p53 oncogene in primary lung cancer. Lancet. 1990;335:675-679. [PMID: 1969059 DOI: 10.1016/0140-6736(90)90801-b] [Cited by in Crossref: 698] [Cited by in F6Publishing: 163] [Article Influence: 22.5] [Reference Citation Analysis]
276 Brooks JD, Bova GS, Marshall FF, Isaacs WB. Tumor Suppressor Gene Allelic Loss in Human Renal Cancers. Journal of Urology 1993;150:1278-83. [DOI: 10.1016/s0022-5347(17)35760-9] [Cited by in Crossref: 37] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
277 Vojtĕsek B, Fisher CJ, Barnes DM, Lane DP. Comparison between p53 staining in tissue sections and p53 proteins levels measured by an ELISA technique. Br J Cancer 1993;67:1254-8. [PMID: 7685617 DOI: 10.1038/bjc.1993.234] [Cited by in Crossref: 34] [Cited by in F6Publishing: 38] [Article Influence: 1.2] [Reference Citation Analysis]
278 Carder PJ, Cripps KJ, Morris R, Collins S, White S, Bird CC, Wyllie AH. Mutation of the p53 gene precedes aneuploid clonal divergence in colorectal carcinoma. Br J Cancer 1995;71:215-8. [PMID: 7841032 DOI: 10.1038/bjc.1995.46] [Cited by in Crossref: 26] [Cited by in F6Publishing: 27] [Article Influence: 1.0] [Reference Citation Analysis]
279 Bernal F, Wade M, Godes M, Davis TN, Whitehead DG, Kung AL, Wahl GM, Walensky LD. A stapled p53 helix overcomes HDMX-mediated suppression of p53. Cancer Cell 2010;18:411-22. [PMID: 21075307 DOI: 10.1016/j.ccr.2010.10.024] [Cited by in Crossref: 212] [Cited by in F6Publishing: 197] [Article Influence: 19.3] [Reference Citation Analysis]
280 Rew D, Karkera R, Mullee M, Julious S, Wilson G. The flow cytometric analysis of total p53 protein content and proliferation indices in colorectal cancer, in relation to clinical outcome. European Journal of Surgical Oncology (EJSO) 1996;22:508-15. [DOI: 10.1016/s0748-7983(96)93027-9] [Cited by in Crossref: 5] [Article Influence: 0.2] [Reference Citation Analysis]
281 Yana I, Nakamura T, Shin E, Karakawa K, Kurahashi H, Kurita Y, Kobayashi T, Mori T, Nishisho I, Takai S. Inactivation of the p53 gene is not required for tumorigenesis of medullary thyroid carcinoma or pheochromocytoma. Jpn J Cancer Res 1992;83:1113-6. [PMID: 1483923 DOI: 10.1111/j.1349-7006.1992.tb02730.x] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 0.8] [Reference Citation Analysis]
282 Ichikawa A, Hotta T, Saito H. Mutations of the p53 Gene in B-cell Lymphoma. Leukemia & Lymphoma 2009;11:21-5. [DOI: 10.3109/10428199309054727] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
283 Triantafillou NG, Grosman IM, Verma RS. Editorial: Genomania of p53 Protein in Gastric Cancer: . Journal of Clinical Gastroenterology 1996;22:170-3. [DOI: 10.1097/00004836-199604000-00003] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
284 Quinn E, Nichols KE. Cancer predisposition syndromes associated with myeloid malignancy. Seminars in Hematology 2017;54:115-22. [DOI: 10.1053/j.seminhematol.2017.04.003] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
285 Wang Y, O'Brate A, Zhou W, Giannakakou P. Resistance to microtubule-stabilizing drugs involves two events: beta-tubulin mutation in one allele followed by loss of the second allele. Cell Cycle 2005;4:1847-53. [PMID: 16294009 DOI: 10.4161/cc.4.12.2264] [Cited by in Crossref: 27] [Cited by in F6Publishing: 25] [Article Influence: 1.7] [Reference Citation Analysis]
286 Miyakura Y, Sugano K, Konishi F, Fukayama N, Igarashi S, Kotake K, Matsui T, Koyama Y, Maekawa M, Nagai H. Methylation profile of theMLH1 promoter region and their relationship to colorectal carcinogenesis. Genes Chromosom Cancer 2003;36:17-25. [DOI: 10.1002/gcc.10134] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 0.9] [Reference Citation Analysis]
287 Weston A, Willey JC, Modali R, Sugimura H, McDowell EM, Resau J, Light B, Haugen A, Mann DL, Trump BF. Differential DNA sequence deletions from chromosomes 3, 11, 13, and 17 in squamous-cell carcinoma, large-cell carcinoma, and adenocarcinoma of the human lung. Proc Natl Acad Sci U S A 1989;86:5099-103. [PMID: 2567993 DOI: 10.1073/pnas.86.13.5099] [Cited by in Crossref: 123] [Cited by in F6Publishing: 129] [Article Influence: 3.8] [Reference Citation Analysis]
288 Nguyen DX, Bos PD, Massagué J. Metastasis: from dissemination to organ-specific colonization. Nat Rev Cancer. 2009;9:274-284. [PMID: 19308067 DOI: 10.1038/nrc2622] [Cited by in Crossref: 1692] [Cited by in F6Publishing: 1555] [Article Influence: 141.0] [Reference Citation Analysis]
289 Thompson AM, Anderson TJ, Condie A, Prosser J, Chetty U, Carter DC, Evans HJ, Steel CM. p53 allele losses, mutations and expression in breast cancer and their relationship to clinico-pathological parameters. Int J Cancer 1992;50:528-32. [DOI: 10.1002/ijc.2910500405] [Cited by in Crossref: 101] [Cited by in F6Publishing: 106] [Article Influence: 3.5] [Reference Citation Analysis]
290 Slee EA, O’Connor DJ, Lu X. To die or not to die: how does p53 decide? Oncogene. 2004;23:2809-2818. [PMID: 15077144 DOI: 10.1038/sj.onc.1207516] [Cited by in Crossref: 190] [Cited by in F6Publishing: 173] [Article Influence: 11.2] [Reference Citation Analysis]
291 Levine AJ, Momand J, Finlay CA. The p53 tumour suppressor gene. Nature. 1991;351:453-456. [PMID: 2046748 DOI: 10.1038/351453a0] [Cited by in Crossref: 2434] [Cited by in F6Publishing: 2457] [Article Influence: 81.1] [Reference Citation Analysis]
292 Yang VW. The molecular genetics of colorectal cancer. Curr Gastroenterol Rep 1999;1:449-54. [PMID: 10980985 DOI: 10.1007/s11894-999-0028-0] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.3] [Reference Citation Analysis]
293 Brüderlein S, Van Der Bosch K, Schlag P, Schwab M. Cytogenetics and DNA amplification in colorectal cancers. Genes Chromosom Cancer 1990;2:63-70. [DOI: 10.1002/gcc.2870020112] [Cited by in Crossref: 26] [Cited by in F6Publishing: 20] [Article Influence: 0.8] [Reference Citation Analysis]
294 Gollin SM, Janecka IP. Cytogenetics of cranial base tumors. J Neurooncol 1994;20:241-54. [PMID: 7844621 DOI: 10.1007/BF01053042] [Cited by in Crossref: 15] [Article Influence: 0.6] [Reference Citation Analysis]
295 Schalken JA, van Moorselaar RJ, Bringuier PP, Debruyne FM. Critical review of the models to study the biologic progression of bladder cancer. Semin Surg Oncol 1992;8:274-8. [PMID: 1462097 DOI: 10.1002/ssu.2980080505] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 0.5] [Reference Citation Analysis]
296 Wiseman RW, Montgomery JC, Hosoi J, Hou EW, Cochran CJ, Lamb PW, Barrett JC. Identification of genes associated with tumor suppression in Syrian hamster embryo cells. Environ Health Perspect 1991;93:105-9. [PMID: 1773782 DOI: 10.1289/ehp.9193105] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 0.5] [Reference Citation Analysis]
297 Ladanyi M, Parsa NZ, Offit K, Wachtel MS, Filippa DA, Jhanwar SC. Clonal cytogenetic abnormalities in Hodgkin's disease. Genes Chromosom Cancer 1991;3:294-9. [DOI: 10.1002/gcc.2870030408] [Cited by in Crossref: 27] [Cited by in F6Publishing: 25] [Article Influence: 0.9] [Reference Citation Analysis]
298 Leppert M, Nakamura Y, Burt R, Hughes JP, Samowitz W, Woodward S, Gardner E, Lalouel J, White R. Eldon Gardner Memorial Lecture: Genetic Mapping and Allelic Heterogeneity of the Familial Polyposis Gene. In: Utsunomiya J, Lynch HT, editors. Hereditary Colorectal Cancer. Tokyo: Springer Japan; 1990. pp. 27-36. [DOI: 10.1007/978-4-431-68337-7_3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.0] [Reference Citation Analysis]
299 Levine AJ. The p53 protein and its interactions with the oncogene products of the small DNA tumor viruses. Virology 1990;177:419-26. [PMID: 2142553 DOI: 10.1016/0042-6822(90)90505-l] [Cited by in Crossref: 126] [Cited by in F6Publishing: 66] [Article Influence: 4.1] [Reference Citation Analysis]
300 Ma H, Lu Y, Malone KE, Marchbanks PA, Deapen DM, Spirtas R, Burkman RT, Strom BL, McDonald JA, Folger SG, Simon MS, Sullivan-Halley J, Press MF, Bernstein L. Mortality risk of black women and white women with invasive breast cancer by hormone receptors, HER2, and p53 status. BMC Cancer 2013;13:225. [PMID: 23642215 DOI: 10.1186/1471-2407-13-225] [Cited by in Crossref: 34] [Cited by in F6Publishing: 27] [Article Influence: 4.3] [Reference Citation Analysis]
301 Nakayama H, Hibi K, Taguchi M, Takase T, Yamazaki T, Kasai Y, Ito K, Akiyama S, Nakao A. Molecular detection of p16 promoter methylation in the serum of colorectal cancer patients. Cancer Lett. 2002;188:115-119. [PMID: 12406556 DOI: 10.1016/s0304-3835(01)00839-4] [Cited by in Crossref: 59] [Cited by in F6Publishing: 19] [Article Influence: 3.3] [Reference Citation Analysis]
302 Johnson P, Gray D, Mowat M, Benchimol S. Expression of wild-type p53 is not compatible with continued growth of p53-negative tumor cells. Mol Cell Biol 1991;11:1-11. [PMID: 1986214 DOI: 10.1128/mcb.11.1.1-11.1991] [Cited by in Crossref: 64] [Article Influence: 2.1] [Reference Citation Analysis]
303 Haber DA, Buckler AJ, Glaser T, Call KM, Pelletier J, Sohn RL, Douglass EC, Housman DE. An internal deletion within an 11p13 zinc finger gene contributes to the development of Wilms' tumor. Cell 1990;61:1257-69. [DOI: 10.1016/0092-8674(90)90690-g] [Cited by in Crossref: 384] [Cited by in F6Publishing: 125] [Article Influence: 12.4] [Reference Citation Analysis]
304 Sameer AS. Colorectal cancer: a researcher’s perspective of the molecular angel’s gone eccentric in the Vale of Kashmir. Tumor Biol 2013;34:1301-15. [DOI: 10.1007/s13277-013-0692-4] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 1.6] [Reference Citation Analysis]
305 Wang XW, Harris CC. p53 tumor-suppressor gene: clues to molecular carcinogenesis. J Cell Physiol 1997;173:247-55. [PMID: 9365531 DOI: 10.1002/(SICI)1097-4652(199711)173:2<247::AID-JCP30>3.0.CO;2-A] [Cited by in Crossref: 50] [Cited by in F6Publishing: 12] [Article Influence: 2.1] [Reference Citation Analysis]
306 Bell SM, Scott N, Cross D, Sagar P, Lewis FA, Blair G, Taylor GR, Dixon MF, Quirke P. Prognostic value of p53 overexpression and c-Ki-ras gene mutations in colorectal cancer. Gastroenterology 1993;104:57-64. [DOI: 10.1016/0016-5085(93)90835-z] [Cited by in Crossref: 166] [Cited by in F6Publishing: 43] [Article Influence: 5.9] [Reference Citation Analysis]
307 Chester KA, Robson L, Begent RH, Pringle H, Primrose L, Talbot IC, Macpherson AJ, Owen SL, Boxer G, Malcolm AD. In situ and slot hybridization analysis of RNA in colorectal tumours and normal colon shows distinct distributions of mitochondrial sequences. J Pathol. 1990;162:309-315. [PMID: 1705284 DOI: 10.1002/path.1711620406] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 0.4] [Reference Citation Analysis]
308 Olson JJ, Polk DM, Reisner A. The Efficacy and Distribution of Suramin in the Treatment of the 9L Gliosarcoma. Neurosurgery 1994;34:297-308. [DOI: 10.1227/00006123-199402000-00013] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 0.3] [Reference Citation Analysis]
309 Quadrato G, Di Giovanni S. Waking up the sleepers: shared transcriptional pathways in axonal regeneration and neurogenesis. Cell Mol Life Sci 2013;70:993-1007. [DOI: 10.1007/s00018-012-1099-x] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
310 Bishop DT, Hall NR. The genetics of colorectal cancer. Eur J Cancer 1994;30A:1946-56. [PMID: 7734206 DOI: 10.1016/0959-8049(94)00385-i] [Cited by in Crossref: 27] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
311 Bando T, Kato Y, Ihara Y, Yamagishi F, Tsukada K, Isobe M. Loss of Heterozygosity of 14q32 in Colorectal Carcinoma. Cancer Genetics and Cytogenetics 1999;111:161-5. [DOI: 10.1016/s0165-4608(98)00242-8] [Cited by in Crossref: 38] [Cited by in F6Publishing: 16] [Article Influence: 1.7] [Reference Citation Analysis]
312 Rizzo MG, Soddu S, Tibursi G, Calabretta B, Sacchi A. Wild-type p53 differentially affects tumorigenic and metastatic potential of murine metastatic cell variants. Clin Exp Metastasis 1993;11:368-76. [PMID: 8375112 DOI: 10.1007/BF00132980] [Cited by in Crossref: 9] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
313 Zhao Y, Chen XQ, Du JZ. Cellular adaptation to hypoxia and p53 transcription regulation. J Zhejiang Univ Sci B. 2009;10:404-410. [PMID: 19434769 DOI: 10.1631/jzus.b0820293] [Cited by in Crossref: 27] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
314 Oliner JD. Discerning the function of p53 by examining its molecular interactions. Bioessays 1993;15:703-7. [DOI: 10.1002/bies.950151102] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 0.8] [Reference Citation Analysis]
315 Collins FS, O'connell P, Ponder BA, Seizinger BR. Progress towards identifying the neurofibromatosis (NF1) gene. Trends in Genetics 1989;5:217-21. [DOI: 10.1016/0168-9525(89)90085-1] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 0.7] [Reference Citation Analysis]
316 Zhao X, He M, Wan D, Ye Y, He Y, Han L, Guo M, Huang Y, Qin W, Wang MW, Chong W, Chen J, Zhang L, Yang N, Xu B, Wu M, Zuo L, Gu J. The minimum LOH region defined on chromosome 17p13.3 in human hepatocellular carcinoma with gene content analysis. Cancer Lett 2003;190:221-32. [PMID: 12565177 DOI: 10.1016/s0304-3835(02)00622-5] [Cited by in Crossref: 24] [Cited by in F6Publishing: 15] [Article Influence: 1.3] [Reference Citation Analysis]
317 Meijer G, Baak J. Cytonuclear morphometry in assesment of dysplasia in polyps Pilot study. Pathology - Research and Practice 1992;188:148-56. [DOI: 10.1016/s0344-0338(11)81172-6] [Cited by in Crossref: 12] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
318 Sherley J. Guanine nucleotide biosynthesis is regulated by the cellular p53 concentration. Journal of Biological Chemistry 1991;266:24815-28. [DOI: 10.1016/s0021-9258(18)54302-7] [Cited by in Crossref: 40] [Article Influence: 1.3] [Reference Citation Analysis]
319 Nakagawa T, Matozaki S. The SKM-1 leukemic cell line established from a patient with progression to myelomonocytic leukemia in myelodysplastic syndrome (MDS)-contribution to better understanding of MDS. Leuk Lymphoma 1995;17:335-9. [PMID: 8580805 DOI: 10.3109/10428199509056841] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 0.8] [Reference Citation Analysis]
320 Moragoda L, Jaszewski R, Kulkarni P, Majumdar APN. Age-associated loss of heterozygosity of tumor suppressor genes in the gastric mucosa of humans. American Journal of Physiology-Gastrointestinal and Liver Physiology 2002;282:G932-6. [DOI: 10.1152/ajpgi.00312.2001] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 0.5] [Reference Citation Analysis]
321 Dunlop MG. Allele losses and onco-suppressor genes. J Pathol 1991;163:1-5. [DOI: 10.1002/path.1711630102] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.2] [Reference Citation Analysis]
322 Brown DR, Deb S, Muñoz RM, Subler MA, Deb SP. The tumor suppressor p53 and the oncoprotein simian virus 40 T antigen bind to overlapping domains on the MDM2 protein. Mol Cell Biol 1993;13:6849-57. [PMID: 8413278 DOI: 10.1128/mcb.13.11.6849-6857.1993] [Cited by in Crossref: 32] [Article Influence: 1.1] [Reference Citation Analysis]
323 el-Azouzi M, Chung RY, Farmer GE, Martuza RL, Black PM, Rouleau GA, Hettlich C, Hedley-Whyte ET, Zervas NT, Panagopoulos K. Loss of distinct regions on the short arm of chromosome 17 associated with tumorigenesis of human astrocytomas. Proc Natl Acad Sci U S A 1989;86:7186-90. [PMID: 2571151 DOI: 10.1073/pnas.86.18.7186] [Cited by in Crossref: 97] [Cited by in F6Publishing: 85] [Article Influence: 3.0] [Reference Citation Analysis]
324 Zarzour P, Boelen L, Luciani F, Beck D, Sakthianandeswaren A, Mouradov D, Sieber OM, Hawkins NJ, Hesson LB, Ward RL, Wong JW. Single nucleotide polymorphism array profiling identifies distinct chromosomal aberration patterns across colorectal adenomas and carcinomas. Genes Chromosomes Cancer 2015;54:303-14. [PMID: 25726927 DOI: 10.1002/gcc.22243] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
325 Remvikos Y, Tominaga O, Hammel P, Laurent-Puig P, Salmon RJ, Dutrillaux B, Thomas G. Increased p53 protein content of colorectal tumours correlates with poor survival. Br J Cancer. 1992;66:758-764. [PMID: 1419618 DOI: 10.1038/bjc.1992.352] [Cited by in Crossref: 90] [Cited by in F6Publishing: 94] [Article Influence: 3.1] [Reference Citation Analysis]
326 Diller L, Kassel J, Nelson CE, Gryka MA, Litwak G, Gebhardt M, Bressac B, Ozturk M, Baker SJ, Vogelstein B. p53 functions as a cell cycle control protein in osteosarcomas. Mol Cell Biol 1990;10:5772-81. [PMID: 2233717 DOI: 10.1128/mcb.10.11.5772-5781.1990] [Cited by in Crossref: 13] [Cited by in F6Publishing: 199] [Article Influence: 0.4] [Reference Citation Analysis]
327 Porcelli B, Frosi B, Terzuoli L, Arezzini L, Marinello E, Vernillo R, De Martino A, Vatti R, Minacci C. Expression of p185 and p53 in benign and malignant colorectal lesions. Histochem J 2001;33:51-7. [PMID: 11352401 DOI: 10.1023/a:1017543930661] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
328 Gil-Martín E, Rodríguez-Berrocal J, Páez de la Cadena M, Fernández-Briera A. Alterations of glycosidases in human colonic adenocarcinoma. Clin Biochem 1997;30:17-25. [PMID: 9056105 DOI: 10.1016/s0009-9120(96)00123-3] [Cited by in Crossref: 9] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
329 Weber L. Patented inhibitors of p53–Mdm2 interaction (2006 – 2008). Expert Opinion on Therapeutic Patents 2010;20:179-91. [DOI: 10.1517/13543770903514129] [Cited by in Crossref: 37] [Cited by in F6Publishing: 34] [Article Influence: 3.4] [Reference Citation Analysis]
330 Chendil D, Oakes R, Alcock RA, Patel N, Mayhew C, Mohiuddin M, Gallicchio VS, Ahmed MM. Low dose fractionated radiation enhances the radiosensitization effect of paclitaxel in colorectal tumor cells with mutant p53: Radiation, Paclitaxel, and p53 Status. Cancer 2000;89:1893-900. [DOI: 10.1002/1097-0142(20001101)89:9<1893::aid-cncr4>3.0.co;2-b] [Cited by in Crossref: 2] [Article Influence: 0.1] [Reference Citation Analysis]
331 Dittmer D, Pati S, Zambetti G, Chu S, Teresky AK, Moore M, Finlay C, Levine AJ. Gain of function mutations in p53. Nat Genet 1993;4:42-6. [PMID: 8099841 DOI: 10.1038/ng0593-42] [Cited by in Crossref: 565] [Cited by in F6Publishing: 551] [Article Influence: 20.2] [Reference Citation Analysis]
332 Kaneko K, Kurahashi T, Makino R, Konishi K, Ito H, Katagiri A, Kumekawa Y, Hirayama Y, Yoneyama K, Kushima M, Kusano M, Tajiri H, Rembacken BJ, Mitamura K, Imawari M. Pathological features and genetic alterations in colorectal carcinomas with characteristics of nonpolypoid growth. Br J Cancer 2004;91:312-8. [PMID: 15213719 DOI: 10.1038/sj.bjc.6601965] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 0.5] [Reference Citation Analysis]
333 Hollstein M, Soussi T, Thomas G, von Brevern MC, Bartsch. P53 gene alterations in human tumors: perspectives for cancer control. Recent Results Cancer Res 1997;143:369-89. [PMID: 8912433 DOI: 10.1007/978-3-642-60393-8_26] [Cited by in Crossref: 35] [Cited by in F6Publishing: 37] [Article Influence: 1.5] [Reference Citation Analysis]
334 Cook A, Milner J. Evidence for allosteric variants of wild-type p53, a tumour suppressor protein. Br J Cancer 1990;61:548-52. [PMID: 2139577 DOI: 10.1038/bjc.1990.123] [Cited by in Crossref: 41] [Cited by in F6Publishing: 49] [Article Influence: 1.3] [Reference Citation Analysis]
335 Kochetkov DV, Ilyinskaya GV, Komarov PG, Strom E, Agapova LS, Ivanov AV, Budanov AV, Frolova EI, Chumakov PM. Transcriptional inhibition of the human papilloma virus reactivates tumor suppressor p53 in cervical carcinoma cells. Mol Biol 2007;41:459-66. [DOI: 10.1134/s0026893307030120] [Cited by in Crossref: 16] [Article Influence: 1.1] [Reference Citation Analysis]
336 Banda MG, Simons JW. Gene therapy for urologic cancer. Urology 1994;44:617-24. [DOI: 10.1016/s0090-4295(94)80075-8] [Cited by in Crossref: 8] [Article Influence: 0.3] [Reference Citation Analysis]
337 Wang Z, Sun Y. Targeting p53 for Novel Anticancer Therapy. Transl Oncol 2010;3:1-12. [PMID: 20165689 DOI: 10.1593/tlo.09250] [Cited by in Crossref: 160] [Cited by in F6Publishing: 142] [Article Influence: 16.0] [Reference Citation Analysis]
338 Broutier L, Andersson-Rolf A, Hindley CJ, Boj SF, Clevers H, Koo BK, Huch M. Culture and establishment of self-renewing human and mouse adult liver and pancreas 3D organoids and their genetic manipulation. Nat Protoc. 2016;11:1724-1743. [PMID: 27560176 DOI: 10.1038/nprot.2016.097] [Cited by in Crossref: 262] [Cited by in F6Publishing: 232] [Article Influence: 52.4] [Reference Citation Analysis]
339 Yuen ST, Chung LP, Leung SY, Luk IS, Chan SY, Ho JC, Ho JW, Wyllie AH. Colorectal carcinoma in Hong Kong: epidemiology and genetic mutations. Br J Cancer 1997;76:1610-6. [PMID: 9413950 DOI: 10.1038/bjc.1997.605] [Cited by in Crossref: 31] [Cited by in F6Publishing: 34] [Article Influence: 1.3] [Reference Citation Analysis]
340 Han E, Moyer MP, Naylor S, Sakaguchi AY. Mutation in theTP53 gene in colorectal carcinoma detected by polymerase chain reaction. Genes Chromosom Cancer 1991;3:313-7. [DOI: 10.1002/gcc.2870030411] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.2] [Reference Citation Analysis]
341 Oiwa H, Maehara Y, Ohno S, Sakaguchi Y, Ichiyoshi Y, Sugimachi K. Growth pattern and p53 overexpression in patients with early gastric cancer. Cancer 1995;75:1454-9. [DOI: 10.1002/1097-0142(19950315)75:6+<1454::aid-cncr2820751511>3.0.co;2-g] [Cited by in Crossref: 24] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
342 Hoshino Y, Horikawa I, Oshimura M, Yuasa Y. Normal human chromosome 5, on which a familial adenomatous polyposis gene is located, has tumor suppressive activity. Biochem Biophys Res Commun 1991;174:298-304. [PMID: 1846539 DOI: 10.1016/0006-291x(91)90520-h] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.1] [Reference Citation Analysis]
343 Williams DS, Mouradov D, Browne C, Palmieri M, Elliott MJ, Nightingale R, Fang CG, Li R, Mariadason JM, Faragher I, Jones IT, Churilov L, Tebbutt NC, Gibbs P, Sieber OM. Overexpression of TP53 protein is associated with the lack of adjuvant chemotherapy benefit in patients with stage III colorectal cancer. Mod Pathol 2020;33:483-95. [DOI: 10.1038/s41379-019-0353-2] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
344 Kamatani Y, Nakamura Y. Genetic variations in medical research in the past, at present and in the future. Proc Jpn Acad Ser B Phys Biol Sci 2021;97:324-35. [PMID: 34121043 DOI: 10.2183/pjab.97.018] [Reference Citation Analysis]
345 Müller-Höcker J. Immunoreactivity of p53, Ki-67, and Bcl-2 in oncocytic adenomas and carcinomas of the thyroid gland. Hum Pathol 1999;30:926-33. [PMID: 10452505 DOI: 10.1016/s0046-8177(99)90246-0] [Cited by in Crossref: 19] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
346 Felix CA, Nau MM, Takahashi T, Mitsudomi T, Chiba I, Poplack DG, Reaman GH, Cole DE, Letterio JJ, Whang-Peng J. Hereditary and acquired p53 gene mutations in childhood acute lymphoblastic leukemia. J Clin Invest 1992;89:640-7. [PMID: 1737852 DOI: 10.1172/JCI115630] [Cited by in Crossref: 53] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
347 Kuwabara S, Ajioka Y, Watanabe H, Hitomi J, Nishikura K, Hatakeyama K. Heterogeneity of p53 mutational status in esophageal squamous cell carcinoma. Jpn J Cancer Res 1998;89:405-10. [PMID: 9617346 DOI: 10.1111/j.1349-7006.1998.tb00578.x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 0.3] [Reference Citation Analysis]
348 Foulkes WD, Stamp GW, Afzal S, Lalani N, McFarlane CP, Trowsdale J, Campbell IG. MDM2 overexpression is rare in ovarian carcinoma irrespective of TP53 mutation status. Br J Cancer 1995;72:883-8. [PMID: 7547235 DOI: 10.1038/bjc.1995.428] [Cited by in Crossref: 22] [Cited by in F6Publishing: 25] [Article Influence: 0.8] [Reference Citation Analysis]
349 Børresen AL, Hovig E, Smith-Sørensen B, Malkin D, Lystad S, Andersen TI, Nesland JM, Isselbacher KJ, Friend SH. Constant denaturant gel electrophoresis as a rapid screening technique for p53 mutations. Proc Natl Acad Sci U S A 1991;88:8405-9. [PMID: 1924299 DOI: 10.1073/pnas.88.19.8405] [Cited by in Crossref: 113] [Cited by in F6Publishing: 114] [Article Influence: 3.8] [Reference Citation Analysis]
350 Garcia-Patiño E, Gomendio B, Lleonart M, Silva JM, Garcia JM, Provencio M, Cubedo R, España P, Ramón y Cajal S, Bonilla F. Loss of heterozygosity in the region including the BRCA1 gene on 17q in colon cancer. Cancer Genet Cytogenet 1998;104:119-23. [PMID: 9666805 DOI: 10.1016/s0165-4608(97)00460-3] [Cited by in Crossref: 24] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
351 Namani A, Li J, Wang XJ, Tang X. A Review of Compounds for Prevention of Colorectal Cancer. Curr Pharmacol Rep 2017;3:221-31. [DOI: 10.1007/s40495-017-0101-6] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
352 Chuang TP, Wang JY, Jao SW, Wu CC, Chen JH, Hsiao KH, Lin CY, Chen SH, Su SY, Chen YJ, Chen YT, Wu DC, Li LH. Over-expression of AURKA, SKA3 and DSN1 contributes to colorectal adenoma to carcinoma progression. Oncotarget 2016;7:45803-18. [PMID: 27329586 DOI: 10.18632/oncotarget.9960] [Cited by in Crossref: 34] [Cited by in F6Publishing: 38] [Article Influence: 11.3] [Reference Citation Analysis]
353 Yin Y, Tainsky MA, Bischoff FZ, Strong LC, Wahl GM. Wild-type p53 restores cell cycle control and inhibits gene amplification in cells with mutant p53 alleles. Cell 1992;70:937-48. [PMID: 1525830 DOI: 10.1016/0092-8674(92)90244-7] [Cited by in Crossref: 733] [Cited by in F6Publishing: 728] [Article Influence: 25.3] [Reference Citation Analysis]
354 González-González M, Gutiérrez ML, Sayagués JM, Muñoz-Bellvís L, Orfao A. Genomic profiling of sporadic liver metastatic colorectal cancer. Semin Cancer Biol 2021;71:98-108. [PMID: 32485312 DOI: 10.1016/j.semcancer.2020.05.013] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
355 Ludlow JW, Shon J, Pipas JM, Livingston DM, DeCaprio JA. The retinoblastoma susceptibility gene product undergoes cell cycle-dependent dephosphorylation and binding to and release from SV40 large T. Cell 1990;60:387-96. [PMID: 2154332 DOI: 10.1016/0092-8674(90)90590-b] [Cited by in Crossref: 254] [Cited by in F6Publishing: 98] [Article Influence: 8.2] [Reference Citation Analysis]
356 Kobayashi H, Espinosa R, Fernald AA, Begy C, Diaz MO, Beau MML, Rowley JD. Analysis of deletions of the long arm of chromosome 11 in hematologic malignancies with fluorescence in situ hybridization. Genes Chromosom Cancer 1993;8:246-52. [DOI: 10.1002/gcc.2870080407] [Cited by in Crossref: 35] [Cited by in F6Publishing: 29] [Article Influence: 1.3] [Reference Citation Analysis]
357 Vogelstein B, Kinzler KW. Achilles' heel of cancer? Nature 2001;412:865-6. [DOI: 10.1038/35091170] [Cited by in Crossref: 41] [Cited by in F6Publishing: 38] [Article Influence: 2.1] [Reference Citation Analysis]
358 Yamagata S, Muto T, Uchida Y, Masaki T, Higuchi Y, Sawada T, Hirooka T. Polypoid growth and K-ras codon 12 mutation in colorectal cancer. Cancer. 1995;75:953-957. [PMID: 7842415 DOI: 10.1002/1097-0142(19950215)75:4%3C953::AID-CNCR2820750409%3E3.0.CO;2-R] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
359 Wang W, Hu Y. Small molecule agents targeting the p53-MDM2 pathway for cancer therapy: p53-MDM2 PATHWAY FOR CANCER THERAPY. Med Res Rev 2012;32:1159-96. [DOI: 10.1002/med.20236] [Cited by in Crossref: 55] [Cited by in F6Publishing: 50] [Article Influence: 5.5] [Reference Citation Analysis]
360 Nguyen HT, Duong HQ. The molecular characteristics of colorectal cancer: Implications for diagnosis and therapy (review). Oncol Lett. 2018;16:9-18. [PMID: 29928381 DOI: 10.3892/ol.2018.8679] [Cited by in Crossref: 31] [Cited by in F6Publishing: 50] [Article Influence: 10.3] [Reference Citation Analysis]
361 Ofner D, Maier H, Riedmann B, Holzberger P, Nogler M, Tötsch M, Bankfalvi A, Winde G, Böcker W, Schmid KW. Immunohistochemically detectable p53 and mdm-2 oncoprotein expression in colorectal carcinoma: prognostic significance. Clin Mol Pathol 1995;48:M12-6. [PMID: 16695968 DOI: 10.1136/mp.48.1.m12] [Cited by in Crossref: 11] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
362 Smith AJ, Smith LA. Viral Carcinogenesis. Prog Mol Biol Transl Sci 2016;144:121-68. [PMID: 27865457 DOI: 10.1016/bs.pmbts.2016.09.007] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.4] [Reference Citation Analysis]
363 Gaidano G, Ballerini P, Gong JZ, Inghirami G, Neri A, Newcomb EW, Magrath IT, Knowles DM, Dalla-Favera R. p53 mutations in human lymphoid malignancies: association with Burkitt lymphoma and chronic lymphocytic leukemia. Proc Natl Acad Sci U S A 1991;88:5413-7. [PMID: 2052620 DOI: 10.1073/pnas.88.12.5413] [Cited by in Crossref: 543] [Cited by in F6Publishing: 521] [Article Influence: 18.1] [Reference Citation Analysis]
364 Li H, Zhang J, Tong JHM, Chan AWH, Yu J, Kang W, To KF. Targeting the Oncogenic p53 Mutants in Colorectal Cancer and Other Solid Tumors. Int J Mol Sci 2019;20:E5999. [PMID: 31795192 DOI: 10.3390/ijms20235999] [Cited by in Crossref: 26] [Cited by in F6Publishing: 29] [Article Influence: 13.0] [Reference Citation Analysis]
365 Faille A, De Cremoux P, Extra JM, Linares G, Espie M, Bourstyn E, De Rocquancourt A, Giacchetti S, Marty M, Calvo F. p53 mutations and overexpression in locally advanced breast cancers. Br J Cancer 1994;69:1145-50. [PMID: 8198984 DOI: 10.1038/bjc.1994.225] [Cited by in Crossref: 47] [Cited by in F6Publishing: 44] [Article Influence: 1.7] [Reference Citation Analysis]
366 Fernández-Figueras MT, Casalots A, Puig L, Llatjós R, Ferrándiz C, Ariza A. Proliferating trichilemmal tumour: p53 immunoreactivity in association with p27Kip1 over-expression indicates a low-grade carcinoma profile. Histopathology 2001;38:454-7. [PMID: 11422483 DOI: 10.1046/j.1365-2559.2001.01149.x] [Cited by in Crossref: 17] [Cited by in F6Publishing: 11] [Article Influence: 0.9] [Reference Citation Analysis]
367 Boland CR, Sato J, Appelman HD, Bresalier RS, Feinberg AP. Microallelotyping defines the sequence and tempo of alleiic losses at tumour suppressor gene loci during colorectal cancer progression. Nat Med 1995;1:902-9. [DOI: 10.1038/nm0995-902] [Cited by in Crossref: 140] [Cited by in F6Publishing: 114] [Article Influence: 5.4] [Reference Citation Analysis]
368 Curtin JC. Novel drug discovery opportunities for colorectal cancer. Expert Opin Drug Discov. 2013;8:1153-1164. [PMID: 23768167 DOI: 10.1517/17460441.2013.807249] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 1.9] [Reference Citation Analysis]
369 Griffin CA, Long PP, Morsberger LA, Douna-issa F, Hruban RH, Yeo CJ. Chromosome abnormalities in pancreatic adenocarcinoma. Genes Chromosom Cancer 1994;9:93-100. [DOI: 10.1002/gcc.2870090204] [Cited by in Crossref: 45] [Cited by in F6Publishing: 41] [Article Influence: 1.7] [Reference Citation Analysis]
370 Chumakov PM. Versatile functions of p53 protein in multicellular organisms. Biochemistry (Mosc) 2007;72:1399-421. [PMID: 18282133 DOI: 10.1134/s0006297907130019] [Cited by in Crossref: 45] [Cited by in F6Publishing: 21] [Article Influence: 3.5] [Reference Citation Analysis]
371 Brentnall TA, Crispin DA, Rabinovitch PS, Haggitt RC, Rubin CE, Stevens AC, Burmer GC. Mutations in the p53 gene: an early marker of neoplastic progression in ulcerative colitis. Gastroenterology 1994;107:369-78. [PMID: 8039614 DOI: 10.1016/0016-5085(94)90161-9] [Cited by in Crossref: 285] [Cited by in F6Publishing: 253] [Article Influence: 10.6] [Reference Citation Analysis]
372 Xirodimas DP, Scheffner M. Ubiquitin Family Members in the Regulation of the Tumor Suppressor p53. In: Groettrup M, editor. Conjugation and Deconjugation of Ubiquitin Family Modifiers. New York: Springer; 2010. pp. 116-35. [DOI: 10.1007/978-1-4419-6676-6_10] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
373 Robbins P. p53 and Breast Cancer. Int J Surg Pathol 1996;4:93-110. [DOI: 10.1177/106689699600400206] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
374 James CD, Peter Collins V. Molecular Genetic Characterization of Cns Tumor Oncogenesis. Elsevier; 1992. pp. 121-42. [DOI: 10.1016/s0065-230x(08)60293-6] [Cited by in Crossref: 14] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
375 Brüstle O, Ohgaki H, Schmitt HP, Walter GF, Ostertag H, Kleihues P. Primitive neuroectodermal tumors after prophylactic central nervous system irradiation in children. Association with an activated K-ras gene. Cancer 1992;69:2385-92. [DOI: 10.1002/1097-0142(19920501)69:9<2385::aid-cncr2820690929>3.0.co;2-3] [Cited by in Crossref: 50] [Cited by in F6Publishing: 8] [Article Influence: 1.7] [Reference Citation Analysis]
376 Christofi T, Apidianakis Y. Drosophila and the hallmarks of cancer. Adv Biochem Eng Biotechnol 2013;135:79-110. [PMID: 23615878 DOI: 10.1007/10_2013_190] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
377 Cheng TM, Coffey RJ, Gelber BR, Scheithauer BW. Simultaneous Presentation of Symptomatic Subependymomas in Siblings. Neurosurgery 1993;33:145-50. [DOI: 10.1097/00006123-199307000-00025] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.0] [Reference Citation Analysis]
378 Yamamura-idei Y, Satonaka K, Fujimori T, Maeda S, Chiba T. p53 Mutations in flat- and polypoid-type colorectal tumors detected by temperature-gradient gel electrophoresis. Digest Dis Sci 1994;39:2043-8. [DOI: 10.1007/bf02088145] [Cited by in Crossref: 11] [Article Influence: 0.4] [Reference Citation Analysis]
379 Srivatsan ES, Ying KL, Seeger RC. Deletion of chromosome 11 and of 14q sequences in neuroblastoma. Genes Chromosom Cancer 1993;7:32-7. [DOI: 10.1002/gcc.2870070106] [Cited by in Crossref: 69] [Cited by in F6Publishing: 65] [Article Influence: 2.5] [Reference Citation Analysis]
380 Parikh N, Hilsenbeck S, Creighton CJ, Dayaram T, Shuck R, Shinbrot E, Xi L, Gibbs RA, Wheeler DA, Donehower LA. Effects of TP53 mutational status on gene expression patterns across 10 human cancer types. J Pathol 2014;232:522-33. [PMID: 24374933 DOI: 10.1002/path.4321] [Cited by in Crossref: 44] [Cited by in F6Publishing: 44] [Article Influence: 6.3] [Reference Citation Analysis]
381 Clark WH. Human cutaneous malignant melanoma as a model for cancer. Cancer Metast Rev 1991;10:83-8. [DOI: 10.1007/bf00049406] [Cited by in Crossref: 22] [Cited by in F6Publishing: 8] [Article Influence: 0.7] [Reference Citation Analysis]
382 Finlay CA. What the papers say: p53 Loss of Function: Implications for the Processes of Immortalization and Tumorigenesis. Bioessays 1992;14:557-60. [DOI: 10.1002/bies.950140811] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 0.6] [Reference Citation Analysis]
383 Metzger AK, Sheffield VC, Duyk G, Daneshvar L, Edwards MS, Cogen PH. Identification of a germ-line mutation in the p53 gene in a patient with an intracranial ependymoma. Proc Natl Acad Sci U S A 1991;88:7825-9. [PMID: 1679237 DOI: 10.1073/pnas.88.17.7825] [Cited by in Crossref: 72] [Cited by in F6Publishing: 62] [Article Influence: 2.4] [Reference Citation Analysis]
384 Marzec KA, Lin MZ, Martin JL, Baxter RC. Involvement of p53 in insulin-like growth factor binding protein-3 regulation in the breast cancer cell response to DNA damage. Oncotarget 2015;6:26583-98. [PMID: 26378048 DOI: 10.18632/oncotarget.5612] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
385 Kochhar R, Hailing KC, Mcdonnell S, Schaid DJ, French AJ, Oʼconnell MJ, Nagorney DM, Thibodeau SN. Allelic Imbalance and Microsatellite Instability in Resected Dukeʼs D Colorectal Cancer: . Diagnostic Molecular Pathology 1997;6:78-84. [DOI: 10.1097/00019606-199704000-00002] [Cited by in Crossref: 29] [Cited by in F6Publishing: 25] [Article Influence: 1.2] [Reference Citation Analysis]
386 Adler AS, McCleland ML, Yee S, Yaylaoglu M, Hussain S, Cosino E, Quinones G, Modrusan Z, Seshagiri S, Torres E. An integrative analysis of colon cancer identifies an essential function for PRPF6 in tumor growth. Genes Dev. 2014;28:1068-1084. [PMID: 24788092 DOI: 10.1101/gad.237206.113] [Cited by in Crossref: 60] [Cited by in F6Publishing: 56] [Article Influence: 8.6] [Reference Citation Analysis]
387 Ohnishi H, Kawamura M, Hanada R, Kaneko Y, Tsunoda Y, Hongo T, Bessho F, Yokomori K, Hayashi Y. Infrequent mutations of theTP53 gene and no amplification of theMDM2 gene in hepatoblastomas. Genes Chromosom Cancer 1996;15:187-90. [DOI: 10.1002/(sici)1098-2264(199603)15:3<187::aid-gcc8>3.0.co;2-z] [Cited by in Crossref: 15] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
388 de Leon MP. Oncogenes and Tumor Suppressor Genes. Familial and Hereditary Tumors. Berlin: Springer Berlin Heidelberg; 1994. pp. 35-47. [DOI: 10.1007/978-3-642-85076-9_4] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
389 Binz SK, Wold MS. Regulatory functions of the N-terminal domain of the 70-kDa subunit of replication protein A (RPA). J Biol Chem 2008;283:21559-70. [PMID: 18515800 DOI: 10.1074/jbc.M802450200] [Cited by in Crossref: 28] [Cited by in F6Publishing: 18] [Article Influence: 2.2] [Reference Citation Analysis]
390 Högberg J, Silins I, Stenius U. Chemical induced alterations in p53 signaling. In: Luch A, editor. Molecular, Clinical and Environmental Toxicology. Basel: Birkhäuser; 2009. pp. 181-208. [DOI: 10.1007/978-3-7643-8336-7_7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
391 Ahlquist DA, Thibodeau SN. Will molecular genetic markers help predict the clinical behavior of colorectal neoplasia? Gastroenterology 1992;102:1419-21. [PMID: 1551551 DOI: 10.1016/0016-5085(92)90788-z] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
392 Goi T, Yamaguchi A, Nakagawara G, Urano T, Shiku H, Furukawa K. Reduced expression of deleted colorectal carcinoma (DCC) protein in established colon cancers. Br J Cancer 1998;77:466-71. [PMID: 9472645 DOI: 10.1038/bjc.1998.74] [Cited by in Crossref: 26] [Cited by in F6Publishing: 30] [Article Influence: 1.1] [Reference Citation Analysis]
393 Martínez-jiménez F, Muiños F, Sentís I, Deu-pons J, Reyes-salazar I, Arnedo-pac C, Mularoni L, Pich O, Bonet J, Kranas H, Gonzalez-perez A, Lopez-bigas N. A compendium of mutational cancer driver genes. Nat Rev Cancer 2020;20:555-72. [DOI: 10.1038/s41568-020-0290-x] [Cited by in Crossref: 94] [Cited by in F6Publishing: 75] [Article Influence: 94.0] [Reference Citation Analysis]
394 Jemaà M, Galluzzi L, Kepp O, Boilève A, Lissa D, Senovilla L, Harper F, Pierron G, Berardinelli F, Antoccia A, Castedo M, Vitale I, Kroemer G. Preferential killing of p53-deficient cancer cells by reversine. Cell Cycle 2012;11:2149-58. [PMID: 22592527 DOI: 10.4161/cc.20621] [Cited by in Crossref: 28] [Cited by in F6Publishing: 30] [Article Influence: 3.1] [Reference Citation Analysis]
395 Owen RG, Davis SA, Randerson J, Rawstron AC, Davies F, Child JA, Jack AS, Morgan GJ. p53 gene mutations in multiple myeloma. Mol Pathol 1997;50:18-20. [PMID: 9208809 DOI: 10.1136/mp.50.1.18] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 0.5] [Reference Citation Analysis]
396 Shaulsky G, Goldfinger N, Ben-Ze'ev A, Rotter V. Nuclear accumulation of p53 protein is mediated by several nuclear localization signals and plays a role in tumorigenesis. Mol Cell Biol 1990;10:6565-77. [PMID: 2247074 DOI: 10.1128/mcb.10.12.6565-6577.1990] [Cited by in Crossref: 194] [Article Influence: 6.5] [Reference Citation Analysis]
397 Zeng F, Tian L, Liu F, Cao J, Quan M, Sheng X. Induction of apoptosis by casticin in cervical cancer cells: reactive oxygen species-dependent sustained activation of Jun N-terminal kinase. Acta Biochim Biophys Sin (Shanghai) 2012;44:442-9. [PMID: 22427461 DOI: 10.1093/abbs/gms013] [Cited by in Crossref: 23] [Cited by in F6Publishing: 17] [Article Influence: 2.6] [Reference Citation Analysis]
398 F. Clausen OP, Lothe RA, Børresen-dale A, Angelis PD, Chen Y, Rognum TO, Meling GI. Association of p53 Accumulation With TP53 Mutations, Loss of Heterozygosity at 17p13, and DNA Ploidy Status in 273 Colorectal Carcinomas: . Diagnostic Molecular Pathology 1998;7:215-23. [DOI: 10.1097/00019606-199808000-00006] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 0.7] [Reference Citation Analysis]
399 Terada R, Yasutake T, Nakamura S, Hisamatsu T, Nakagoe T, Ayabe H, Tagawa Y. Evaluation of metastatic potential of gastric tumors by staining for proliferating cell nuclear antigen and chromosome 17 numerical aberrations. Ann Surg Oncol. 2001;8:525-532. [PMID: 11456052 DOI: 10.1007/s10434-001-0525-3] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
400 Hynes MJ, Huang KM, Huang EH. Review Paper: Implications of the “Cancer Stem Cell” Hypothesis on Murine Models of Colon Cancer and Colitis-associated Cancer. Vet Pathol 2009;46:819-35. [DOI: 10.1354/vp.08-vp-0172-h-rev] [Cited by in Crossref: 8] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
401 Naito M, Satake M, Sakai E, Hirano Y, Tsuchida N, Kanzaki H, Ito Y, Mori T. Detection of p53 gene mutations in human ovarian and endometrial cancers by polymerase chain reaction-single strand conformation polymorphism analysis. Jpn J Cancer Res 1992;83:1030-6. [PMID: 1333465 DOI: 10.1111/j.1349-7006.1992.tb02717.x] [Cited by in Crossref: 26] [Cited by in F6Publishing: 25] [Article Influence: 0.9] [Reference Citation Analysis]
402 Stephenson T, Royds J, Silcocks P, Bleehen S. Mutant p53 oncogene expression in keratoacanthoma and squamous cell carcinoma. Br J Dermatol 1992;127:566-70. [DOI: 10.1111/j.1365-2133.1992.tb14866.x] [Cited by in Crossref: 39] [Cited by in F6Publishing: 34] [Article Influence: 1.3] [Reference Citation Analysis]
403 Mikkelsen T. Genetics of Astrocytic Tumor Progression. Molecular Genetic Medicine. Elsevier; 1993. pp. 69-94. [DOI: 10.1016/b978-0-12-462003-2.50007-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
404 Hibi K, Nakayama H, Kanyama Y, Kodera Y, Ito K, Akiyama S, Nakao A. Methylation pattern of HLTF gene in digestive tract cancers. Int J Cancer. 2003;104:433-436. [PMID: 12584739 DOI: 10.1002/ijc.10985] [Cited by in Crossref: 26] [Cited by in F6Publishing: 27] [Article Influence: 1.4] [Reference Citation Analysis]
405 Michalovitz D, Halevy O, Oren M. p53 mutations: gains or losses. J Cell Biochem. 1991;45:22-29. [PMID: 2005181 DOI: 10.1002/jcb.240450108] [Cited by in Crossref: 70] [Cited by in F6Publishing: 77] [Article Influence: 2.3] [Reference Citation Analysis]
406 Minna JD, Nau MM, Takahashi T, Schütte J, Chiba I, Viallet J, Kaye F, Whang-peng J, Oie H, Russell E, Gazdar AF. Molecular Pathogenesis of Lung Cancer. Molecular Mechanisms and their Clinical Application in Malignancies. Elsevier; 1991. pp. 63-83. [DOI: 10.1016/b978-0-12-091075-5.50011-1] [Cited by in Crossref: 2] [Article Influence: 0.1] [Reference Citation Analysis]
407 Sehgal A. Molecular changes during the genesis of human gliomas. Semin Surg Oncol 1998;14:3-12. [DOI: 10.1002/(sici)1098-2388(199801/02)14:1<3::aid-ssu2>3.0.co;2-f] [Cited by in Crossref: 58] [Cited by in F6Publishing: 30] [Article Influence: 2.5] [Reference Citation Analysis]
408 Lazarus P, Garewal HS, Sciubba J, Zwiebel N, Calcagnotto A, Fair A, Schaefer S, Richie JP Jr. A low incidence of p53 mutations in pre-malignant lesions of the oral cavity from non-tobacco users. Int J Cancer 1995;60:458-63. [PMID: 7829258 DOI: 10.1002/ijc.2910600406] [Cited by in Crossref: 29] [Cited by in F6Publishing: 29] [Article Influence: 1.1] [Reference Citation Analysis]
409 Koorey DJ, McCaughan GW. Tumour suppressor genes and colorectal neoplasia. J Gastroenterol Hepatol 1993;8:174-84. [PMID: 8471756 DOI: 10.1111/j.1440-1746.1993.tb01511.x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
410 Konishi K, Yamanishi K, Ishizaki K, Yamada K, Kishimoto S, Yasuno H. Analysis of p53 gene mutations and loss of heterozygosity for loci on chromosome 9q in basal cell carcinoma. Cancer Lett 1994;79:67-72. [PMID: 8187055 DOI: 10.1016/0304-3835(94)90064-7] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.1] [Reference Citation Analysis]
411 Iwashita I, Ueyama T, Iwashita A, Kawamoto K, Kitagawa S, Motooka M, Utsunomiya T, Masuda K. Natural history of colorectal carcinoma: can the tumor volume doubling time be predicted by radiologic findings or immunohistochemical variables? J Surg Oncol 1998;68:215-24. [PMID: 9721706 DOI: 10.1002/(sici)1096-9098(199808)68:4<215::aid-jso3>3.0.co;2-7] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
412 Hibi K, Taguchi M, Nakamura H, Hirai A, Fujikake Y, Matsui T, Kasai Y, Akiyama S, Ito K, Takagi H. Alternative splicing of the FHIT gene in colorectal cancers. Jpn J Cancer Res. 1997;88:385-388. [PMID: 9197530 DOI: 10.1111/j.1349-7006.1997.tb00393.x] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 0.6] [Reference Citation Analysis]
413 Gilbert B, Ahmad K, Roos J, Lehmann C, Chiba T, Ulrich-rückert S, Smeenk L, van Heeringen S, Maier TJ, Groner B, Steinhilber D. 5-Lipoxygenase is a direct p53 target gene in humans. Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms 2015;1849:1003-16. [DOI: 10.1016/j.bbagrm.2015.06.004] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 2.2] [Reference Citation Analysis]
414 Bettegowda C, Agrawal N, Jiao Y, Sausen M, Wood LD, Hruban RH, Rodriguez FJ, Cahill DP, McLendon R, Riggins G, Velculescu VE, Oba-Shinjo SM, Marie SK, Vogelstein B, Bigner D, Yan H, Papadopoulos N, Kinzler KW. Mutations in CIC and FUBP1 contribute to human oligodendroglioma. Science 2011;333:1453-5. [PMID: 21817013 DOI: 10.1126/science.1210557] [Cited by in Crossref: 383] [Cited by in F6Publishing: 318] [Article Influence: 38.3] [Reference Citation Analysis]
415 Chastre E, Empereur S, Di Gioia Y, El Mahdani N, Mareel M, Vleminckx K, Van Roy F, Bex V, Emami S, Spandidos DA, Gespach C. Neoplastic progression of human and rat intestinal cell lines after transfer of the ras and polyoma middle T oncogenes. Gastroenterology 1993;105:1776-89. [DOI: 10.1016/0016-5085(93)91076-t] [Cited by in Crossref: 26] [Cited by in F6Publishing: 4] [Article Influence: 0.9] [Reference Citation Analysis]
416 Sieben M, Herzer K, Zeidler M, Heinrichs V, Leuchs B, Schuler M, Cornelis JJ, Galle PR, Rommelaere J, Moehler M. Killing of p53-deficient hepatoma cells by parvovirus H-1 and chemotherapeutics requires promyelocytic leukemia protein. World J Gastroenterol 2008; 14(24): 3819-3828 [PMID: 18609705 DOI: 10.3748/wjg.14.3819] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 12] [Article Influence: 0.8] [Reference Citation Analysis]
417 Daruwalla J, Christophi C. Hyperbaric oxygen therapy for malignancy: a review. World J Surg 2006;30:2112-31. [PMID: 17102915 DOI: 10.1007/s00268-006-0190-6] [Cited by in Crossref: 64] [Cited by in F6Publishing: 57] [Article Influence: 4.6] [Reference Citation Analysis]
418 Goddard AD, Solomon E. Genetic Aspects of Cancer. In: Harris H, Hirschhorn K, editors. Advances in Human Genetics 21. Boston: Springer US; 1993. pp. 321-76. [DOI: 10.1007/978-1-4615-3010-7_4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
419 Kawasaki ES. The Polymerase Chain Reaction: Its use in the Molecular Characterization and Diagnosis of Cancers. Cancer Investigation 2009;10:417-29. [DOI: 10.3109/07357909209024799] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
420 Yukawa M, Fujimori T, Maeda S, Tabuchi M, Nagasako K. Comparative clinicopathological and immunohistochemical study of ras and p53 in flat and polypoid type colorectal tumours. Gut 1994;35:1258-61. [PMID: 7959233 DOI: 10.1136/gut.35.9.1258] [Cited by in Crossref: 44] [Cited by in F6Publishing: 38] [Article Influence: 1.6] [Reference Citation Analysis]
421 Woods SJ, Hannan KM, Pearson RB, Hannan RD. The nucleolus as a fundamental regulator of the p53 response and a new target for cancer therapy. Biochim Biophys Acta 2015;1849:821-9. [PMID: 25464032 DOI: 10.1016/j.bbagrm.2014.10.007] [Cited by in Crossref: 82] [Cited by in F6Publishing: 81] [Article Influence: 11.7] [Reference Citation Analysis]
422 Fitzpatrick FA. Inflammation, carcinogenesis and cancer. Int Immunopharmacol. 2001;1:1651-1667. [PMID: 11562058 DOI: 10.1016/s1567-5769(01)00102-3] [Cited by in Crossref: 103] [Cited by in F6Publishing: 33] [Article Influence: 5.4] [Reference Citation Analysis]
423 Nehls O, Klump B, Holzmann K, Lammering G, Borchard F, Gruenagel H, Gaco V, Gregor M, Porschen R. Influence of p53 status on prognosis in preoperatively irradiated rectal carcinoma. Cancer 1999;85:2541-8. [DOI: 10.1002/(sici)1097-0142(19990615)85:12<2541::aid-cncr8>3.0.co;2-x] [Cited by in Crossref: 30] [Article Influence: 1.4] [Reference Citation Analysis]
424 Iino H, Fukayama M, Maeda Y, Koike M, Mori T, Takahashi T, Kikuchi-yanoshita R, Miyaki M, Mizuno S, Watanabe S. Molecular genetics for clinical management of colorectal carcinoma. 17p, 18q, and 22q loss of heterozygosity and decreased DCC expression are correlated with the metastatic potential. Cancer 1994;73:1324-31. [DOI: 10.1002/1097-0142(19940301)73:5<1324::aid-cncr2820730503>3.0.co;2-w] [Cited by in Crossref: 68] [Cited by in F6Publishing: 21] [Article Influence: 2.5] [Reference Citation Analysis]
425 Sclafani F, Gonzalez D, Cunningham D, Hulkki Wilson S, Peckitt C, Tabernero J, Glimelius B, Cervantes A, Dewdney A, Wotherspoon A, Brown G, Tait D, Oates J, Chau I. TP53 Mutational Status and Cetuximab Benefit in Rectal Cancer: 5-Year Results of the EXPERT-C Trial. JNCI: Journal of the National Cancer Institute 2014;106. [DOI: 10.1093/jnci/dju121] [Cited by in Crossref: 40] [Cited by in F6Publishing: 33] [Article Influence: 5.7] [Reference Citation Analysis]
426 Gope ML, Chun M, Gope R. Comparative study of the expression of Rb and p53 genes in human colorectal cancers, colon carcinoma cell lines and synchronized human fibroblasts. Mol Cell Biochem 1991;107:55-63. [PMID: 1784274 DOI: 10.1007/BF02424576] [Cited by in Crossref: 17] [Cited by in F6Publishing: 9] [Article Influence: 0.6] [Reference Citation Analysis]
427 Mulshine JL, Birrer M, Treston AM, Scott F, Quinn K, Avis I, Cuttitta F. Growth Factors and Other Targets for Rational Application as Intervention Agents. In: Newell GR, Hong WK, editors. The Biology and Prevention of Aerodigestive Tract Cancers. Boston: Springer US; 1992. pp. 81-8. [DOI: 10.1007/978-1-4615-3468-6_11] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.0] [Reference Citation Analysis]
428 Di Giovanni S, Rathore K. p53-Dependent pathways in neurite outgrowth and axonal regeneration. Cell Tissue Res 2012;349:87-95. [PMID: 22271139 DOI: 10.1007/s00441-011-1292-5] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 2.4] [Reference Citation Analysis]
429 Lewis DJ, Sesterhenn IA, McCarthy WF, Moul JW. Immunohistochemical expression of P53 tumor suppressor gene protein in adult germ cell testis tumors: clinical correlation in stage I disease. J Urol 1994;152:418-23. [PMID: 8015085 DOI: 10.1016/s0022-5347(17)32753-2] [Cited by in Crossref: 43] [Cited by in F6Publishing: 2] [Article Influence: 1.6] [Reference Citation Analysis]
430 Sakai E, Fukuyo M, Matsusaka K, Ohata K, Doi N, Takane K, Matsuhashi N, Fukushima J, Nakajima A, Kaneda A. TP53 mutation at early stage of colorectal cancer progression from two types of laterally spreading tumors. Cancer Sci 2016;107:820-7. [PMID: 26991699 DOI: 10.1111/cas.12930] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 2.6] [Reference Citation Analysis]
431 Gaiani F, Marchesi F, Negri F, Greco L, Malesci A, de'Angelis GL, Laghi L. Heterogeneity of Colorectal Cancer Progression: Molecular Gas and Brakes. Int J Mol Sci 2021;22:5246. [PMID: 34063506 DOI: 10.3390/ijms22105246] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
432 Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell. 1990;61:759-767. [PMID: 2188735 DOI: 10.1016/0092-8674(90)90186-i] [Cited by in Crossref: 7557] [Cited by in F6Publishing: 2734] [Article Influence: 243.8] [Reference Citation Analysis]
433 Gjerset RA, Arya J, Volkman S, Haas M. Association of induction of a fully tumorigenic phenotype in murine radiation-induced T-lymphoma cells with loss of differentiation antigens, gain of CD44, and alterations in p53 protein levels. Mol Carcinog 1992;5:190-8. [DOI: 10.1002/mc.2940050305] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 0.2] [Reference Citation Analysis]
434 Zhang X, Wu Z, Peng Y, Li D, Jiang Y, Pan F, Li Y, Lai Y, Cui Z, Zhang K. Correlationship between Ki67, VEGF, and p53 and Hepatocellular Carcinoma Recurrence in Liver Transplant Patients. Biomed Res Int 2021;2021:6651397. [PMID: 33954191 DOI: 10.1155/2021/6651397] [Reference Citation Analysis]
435 Simon D, Goretzki PE, Goreley V, Ebling B, Reishaus E, Lyons J, Haubruck H, R�her HD. Significance of P53 in human thyroid tumors. World J Surg 1994;18:535-40. [DOI: 10.1007/bf00353758] [Cited by in Crossref: 13] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
436 McLaughlin-Drubin ME, Munger K. Viruses associated with human cancer. Biochim Biophys Acta 2008;1782:127-50. [PMID: 18201576 DOI: 10.1016/j.bbadis.2007.12.005] [Cited by in Crossref: 203] [Cited by in F6Publishing: 163] [Article Influence: 14.5] [Reference Citation Analysis]
437 Sedman SA, Hubbert NL, Vass WC, Lowy DR, Schiller JT. Mutant p53 can substitute for human papillomavirus type 16 E6 in immortalization of human keratinocytes but does not have E6-associated trans-activation or transforming activity. J Virol 1992;66:4201-8. [DOI: 10.1128/jvi.66.7.4201-4208.1992] [Cited by in Crossref: 56] [Cited by in F6Publishing: 20] [Article Influence: 1.9] [Reference Citation Analysis]
438 Leary RJ, Sausen M, Kinde I, Papadopoulos N, Carpten JD, Craig D, O'Shaughnessy J, Kinzler KW, Parmigiani G, Vogelstein B, Diaz LA Jr, Velculescu VE. Detection of chromosomal alterations in the circulation of cancer patients with whole-genome sequencing. Sci Transl Med 2012;4:162ra154. [PMID: 23197571 DOI: 10.1126/scitranslmed.3004742] [Cited by in Crossref: 419] [Cited by in F6Publishing: 384] [Article Influence: 52.4] [Reference Citation Analysis]
439 Oka K, Ishikawa J, Bruner JM, Takahashi R, Saya H. Detection of loss of heterozygosity in thep53 gene in renal cell carcinoma and bladder cancer using the polymerase chain reaction. Mol Carcinog 1991;4:10-3. [DOI: 10.1002/mc.2940040104] [Cited by in Crossref: 43] [Cited by in F6Publishing: 38] [Article Influence: 1.4] [Reference Citation Analysis]
440 Nakai H, Misawa S, Horiike S, Maekawa T, Kashima K, Ishizaki K. Hemizygous expression of the wild-type p53 allele may confer a selective growth advantage before complete inactivation of the p53 gene in the progression of chronic myelogenous leukaemia. Br J Haematol 1995;90:147-55. [DOI: 10.1111/j.1365-2141.1995.tb03393.x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.2] [Reference Citation Analysis]
441 Erlich HA. Polymerase chain reaction. J Clin Immunol 1989;9:437-47. [PMID: 2698397 DOI: 10.1007/BF00918012] [Cited by in Crossref: 34] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]
442 Wynford-thomas D. Oncogenes and anti-oncogenes; the molecular basis of tumour behaviour. J Pathol 1991;165:187-201. [DOI: 10.1002/path.1711650302] [Cited by in Crossref: 60] [Cited by in F6Publishing: 53] [Article Influence: 2.0] [Reference Citation Analysis]
443 Buchhagen DL. Molecular mechanisms in lung pathogenesis. Biochim Biophys Acta 1991;1072:159-76. [PMID: 1751546 DOI: 10.1016/0304-419x(91)90012-a] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.0] [Reference Citation Analysis]
444 Miyakoshi J, Scudiero DA, Allalunis-Turner J, Day RS 3rd. The sensitivities of SV40-transformed human fibroblasts to monofunctional and DNA-crosslinking alkylating agents. Mutat Res 1991;254:55-64. [PMID: 1846027 DOI: 10.1016/0921-8777(91)90040-v] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
445 Smith-Sørensen B, Gebhardt MC, Kloen P, McIntyre J, Aguilar F, Cerutti P, Børresen AL. Screening for TP53 mutations in osteosarcomas using constant denaturant gel electrophoresis (CDGE). Hum Mutat 1993;2:274-85. [PMID: 8401536 DOI: 10.1002/humu.1380020407] [Cited by in Crossref: 27] [Cited by in F6Publishing: 31] [Article Influence: 1.0] [Reference Citation Analysis]
446 Raffel C, Thomas GA, Tishler DM, Lassoff S, Allen JC. Absence of p53 Mutations in Childhood Central Nervous System Primitive Neuroectodermal Tumors. Neurosurgery 1993;33:301-6. [DOI: 10.1097/00006123-199308000-00018] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 0.5] [Reference Citation Analysis]
447 Tabiti K, Smith DR, Goh HS, Pallen CJ. Increased mRNA expression of the receptor-like protein tyrosine phosphatase alpha in late stage colon carcinomas. Cancer Lett 1995;93:239-48. [PMID: 7621435 DOI: 10.1016/0304-3835(95)03816-f] [Cited by in Crossref: 39] [Cited by in F6Publishing: 13] [Article Influence: 1.5] [Reference Citation Analysis]
448 Gryfe R. Overview of Colorectal Cancer Genetics. Surgical Oncology Clinics of North America 2009;18:573-83. [DOI: 10.1016/j.soc.2009.08.004] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
449 Salehi F, Baronio R, Idrogo-Lam R, Vu H, Hall LV, Kaiser P, Lathrop RH. CHOPER filters enable rare mutation detection in complex mutagenesis populations by next-generation sequencing. PLoS One 2015;10:e0116877. [PMID: 25692681 DOI: 10.1371/journal.pone.0116877] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
450 Demir S, Boldrin E, Sun Q, Hampp S, Tausch E, Eckert C, Ebinger M, Handgretinger R, Kronnie GT, Wiesmüller L, Stilgenbauer S, Selivanova G, Debatin KM, Meyer LH. Therapeutic targeting of mutant p53 in pediatric acute lymphoblastic leukemia. Haematologica 2020;105:170-81. [PMID: 31073076 DOI: 10.3324/haematol.2018.199364] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 7.0] [Reference Citation Analysis]
451 Markowitz SD, Bertagnolli MM. Molecular origins of cancer: Molecular basis of colorectal cancer. N Engl J Med. 2009;361:2449-2460. [PMID: 20018966 DOI: 10.1056/NE] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
452 Mecucci C, Battista VD, Nofrini V. The myelodysplastic syndromes. In: Tosi S, Reid AG, editors. The Genetic Basis of Haematological Cancers. Chichester: John Wiley & Sons, Ltd; 2016. pp. 1-79. [DOI: 10.1002/9781118527948.ch1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
453 Law JC, Ritke MK, Yalowich JC, Leder GH, Ferrell RE. Mutational inactivation of the p53 gene in the human erythroid leukemic K562 cell line. Leukemia Research 1993;17:1045-50. [DOI: 10.1016/0145-2126(93)90161-d] [Cited by in Crossref: 96] [Cited by in F6Publishing: 35] [Article Influence: 3.4] [Reference Citation Analysis]
454 Budde A, Grummt I. p53 represses ribosomal gene transcription. Oncogene 1999;18:1119-24. [PMID: 10023689 DOI: 10.1038/sj.onc.1202402] [Cited by in Crossref: 106] [Cited by in F6Publishing: 113] [Article Influence: 4.8] [Reference Citation Analysis]
455 Lubin MB, Lin HJ, Vadheim CM, Rotter JI. Genetics of Common Diseases of Adulthood. Clinics in Perinatology 1990;17:889-910. [DOI: 10.1016/s0095-5108(18)30551-7] [Cited by in Crossref: 4] [Article Influence: 0.1] [Reference Citation Analysis]
456 Fero ML, Randel E, Gurley KE, Roberts JM, Kemp CJ. The murine gene p27Kip1 is haplo-insufficient for tumour suppression. Nature. 1998;396:177-180. [PMID: 9823898 DOI: 10.1038/24179] [Cited by in Crossref: 525] [Cited by in F6Publishing: 517] [Article Influence: 22.8] [Reference Citation Analysis]
457 Stephen CW, Lane DP. Mutant conformation of p53. Journal of Molecular Biology 1992;225:577-83. [DOI: 10.1016/0022-2836(92)90386-x] [Cited by in Crossref: 130] [Cited by in F6Publishing: 37] [Article Influence: 4.5] [Reference Citation Analysis]
458 Sidransky D, Mikkelsen T, Schwechheimer K, Rosenblum ML, Cavanee W, Vogelstein B. Clonal expansion of p53 mutant cells is associated with brain tumour progression. Nature 1992;355:846-7. [PMID: 1311419 DOI: 10.1038/355846a0] [Cited by in Crossref: 445] [Cited by in F6Publishing: 421] [Article Influence: 15.3] [Reference Citation Analysis]
459 Valdez JM, Nichols KE, Kesserwan C. Li-Fraumeni syndrome: a paradigm for the understanding of hereditary cancer predisposition. Br J Haematol 2017;176:539-52. [DOI: 10.1111/bjh.14461] [Cited by in Crossref: 50] [Cited by in F6Publishing: 32] [Article Influence: 10.0] [Reference Citation Analysis]
460 Michalovitz D, Halevy O, Oren M. Conditional inhibition of transformation and of cell proliferation by a temperature-sensitive mutant of p53. Cell 1990;62:671-80. [DOI: 10.1016/0092-8674(90)90113-s] [Cited by in Crossref: 491] [Cited by in F6Publishing: 221] [Article Influence: 15.8] [Reference Citation Analysis]
461 Faro A, Boj SF, Clevers H. Fishing for intestinal cancer models: unraveling gastrointestinal homeostasis and tumorigenesis in zebrafish. Zebrafish 2009;6:361-76. [PMID: 19929219 DOI: 10.1089/zeb.2009.0617] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 1.5] [Reference Citation Analysis]
462 Kern SE. p53: tumor suppression through control of the cell cycle. Gastroenterology 1994;106:1708-11. [PMID: 8194721 DOI: 10.1016/0016-5085(94)90431-6] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 0.7] [Reference Citation Analysis]
463 Armour JA, Sismani C, Patsalis PC, Cross G. Measurement of locus copy number by hybridisation with amplifiable probes. Nucleic Acids Res 2000;28:605-9. [PMID: 10606661 DOI: 10.1093/nar/28.2.605] [Cited by in Crossref: 135] [Cited by in F6Publishing: 126] [Article Influence: 6.4] [Reference Citation Analysis]
464 Ferreira A, Kosik K. Accelerated neuronal differentiation induced by p53 suppression. Journal of Cell Science 1996;109:1509-16. [DOI: 10.1242/jcs.109.6.1509] [Cited by in Crossref: 22] [Cited by in F6Publishing: 16] [Article Influence: 0.9] [Reference Citation Analysis]
465 Martella M, Catalanotto C, Talora C, La Teana A, Londei P, Benelli D. Inhibition of Eukaryotic Translation Initiation Factor 5A (eIF5A) Hypusination Suppress p53 Translation and Alters the Association of eIF5A to the Ribosomes. Int J Mol Sci 2020;21:E4583. [PMID: 32605139 DOI: 10.3390/ijms21134583] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
466 Roberts RA. Transgenic rodent mutation/cancer bioassays: cell cycle control, cell proliferation and apoptosis as modifiers of outcome1No. 84 was published in Mutation Research – Genetic Toxicology and Environmental Mutagenesis.1. Mutation Research/Fundamental and Molecular Mechanisms of Mutagenesis 1998;398:189-95. [DOI: 10.1016/s0027-5107(97)00239-x] [Cited by in Crossref: 4] [Article Influence: 0.2] [Reference Citation Analysis]
467 Gallie BL, Dunn JM, Chan HS, Hamel PA, Phillips RA. The Genetics of Retinoblastoma: Relevance to the Patient. Pediatric Clinics of North America 1991;38:299-315. [DOI: 10.1016/s0031-3955(16)38079-8] [Cited by in Crossref: 35] [Cited by in F6Publishing: 4] [Article Influence: 1.2] [Reference Citation Analysis]
468 Hori M, Suzuki K, Udono MU, Yamauchi M, Mine M, Watanabe M, Kondo S, Hozumi Y. Establishment of ponasterone A-inducible the wild-type p53 protein-expressing clones from HSC-1 cells, cell growth suppression by p53 expression and the suppression mechanism. Arch Dermatol Res 2009;301:631-46. [PMID: 19009304 DOI: 10.1007/s00403-008-0915-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
469 Grewal H, Guillem JG, Klimstra DS, Cohen AM. p53 Nuclear overexpression may not be an independent prognostic marker in early colorectal cancer. Diseases of the Colon & Rectum 1995;38:1176-81. [DOI: 10.1007/bf02048333] [Cited by in Crossref: 17] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
470 Wagner S, Beger NT, Matschos S, Szymanski A, Przybylla R, Bürtin F, Prall F, Linnebacher M, Mullins CS. Tumour-Derived Cell Lines and Their Potential for Therapy Prediction in Patients with Metastatic Colorectal Cancer. Cancers (Basel) 2021;13:4717. [PMID: 34572946 DOI: 10.3390/cancers13184717] [Reference Citation Analysis]
471 Lozano G, Levine AJ. Tissue-specific expression of p53 in transgenic mice is regulated by intron sequences. Mol Carcinog 1991;4:3-9. [PMID: 1848986 DOI: 10.1002/mc.2940040103] [Cited by in Crossref: 52] [Cited by in F6Publishing: 57] [Article Influence: 1.7] [Reference Citation Analysis]
472 Levine AJ. The road to the discovery of the p53 protein. The Steiner Cancer Prize Award Lecture. Int J Cancer 1994;56:775-6. [PMID: 8119764 DOI: 10.1002/ijc.2910560602] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
473 Chandar N, Billig B, McMaster J, Novak J. Inactivation of p53 gene in human and murine osteosarcoma cells. Br J Cancer. 1992;65:208-214. [PMID: 1739619 DOI: 10.1038/bjc.1992.43] [Cited by in Crossref: 114] [Cited by in F6Publishing: 111] [Article Influence: 3.9] [Reference Citation Analysis]
474 Kojima M, Konishi F, Tsukamoto T, Yamashita K, Kanazawa K. Ki-ras point mutation in different types of colorectal carcinomas in early stages. Dis Colon Rectum. 1997;40:161-167. [PMID: 9075750 DOI: 10.1007/bf02054981] [Cited by in Crossref: 13] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
475 Abood ME. Molecular biology of cannabinoid receptors. Handb Exp Pharmacol 2005;:81-115. [PMID: 16596772 DOI: 10.1007/3-540-26573-2_3] [Cited by in Crossref: 31] [Cited by in F6Publishing: 28] [Article Influence: 2.1] [Reference Citation Analysis]
476 Newton HB, Rosenblum MK, Malkin MG. Turcot's syndrome. Flow cytometric analysis. Cancer 1991;68:1633-9. [DOI: 10.1002/1097-0142(19911001)68:7<1633::aid-cncr2820680728>3.0.co;2-1] [Cited by in Crossref: 10] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
477 Solomon DA, Kim JS, Ressom HW, Sibenaller Z, Ryken T, Jean W, Bigner D, Yan H, Waldman T. Sample type bias in the analysis of cancer genomes. Cancer Res 2009;69:5630-3. [PMID: 19567670 DOI: 10.1158/0008-5472.CAN-09-1055] [Cited by in Crossref: 23] [Cited by in F6Publishing: 15] [Article Influence: 1.9] [Reference Citation Analysis]
478 Lane D, Levine A. p53 Research: the past thirty years and the next thirty years. Cold Spring Harb Perspect Biol 2010;2:a000893. [PMID: 20463001 DOI: 10.1101/cshperspect.a000893] [Cited by in Crossref: 194] [Cited by in F6Publishing: 227] [Article Influence: 17.6] [Reference Citation Analysis]
479 Rochlitz CF, Heide I, de Kant E, Neubauer A, Schmidt CA, Neuhaus P, Huhn D, Herrmann R. Molecular alterations in a patient with Turcot's syndrome. Br J Cancer 1993;68:519-23. [PMID: 8394730 DOI: 10.1038/bjc.1993.379] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 0.3] [Reference Citation Analysis]
480 Nowell PC. Cytogenetics of tumor progression. Cancer 1990;65:2172-7. [DOI: 10.1002/1097-0142(19900515)65:10<2172::aid-cncr2820651003>3.0.co;2-k] [Cited by in Crossref: 24] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
481 Maurici D, Perez-atayde A, Grier HE, Baldini N, Serra M, Fletcher JA. Frequency and Implications of Chromosome 8 and 12 Gains in Ewing Sarcoma. Cancer Genetics and Cytogenetics 1998;100:106-10. [DOI: 10.1016/s0165-4608(97)00028-9] [Cited by in Crossref: 50] [Cited by in F6Publishing: 14] [Article Influence: 2.2] [Reference Citation Analysis]
482 Ribeiro U, Safatle-ribeiro AV, Posner MC, Rosendale B, Bakker A, Swalsky PA, Kim R, Reynolds JC, Finkelstein SD. Comparative p53 mutational analysis of multiple primary cancers of the upper aerodigestive tract. Surgery 1996;120:45-53. [DOI: 10.1016/s0039-6060(96)80240-6] [Cited by in Crossref: 22] [Cited by in F6Publishing: 2] [Article Influence: 0.9] [Reference Citation Analysis]
483 Giorgi C, Bonora M, Missiroli S, Morganti C, Morciano G, Wieckowski MR, Pinton P. Alterations in Mitochondrial and Endoplasmic Reticulum Signaling by p53 Mutants. Front Oncol 2016;6:42. [PMID: 26942128 DOI: 10.3389/fonc.2016.00042] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 3.2] [Reference Citation Analysis]
484 Ozaki T, Nakagawara A. p53: the attractive tumor suppressor in the cancer research field. J Biomed Biotechnol 2011;2011:603925. [PMID: 21188172 DOI: 10.1155/2011/603925] [Cited by in Crossref: 53] [Cited by in F6Publishing: 59] [Article Influence: 4.8] [Reference Citation Analysis]
485 Thompson A, Steel C, Chetty U, Carter D. Evidence for the multistep theory of carcinogenesis in human breast cancer. The Breast 1992;1:29-34. [DOI: 10.1016/0960-9776(92)90009-q] [Cited by in Crossref: 4] [Article Influence: 0.1] [Reference Citation Analysis]
486 Stemmermann G, Heffelfinger SC, Noffsinger A, Hui YZ, Miller MA, Fenoglio-Preiser CM. The molecular biology of esophageal and gastric cancer and their precursors: oncogenes, tumor suppressor genes, and growth factors. Hum Pathol. 1994;25:968-981. [PMID: 7927320 DOI: 10.1016/0046-8177(94)90056-6] [Cited by in Crossref: 82] [Cited by in F6Publishing: 83] [Article Influence: 3.0] [Reference Citation Analysis]
487 Kraiss S, Espig R, Vetter U, Hartmann W, Montenarh M. Expression of p53 in human leukemic cell lines. Leukemia Research 1990;14:1041-51. [DOI: 10.1016/0145-2126(90)90118-s] [Cited by in Crossref: 3] [Article Influence: 0.1] [Reference Citation Analysis]
488 Park JY, Mitrou PN, Keen J, Dahm CC, Gay LJ, Luben RN, McTaggart A, Khaw KT, Ball RY, Arends MJ, Rodwell SA. Lifestyle factors and p53 mutation patterns in colorectal cancer patients in the EPIC-Norfolk study. Mutagenesis 2010;25:351-8. [PMID: 20228093 DOI: 10.1093/mutage/geq012] [Cited by in F6Publishing: 9] [Reference Citation Analysis]
489 Matsusaka K, Funata S, Fukayama M, Kaneda A. DNA methylation in gastric cancer, related to Helicobacter pylori and Epstein-Barr virus. World J Gastroenterol 2014; 20(14): 3916-3926 [PMID: 24744581 DOI: 10.3748/wjg.v20.i14.3916] [Cited by in CrossRef: 56] [Cited by in F6Publishing: 51] [Article Influence: 8.0] [Reference Citation Analysis]
490 Bhagirath T, Condie A, Dunlop MG, Wyllie AH, Prosser J. Exclusion of constitutional p53 mutations as a cause of genetic susceptibility to colorectal cancer. Br J Cancer 1993;68:712-4. [PMID: 8398698 DOI: 10.1038/bjc.1993.415] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
491 Garatti SA, Roscetti E, Trecca D, Fracchiolla NS, Neri A, Berti E. bcl-1, bcl-2, p53, c-myc, and lyt-10 Analysis in Cutaneous Lymphomas. In: Garbe C, Schmitz S, Orfanos CE, editors. Skin Cancer: Basic Science, Clinical Research and Treatment. Berlin: Springer Berlin Heidelberg; 1995. pp. 249-61. [DOI: 10.1007/978-3-642-78771-3_19] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 0.8] [Reference Citation Analysis]
492 Bargonetti J, Friedman PN, Kern SE, Vogelstein B, Prives C. Wild-type but not mutant p53 immunopurified proteins bind to sequences adjacent to the SV40 origin of replication. Cell 1991;65:1083-91. [PMID: 1646078 DOI: 10.1016/0092-8674(91)90560-l] [Cited by in Crossref: 227] [Cited by in F6Publishing: 122] [Article Influence: 7.6] [Reference Citation Analysis]
493 Imam SA, Stampfer MR, Yilmaz A, Taylor CR. Identification of a cell-surface glycoprotein associated with normal mammary and extramammary epithelial cells. Br J Cancer 1994;69:439-44. [PMID: 8123470 DOI: 10.1038/bjc.1994.80] [Reference Citation Analysis]
494 Yokozaki H, Kuniyasu H, Kitadai Y, Nishimura K, Todo H, Ayhan A, Yasui W, Ito H, Tahara E. p53 point mutations in primary human gastric carcinomas. J Cancer Res Clin Oncol. 1992;119:67-70. [PMID: 1429828 DOI: 10.1007/bf01209657] [Cited by in Crossref: 47] [Cited by in F6Publishing: 24] [Article Influence: 1.6] [Reference Citation Analysis]
495 Deutsch MD, Li Y, Utz G, Mcdonald JS, Nguyen C, Pavelic L, Wilson KM, Gluckman JL, Pavelic ZP. The Role of the p53 Tumor Suppressor Gene in the Tumorigenesis of Inverting Papilloma of the Nose and Paranasal Sinuses. American Journal of Rhinology 1996;10:97-100. [DOI: 10.2500/105065896781795012] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
496 Tariq K, Ghias K. Colorectal cancer carcinogenesis: a review of mechanisms. Cancer Biol Med. 2016;13:120-135. [PMID: 27144067 DOI: 10.28092/j.issn.2095-3941.2015.0103] [Cited by in F6Publishing: 72] [Reference Citation Analysis]
497 Hainaut P, Pfeifer GP. Somatic TP53 Mutations in the Era of Genome Sequencing. Cold Spring Harb Perspect Med 2016;6:a026179. [PMID: 27503997 DOI: 10.1101/cshperspect.a026179] [Cited by in Crossref: 87] [Cited by in F6Publishing: 80] [Article Influence: 17.4] [Reference Citation Analysis]
498 Baretton GB, Vogt M, Müller C, Diebold J, Schneiderbanger K, Schmidt M, Löhrs U. Prognostic Significance of p53 Expression, Chromosome 17 Copy Number, and DNA Ploidy in Non-Metastasized Colorectal Carcinomas (Stages IB and II). Scandinavian Journal of Gastroenterology 2009;31:481-9. [DOI: 10.3109/00365529609006769] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.0] [Reference Citation Analysis]
499 Tiwari B, Jones AE, Abrams JM. Transposons, p53 and Genome Security. Trends Genet 2018;34:846-55. [PMID: 30195581 DOI: 10.1016/j.tig.2018.08.003] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 3.7] [Reference Citation Analysis]
500 Houbiers JG, van der Burg SH, van de Watering LM, Tollenaar RA, Brand A, van de Velde CJ, Melief CJ. Antibodies against p53 are associated with poor prognosis of colorectal cancer. Br J Cancer 1995;72:637-41. [PMID: 7669574 DOI: 10.1038/bjc.1995.386] [Cited by in Crossref: 94] [Cited by in F6Publishing: 93] [Article Influence: 3.6] [Reference Citation Analysis]
501 Raycroft L, Schmidt JR, Yoas K, Hao MM, Lozano G. Analysis of p53 mutants for transcriptional activity. Mol Cell Biol 1991;11:6067-74. [PMID: 1944276 DOI: 10.1128/mcb.11.12.6067-6074.1991] [Cited by in Crossref: 1] [Cited by in F6Publishing: 36] [Article Influence: 0.0] [Reference Citation Analysis]
502 Nigro JM, Baker SJ, Preisinger AC, Jessup JM, Hosteller R, Cleary K, Signer SH, Davidson N, Baylin S, Devilee P, Glover T, Collins FS, Weslon A, Modali R, Harris CC, Vogelstein B. Mutations in the p53 gene occur in diverse human tumour types. Nature 1989;342:705-8. [DOI: 10.1038/342705a0] [Cited by in Crossref: 1811] [Cited by in F6Publishing: 1787] [Article Influence: 56.6] [Reference Citation Analysis]
503 Cardoso J, Boer J, Morreau H, Fodde R. Expression and genomic profiling of colorectal cancer. Biochim Biophys Acta. 2007;1775:103-137. [PMID: 17010523 DOI: 10.1016/j.bbcan.2006.08.004] [Cited by in Crossref: 23] [Cited by in F6Publishing: 52] [Article Influence: 1.5] [Reference Citation Analysis]
504 Fazeli A, Steen RG, Dickinson SL, Bautista D, Dietrich WF, Bronson RT, Bresalier RS, Lander ES, Costa J, Weinberg RA. Effects of p53 mutations on apoptosis in mouse intestinal and human colonic adenomas. Proc Natl Acad Sci USA. 1997;94:10199-10204. [PMID: 9294187 DOI: 10.1073/pnas.94.19.10199] [Cited by in Crossref: 50] [Cited by in F6Publishing: 50] [Article Influence: 2.1] [Reference Citation Analysis]
505 Fung C, Bragg T, Newland R, Dent O, Nicholson G, Bokey L, Chapuis P. K-RAS MUTATION AND LOSS OF HETEROZYGOSITY OF CHROMOSOME 17P AND SURVIVAL IN COLORECTAL CANCER. ANZ J Surg 1997;67:239-44. [DOI: 10.1111/j.1445-2197.1997.tb01955.x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.3] [Reference Citation Analysis]
506 Levine AJ. The common mechanisms of transformation by the small DNA tumor viruses: The inactivation of tumor suppressor gene products: p53. Virology 2009;384:285-93. [DOI: 10.1016/j.virol.2008.09.034] [Cited by in Crossref: 132] [Cited by in F6Publishing: 129] [Article Influence: 11.0] [Reference Citation Analysis]
507 Martin D, Muñoz R, Subler M, Deb S. p53 binds to the TATA-binding protein-TATA complex. Journal of Biological Chemistry 1993;268:13062-7. [DOI: 10.1016/s0021-9258(19)38619-3] [Cited by in Crossref: 58] [Article Influence: 2.1] [Reference Citation Analysis]
508 Wang Y, Putnam CD, Kane MF, Zhang W, Edelmann L, Russell R, Carrión DV, Chin L, Kucherlapati R, Kolodner RD, Edelmann W. Mutation in Rpa1 results in defective DNA double-strand break repair, chromosomal instability and cancer in mice. Nat Genet 2005;37:750-5. [DOI: 10.1038/ng1587] [Cited by in Crossref: 110] [Cited by in F6Publishing: 102] [Article Influence: 6.9] [Reference Citation Analysis]
509 Deb S, Jackson CT, Subler MA, Martin DW. Modulation of cellular and viral promoters by mutant human p53 proteins found in tumor cells. J Virol 1992;66:6164-70. [PMID: 1356162 DOI: 10.1128/JVI.66.10.6164-6170.1992] [Cited by in Crossref: 121] [Cited by in F6Publishing: 51] [Article Influence: 4.2] [Reference Citation Analysis]
510 Ohashi M, Sugikawa E, Nakanishi N. Inhibition of p53 protein phosphorylation by 9-hydroxyellipticine: a possible anticancer mechanism. Jpn J Cancer Res 1995;86:819-27. [PMID: 7591958 DOI: 10.1111/j.1349-7006.1995.tb03091.x] [Cited by in Crossref: 54] [Cited by in F6Publishing: 41] [Article Influence: 2.1] [Reference Citation Analysis]
511 Kataoka M, Okabayashi T, Orita K. Decreased expression of DCC mRNA in gastric and colorectal cancer. Surg Today 1995;25:1001-7. [DOI: 10.1007/bf00311682] [Cited by in Crossref: 12] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
512 Gotlieb WH, Watson JM, Rezai A, Johnson M, Martínez-Maza O, Berek JS. Cytokine-induced modulation of tumor suppressor gene expression in ovarian cancer cells: up-regulation of p53 gene expression and induction of apoptosis by tumor necrosis factor-alpha. Am J Obstet Gynecol 1994;170:1121-8; discussion 1128-30. [PMID: 8166195 DOI: 10.1016/s0002-9378(94)70106-7] [Cited by in Crossref: 24] [Cited by in F6Publishing: 3] [Article Influence: 0.9] [Reference Citation Analysis]
513 Alexander RJ, Raicht RF. Purification of total RNA from human stool samples. Dig Dis Sci 1998;43:2652-8. [PMID: 9881497 DOI: 10.1023/a:1026699126899] [Cited by in Crossref: 16] [Cited by in F6Publishing: 8] [Article Influence: 0.7] [Reference Citation Analysis]
514 Lu Y, Yu Y, Zhu Z, Xu H, Ji J, Bu L, Liu B, Jiang H, Lin Y, Kong X. Identification of a new target region by loss of heterozygosity at 5p15.33 in sporadic gastric carcinomas: genotype and phenotype related. Cancer Lett. 2005;224:329-337. [PMID: 15914283 DOI: 10.1016/j.canlet.2004.11.057] [Cited by in Crossref: 15] [Cited by in F6Publishing: 19] [Article Influence: 0.9] [Reference Citation Analysis]
515 Stephenson TJ, Royds JA, Silcocks PB, Brammer HJ, Shorthouse AJ, Underwood JCE. Diagnostic associations of p53 immunostaining in fine needle aspiration cytology of the breast. Cytopathology 1994;5:146-53. [DOI: 10.1111/j.1365-2303.1994.tb00410.x] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 0.4] [Reference Citation Analysis]
516 Ando M, Maruyama M, Oto M, Takemura K, Endo M, Yuasa Y. Higher frequency of point mutations in the c-K-ras 2 gene in human colorectal adenomas with severe atypia than in carcinomas. Jpn J Cancer Res 1991;82:245-9. [PMID: 1708754 DOI: 10.1111/j.1349-7006.1991.tb01836.x] [Cited by in Crossref: 29] [Cited by in F6Publishing: 30] [Article Influence: 1.0] [Reference Citation Analysis]
517 Rodriguez MA, Ford RJ, Goodacre A, Selvanayagam P, Cabanillas F, Deisseroth AB. Chromosome 17p and p53 changes in lymphoma. Br J Haematol 1991;79:575-82. [DOI: 10.1111/j.1365-2141.1991.tb08084.x] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 0.8] [Reference Citation Analysis]
518 Cline MJ, Jat PS, Foti A. Molecular Mechanisms in the Evolution of Chronic Myelocytic Leukemia. Leukemia & Lymphoma 2009;7:283-7. [DOI: 10.3109/10428199209049779] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 0.9] [Reference Citation Analysis]
519 Tolcher AW, Hao D, de Bono J, Miller A, Patnaik A, Hammond LA, Smetzer L, Van Wart Hood J, Merritt J, Rowinsky EK, Takimoto C, Von Hoff D, Eckhardt SG. Phase I, Pharmacokinetic, and Pharmacodynamic Study of Intravenously Administered Ad5CMV-p53, an Adenoviral Vector Containing the Wild-Type p53 Gene, in Patients With Advanced Cancer. JCO 2006;24:2052-8. [DOI: 10.1200/jco.2005.03.6756] [Cited by in Crossref: 38] [Cited by in F6Publishing: 14] [Article Influence: 2.5] [Reference Citation Analysis]
520 Pories SE, Weber TK, Simpson H, Greathead P, Steele G, Summerhayes IC. Immortalization and neoplastic transformation of normal rat colon epithelium: An in vitro model of colonic neoplastic progression. Gastroenterology 1993;104:1346-55. [DOI: 10.1016/0016-5085(93)90343-b] [Cited by in Crossref: 11] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
521 Borland RN, Brendler CB, Isaacs WB. Molecular Biology of Bladder Cancer. Hematology/Oncology Clinics of North America 1992;6:31-9. [DOI: 10.1016/s0889-8588(18)30361-7] [Cited by in Crossref: 11] [Article Influence: 0.4] [Reference Citation Analysis]
522 Crook T, Fisher C, Vousden KH. Modulation of immortalizing properties of human papillomavirus type 16 E7 by p53 expression. J Virol 1991;65:505-10. [DOI: 10.1128/jvi.65.1.505-510.1991] [Cited by in Crossref: 20] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
523 Temin HM. Overview of biological effects of addition of DNA molecules to cells. J Med Virol 1990;31:13-7. [PMID: 2142957 DOI: 10.1002/jmv.1890310105] [Cited by in Crossref: 24] [Cited by in F6Publishing: 21] [Article Influence: 0.8] [Reference Citation Analysis]
524 Takayama T, Miyanishi K, Hayashi T, Sato Y, Niitsu Y. Colorectal cancer: genetics of development and metastasis. J Gastroenterol. 2006;41:185-192. [PMID: 16699851 DOI: 10.1007/s00535-006-1801-6.] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
525 Schwartz J, Shklar G, Trickler D. p53 in the anticancer mechanism of vitamin E. European Journal of Cancer Part B: Oral Oncology 1993;29:313-8. [DOI: 10.1016/0964-1955(93)90055-j] [Cited by in Crossref: 31] [Cited by in F6Publishing: 2] [Article Influence: 1.1] [Reference Citation Analysis]
526 Roa I, Araya JC, Shiraishi T, Yatani R, Wistuba I, Villaseca M, Aretxabala XD. DNA content in gallbladder carcinoma: a flow cytometric study of 96 cases. Histopathology 1993;23:459-64. [DOI: 10.1111/j.1365-2559.1993.tb00495.x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
527 Hernández Borrero LJ, El-Deiry WS. Tumor suppressor p53: Biology, signaling pathways, and therapeutic targeting. Biochim Biophys Acta Rev Cancer 2021;1876:188556. [PMID: 33932560 DOI: 10.1016/j.bbcan.2021.188556] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
528 Hiraga S, Arita N, Ohnishi T, Izumoto S, Taki T, Higuchi M, Iwaisako K, Sakoda S, Yamamoto Y, Hayakawa T. Establishment of spontaneously immortalized rat type 1 astroglial cell lines: the role of p53 in astroglial carcinogenesis. Glia 1996;18:185-99. [PMID: 8915651 DOI: 10.1002/(SICI)1098-1136(199611)18:3<185::AID-GLIA3>3.0.CO;2-Z] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
529 Lee CS, Pirdas A. p53 protein immunoreactivity in cancers of the gallbladder, extrahepatic bile ducts and ampulla of Vater. Pathology. 1995;27:117-120. [PMID: 7567135 DOI: 10.1080/00313029500169692] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 0.5] [Reference Citation Analysis]
530 Robson ME, Boyd J, Borgen PI, Cody HS. Hereditary breast cancer. Current Problems in Surgery 2001;38:387-480. [DOI: 10.1016/s0011-3840(01)70035-4] [Cited by in Crossref: 108] [Article Influence: 5.4] [Reference Citation Analysis]
531 Yumimoto K, Yamauchi Y, Nakayama KI. F-Box Proteins and Cancer. Cancers (Basel) 2020;12:E1249. [PMID: 32429232 DOI: 10.3390/cancers12051249] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
532 Chen L, Mukerjee G, Dorfman R, Moghadas SM. Disease Risk Assessment Using a Voronoi-Based Network Analysis of Genes and Variants Scores. Front Genet 2017;8:29. [PMID: 28326099 DOI: 10.3389/fgene.2017.00029] [Reference Citation Analysis]
533 Hollstein M, Shomer B, Greenblatt M, Soussi T, Hovig E, Montesano R, Harris CC. Somatic point mutations in the p53 gene of human tumors and cell lines: updated compilation. Nucleic Acids Res 1996;24:141-6. [PMID: 8594564 DOI: 10.1093/nar/24.1.141] [Cited by in Crossref: 306] [Cited by in F6Publishing: 287] [Article Influence: 12.2] [Reference Citation Analysis]
534 Ajay AK, Upadhyay AK, Singh S, Vijayakumar MV, Kumari R, Pandey V, Boppana R, Bhat MK. Cdk5 phosphorylates non-genotoxically overexpressed p53 following inhibition of PP2A to induce cell cycle arrest/apoptosis and inhibits tumor progression. Mol Cancer 2010;9:204. [PMID: 20673369 DOI: 10.1186/1476-4598-9-204] [Cited by in Crossref: 35] [Cited by in F6Publishing: 33] [Article Influence: 3.2] [Reference Citation Analysis]
535 Jhanwar-Uniyal M, Gulati SC. p53 gene mutation in the bone-marrow of a patient with diffuse mixed cell type lymphoma at diagnosis predicting eventual progression to large cell lymphoma. Leuk Lymphoma 1998;29:415-21. [PMID: 9684939 DOI: 10.3109/10428199809068578] [Reference Citation Analysis]
536 Durbin AD, Somers GR, Forrester M, Pienkowska M, Hannigan GE, Malkin D. JNK1 determines the oncogenic or tumor-suppressive activity of the integrin-linked kinase in human rhabdomyosarcoma. J Clin Invest. 2009;119:1558-1570. [PMID: 19478459 DOI: 10.1172/jci37958] [Cited by in Crossref: 6] [Cited by in F6Publishing: 21] [Article Influence: 0.5] [Reference Citation Analysis]
537 Couto SS. The Pathologist’s Slide Reveals More Than Meets the Eye: Loss of Heterozygosity and Cancer Biology. Vet Pathol 2011;48:236-44. [DOI: 10.1177/0300985810379432] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.6] [Reference Citation Analysis]
538 Bártkov´ J, Bártek J, Lukáŝ J, Vojtêŝek B, Staŝková Z, Rejthar A, Kova??ík J, Midgley CA, Lane DP. p53 Protein alterations in human testicular cancer including pre-invasive intratubular germ-cell neoplasia. Int J Cancer 1991;49:196-202. [DOI: 10.1002/ijc.2910490209] [Cited by in Crossref: 97] [Cited by in F6Publishing: 90] [Article Influence: 3.2] [Reference Citation Analysis]
539 Chang F, Syrjänen S, Tervahauta A, Syrjänen K. Tumourigenesis associated with the p53 tumour suppressor gene. Br J Cancer 1993;68:653-61. [PMID: 8398688 DOI: 10.1038/bjc.1993.404] [Cited by in Crossref: 78] [Cited by in F6Publishing: 83] [Article Influence: 2.8] [Reference Citation Analysis]
540 Cho KR, Vogelstein B. Suppressor gene alterations in the colorectal adenoma-carcinoma sequence. J Cell Biochem Suppl 1992;16G:137-41. [PMID: 1469893 DOI: 10.1002/jcb.240501124] [Cited by in Crossref: 40] [Cited by in F6Publishing: 38] [Article Influence: 1.4] [Reference Citation Analysis]
541 Miyaki M, Iijima T, Ohue M, Kita Y, Hishima T, Kuroki T, Iwama T, Mori T. A novel case with germline p53 gene mutation having concurrent multiple primary colon tumours. Gut 2003;52:304-6. [PMID: 12524418 DOI: 10.1136/gut.52.2.304] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 0.6] [Reference Citation Analysis]
542 Meling GI, Lothe RA, Børresen AL, Graue C, Hauge S, Clausen OP, Rognum TO. The TP53 tumour suppressor gene in colorectal carcinomas. I. Genetic alterations on chromosome 17. Br J Cancer 1993;67:88-92. [PMID: 8094008 DOI: 10.1038/bjc.1993.14] [Cited by in Crossref: 19] [Cited by in F6Publishing: 22] [Article Influence: 0.7] [Reference Citation Analysis]
543 Leroy B, Anderson M, Soussi T. TP53 mutations in human cancer: database reassessment and prospects for the next decade. Hum Mutat. 2014;35:672-688. [PMID: 24665023 DOI: 10.1002/humu.22552] [Cited by in Crossref: 163] [Cited by in F6Publishing: 148] [Article Influence: 23.3] [Reference Citation Analysis]
544 Wrafter PF, Connelly TM, Khan J, Devane L, Kelly J, Joyce WP. The 100 most influential manuscripts in colorectal cancer: A bibliometric analysis. Surgeon 2016;14:327-36. [PMID: 27091391 DOI: 10.1016/j.surge.2016.03.001] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
545 Nimura Y, Mihara M, Ichimiya S, Sakiyama S, Seki N, Ohira M, Nomura N, Fujimori M, Adachi W, Amano J, He M, Ping YM, Nakagawara A. p73, a gene related to p53, is not mutated in esophageal carcinomas. Int J Cancer 1998;78:437-40. [PMID: 9797131 DOI: 10.1002/(sici)1097-0215(19981109)78:4<437::aid-ijc8>3.0.co;2-v] [Cited by in Crossref: 48] [Cited by in F6Publishing: 16] [Article Influence: 2.1] [Reference Citation Analysis]
546 Rubin MA, Demichelis F. The Genomics of Prostate Cancer: A Historic Perspective. Cold Spring Harb Perspect Med 2019;9:a034942. [PMID: 29712681 DOI: 10.1101/cshperspect.a034942] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
547 Ohnishi Y, Shigeto M, Ishibashi T, Hirata J. Familial pericentric inversion of chromosome 11 in a child with sporadic unilateral retinoblastoma. Ophthalmic Paediatrics and Genetics 2009;11:281-5. [DOI: 10.3109/13816819009015714] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
548 Hiyoshi H, Matsuno Y, Kato H, Shimosato Y, Hirohashi S. Clinicopathological significance of nuclear accumulation of tumor suppressor gene p53 product in primary lung cancer. Jpn J Cancer Res 1992;83:101-6. [PMID: 1544866 DOI: 10.1111/j.1349-7006.1992.tb02358.x] [Cited by in Crossref: 41] [Cited by in F6Publishing: 37] [Article Influence: 1.4] [Reference Citation Analysis]
549 D'Orazio JA. Inherited cancer syndromes in children and young adults. J Pediatr Hematol Oncol 2010;32:195-228. [PMID: 20186103 DOI: 10.1097/MPH.0b013e3181ced34c] [Cited by in Crossref: 25] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
550 Cho KR, Vogelstein B. Genetic alterations in the adenoma--carcinoma sequence. Cancer 1992;70:1727-31. [PMID: 1516027 DOI: 10.1002/1097-0142(19920915)70:4+<1727::aid-cncr2820701613>3.0.co;2-p] [Cited by in Crossref: 207] [Cited by in F6Publishing: 91] [Article Influence: 7.1] [Reference Citation Analysis]
551 Jones RF, Matuszyk J, Debiec-rychter M, Wang CY. Mutation and altered expression ofp53 genes in experimental rat bladder tumor cells. Mol Carcinog 1994;9:95-104. [DOI: 10.1002/mc.2940090207] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 0.3] [Reference Citation Analysis]
552 Mercer WE, Shields MT, Amin M, Sauve GJ, Appella E, Romano JW, Ullrich SJ. Negative growth regulation in a glioblastoma tumor cell line that conditionally expresses human wild-type p53. Proc Natl Acad Sci USA. 1990;87:6166-6170. [PMID: 2143581 DOI: 10.1073/pnas.87.16.6166] [Cited by in Crossref: 275] [Cited by in F6Publishing: 294] [Article Influence: 8.9] [Reference Citation Analysis]
553 Effert PJ, Neubauer A, Walther PJ, Liu ET. Alterations of The P53 Gene Are Associated With The Progression Of A Human Prostate Carcinoma. Journal of Urology 1992;147:789-93. [DOI: 10.1016/s0022-5347(17)37387-1] [Cited by in Crossref: 75] [Cited by in F6Publishing: 13] [Article Influence: 2.6] [Reference Citation Analysis]
554 Berger AH, Knudson AG, Pandolfi PP. A continuum model for tumour suppression. Nature. 2011;476:163-169. [PMID: 21833082 DOI: 10.1038/nature10275] [Cited by in Crossref: 332] [Cited by in F6Publishing: 289] [Article Influence: 33.2] [Reference Citation Analysis]
555 Seliger B, Papadileris S, Vogel D, Hess G, Brendel C, Störkel S, Ortel J, Kolbe K, Huber C, Huhn D, Neubauer A. Analysis of the p53 and MDM-2 gene in acute myeloid leukemia. Eur J Haematol 1996;57:230-40. [PMID: 8898928 DOI: 10.1111/j.1600-0609.1996.tb01369.x] [Cited by in Crossref: 40] [Cited by in F6Publishing: 42] [Article Influence: 1.6] [Reference Citation Analysis]
556 Shi Y. Arnold J. Levine and my career development. J Mol Cell Biol 2019;11:546-50. [PMID: 31336383 DOI: 10.1093/jmcb/mjz069] [Reference Citation Analysis]
557 Moriichi K, Fujiya M, Kobayashi Y, Murakami Y, Iwama T, Kunogi T, Sasaki T, Ijiri M, Takahashi K, Tanaka K, Sakatani A, Ando K, Nomura Y, Ueno N, Kashima S, Ikuta K, Tanabe H, Mizukami Y, Saitoh Y, Okumura T. Autofluorescence Imaging Reflects the Nuclear Enlargement of Tumor Cells as well as the Cell Proliferation Ability and Aberrant Status of the p53, Ki-67, and p16 Genes in Colon Neoplasms. Molecules 2019;24:E1106. [PMID: 30897785 DOI: 10.3390/molecules24061106] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
558 Jessup JM, Loda M. Prognostic markers in rectal carcinoma. Semin Surg Oncol 1998;15:131-40. [DOI: 10.1002/(sici)1098-2388(199809)15:2<131::aid-ssu11>3.0.co;2-5] [Cited by in Crossref: 13] [Cited by in F6Publishing: 1] [Article Influence: 0.6] [Reference Citation Analysis]
559 Galamb O, Sipos F, Fischer K, Tulassay Z, Molnar B. The results of the expression array studies correlate and enhance the known genetic basis of gastric and colorectal cancer. Cytometry B Clin Cytom. 2005;68:1-17. [PMID: 16208682 DOI: 10.1002/cyto.b.20069] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 0.3] [Reference Citation Analysis]
560 Ji H, Whitehead RH, Reid GE, Moritz RL, Ward LD, Simpson RJ. Two-dimensional electrophoretic analysis of proteins expressed by normal and cancerous human crypts: Application of mass spectrometry to peptide-mass fingerprinting. Electrophoresis 1994;15:391-405. [DOI: 10.1002/elps.1150150158] [Cited by in Crossref: 56] [Cited by in F6Publishing: 56] [Article Influence: 2.1] [Reference Citation Analysis]
561 Vijeyasingam R, Darnton SJ, Jenner K, Allen CA, Billingham C, Matthews HR. Expression of p53 protein in oesophageal carcinoma: Clinicopathological correlation and prognostic significance. British Journal of Surgery 1994;81:1623-6. [DOI: 10.1002/bjs.1800811120] [Cited by in Crossref: 24] [Cited by in F6Publishing: 26] [Article Influence: 1.5] [Reference Citation Analysis]
562 Soussi T. Locus-Specific Databases in Cancer: What Future in a Post-Genomic Era? The TP53 LSDB paradigm. Human Mutation 2014;35:643-53. [DOI: 10.1002/humu.22518] [Cited by in Crossref: 14] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
563 Lifschitz-mercer B, Amitai R, Maymon BB, Shechtman L, Czernobilsky B, Leider-trejo L, Ben-ze'ev A, Geiger B. Nuclear Localization of β-Catenin and Plakoglobin in Primary and Metastatic Human Colonic Carcinomas, Colonic Adenomas, and Normal Colon. Int J Surg Pathol 2001;9:273-9. [DOI: 10.1177/106689690100900403] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
564 Short E, Sampson J. The role of inherited genetic variants in colorectal polyposis syndromes. Adv Genet 2019;103:183-217. [PMID: 30904095 DOI: 10.1016/bs.adgen.2018.11.002] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
565 Scheffer H, Kruize Y, Osinga J, Kuiken G, Oosterhuis J, Leeuw J, Schraffordt Koops H, Buys C. Complete association of loss of heterozygosity of chromosomes 13 and 17 in osteosarcoma. Cancer Genetics and Cytogenetics 1991;53:45-55. [DOI: 10.1016/0165-4608(91)90113-9] [Cited by in Crossref: 32] [Cited by in F6Publishing: 27] [Article Influence: 1.1] [Reference Citation Analysis]
566 Gelb AB, Schrock TR. Prognostic Factors in Colorectal Carcinoma. Surgical Oncology Clinics of North America 1997;6:463-94. [DOI: 10.1016/s1055-3207(18)30313-2] [Cited by in Crossref: 4] [Article Influence: 0.2] [Reference Citation Analysis]
567 Kopnin B. Genetic Events Responsible for Colorectal Tumorigenesis: Achievements and Challenges. Tumori 1993;79:235-43. [DOI: 10.1177/030089169307900401] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
568 Iacopetta B. TP53 mutation in colorectal cancer. Hum Mutat 2003;21:271-6. [DOI: 10.1002/humu.10175] [Cited by in Crossref: 192] [Cited by in F6Publishing: 169] [Article Influence: 10.7] [Reference Citation Analysis]
569 Aka K, Bruner JM, Bondy ML, Ligon K, Nishi T, del Giglio A, Moser RP, Levin VA, Saya H. Detection of p53 alterations in human astrocytomas using frozen tissue sections for the polymerase chain reaction. J Neurooncol 1993;16:125-33. [PMID: 7904621 DOI: 10.1007/BF01324699] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
570 Beenken SW, Karsenty G, Raycroft L, Lozano G. An intron binding protein is required for transformation ability of p53. Nucleic Acids Res 1991;19:4747-52. [PMID: 1891364 DOI: 10.1093/nar/19.17.4747] [Cited by in Crossref: 49] [Cited by in F6Publishing: 15] [Article Influence: 1.6] [Reference Citation Analysis]
571 Chan JYK, Zhen G, Agrawal N. The role of tumor DNA as a diagnostic tool for head and neck squamous cell carcinoma. Semin Cancer Biol 2019;55:1-7. [PMID: 30082187 DOI: 10.1016/j.semcancer.2018.07.008] [Cited by in Crossref: 10] [Cited by in F6Publishing: 13] [Article Influence: 3.3] [Reference Citation Analysis]
572 Lurje G, Zhang W, Lenz HJ. Molecular prognostic markers in locally advanced colon cancer. Clin Colorectal Cancer. 2007;6:683-690. [PMID: 18039421 DOI: 10.3816/ccc.2007.n.037] [Cited by in Crossref: 39] [Cited by in F6Publishing: 24] [Article Influence: 3.0] [Reference Citation Analysis]
573 Augenlicht LH. The molecular genetics of colonic cancer. In: Benson AB, editor. Gastrointestinal Oncology. Boston: Springer US; 1998. pp. 351-82. [DOI: 10.1007/978-1-4615-4977-2_13] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.0] [Reference Citation Analysis]
574 Halaschek-wiener J, Wacheck V, Schlagbauer-wadl H, Wolff K, Kloog Y, Jansen B. A Novel Ras Antagonist Regulates Both Oncogenic Ras and the Tumor Suppressor p53 in Colon Cancer Cells. Mol Med 2000;6:693-704. [DOI: 10.1007/bf03402049] [Cited by in Crossref: 37] [Article Influence: 1.8] [Reference Citation Analysis]
575 Meireles Da Costa N, Palumbo A Jr, De Martino M, Fusco A, Ribeiro Pinto LF, Nasciutti LE. Interplay between HMGA and TP53 in cell cycle control along tumor progression. Cell Mol Life Sci 2021;78:817-31. [PMID: 32920697 DOI: 10.1007/s00018-020-03634-4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
576 Berney CR, Fisher RJ, Yang J, Russell PJ, Crowe PJ. Genomic alterations (LOH, MI) on chromosome 17q21-23 and prognosis of sporadic colorectal cancer. Int J Cancer 2000;89:1-7. [DOI: 10.1002/(sici)1097-0215(20000120)89:1<1::aid-ijc1>3.0.co;2-7] [Cited by in Crossref: 16] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
577 Lam KT, Calderwood SK. Hsp70 binds specifically to a peptide derived from the highly conserved domain (I) region of P53. Biochemical and Biophysical Research Communications 1992;184:167-74. [DOI: 10.1016/0006-291x(92)91174-o] [Cited by in Crossref: 29] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
578 Roy B, Beamon J, Balint E, Reisman D. Transactivation of the human p53 tumor suppressor gene by c-Myc/Max contributes to elevated mutant p53 expression in some tumors. Mol Cell Biol 1994;14:7805-15. [PMID: 7969121 DOI: 10.1128/mcb.14.12.7805-7815.1994] [Cited by in Crossref: 76] [Article Influence: 2.8] [Reference Citation Analysis]
579 Fahy B, Bold RJ. Epidemiology and molecular genetics of colorectal cancer. Surg Oncol 1998;7:115-23. [PMID: 10677163 DOI: 10.1016/s0960-7404(99)00021-3] [Cited by in Crossref: 23] [Cited by in F6Publishing: 15] [Article Influence: 1.1] [Reference Citation Analysis]
580 Macaulay S, Goodyear QC, Kruger M, Chen W, Essop F, Krause A. The first two confirmed sub-Saharan African families with germline TP53 mutations causing Li-Fraumeni syndrome. Fam Cancer 2018;17:607-13. [PMID: 29392648 DOI: 10.1007/s10689-018-0075-5] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
581 Tsuda H, Zhang WD, Shimosato Y, Yokota J, Terada M, Sugimura T, Miyamura T, Hirohashi S. Allele loss on chromosome 16 associated with progression of human hepatocellular carcinoma. Proc Natl Acad Sci USA. 1990;87:6791-6794. [PMID: 2168560 DOI: 10.1073/pnas.87.17.6791] [Cited by in Crossref: 191] [Cited by in F6Publishing: 191] [Article Influence: 6.2] [Reference Citation Analysis]
582 Zhu ZZ, Wang AZ, Jia HR, Jin XX, He XL, Hou LF, Zhu G. Association of the TP53 codon 72 polymorphism with colorectal cancer in a Chinese population. Jpn J Clin Oncol. 2007;37:385-390. [PMID: 17599946 DOI: 10.1093/jjco/hym034] [Cited by in Crossref: 38] [Cited by in F6Publishing: 37] [Article Influence: 2.9] [Reference Citation Analysis]
583 Xu SF, Peng ZH, Li DP, Qiu GQ, Zhang F. Refinement of heterozygosity loss on chromosome 5p15 in sporadic colorectal cancer. World J Gastroenterol 2003; 9(8): 1713-1718 [PMID: 12918106 DOI: 10.3748/wjg.v9.i8.1713] [Cited by in CrossRef: 18] [Cited by in F6Publishing: 18] [Article Influence: 1.0] [Reference Citation Analysis]
584 Deimling A, Bender B, Louis DN, Wiestler OD. A rapid and non-radioactive PCR based assay for the detection of allelic loss in human gliomas. Neuropathol Appl Neurobiol 1993;19:524-9. [DOI: 10.1111/j.1365-2990.1993.tb00481.x] [Cited by in Crossref: 50] [Cited by in F6Publishing: 51] [Article Influence: 1.8] [Reference Citation Analysis]
585 Acuña G, Würgler FE, Sengstag C. Reciprocal mitotic recombination is the predominant mechanism for the loss of a heterozygous gene insaccharomyces cerevisiae. Environ Mol Mutagen 1994;24:307-16. [DOI: 10.1002/em.2850240408] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 0.3] [Reference Citation Analysis]
586 El-ashry D, Lippman ME. Molecular biology of breast carcinoma. World J Surg 1994;18:12-20. [DOI: 10.1007/bf00348187] [Cited by in Crossref: 12] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
587 Fukasawa K, Sakoulas G, Pollack RE, Chen S. Excess wild-type p53 blocks initiation and maintenance of simian virus 40 transformation. Mol Cell Biol 1991;11:3472-83. [PMID: 1646391 DOI: 10.1128/mcb.11.7.3472-3483.1991] [Cited by in Crossref: 14] [Article Influence: 0.5] [Reference Citation Analysis]
588 Baugh EH, Ke H, Levine AJ, Bonneau RA, Chan CS. Why are there hotspot mutations in the TP53 gene in human cancers? Cell Death Differ 2018;25:154-60. [PMID: 29099487 DOI: 10.1038/cdd.2017.180] [Cited by in Crossref: 139] [Cited by in F6Publishing: 131] [Article Influence: 34.8] [Reference Citation Analysis]
589 Oliveira DM, Laudanna C, Migliozzi S, Zoppoli P, Santamaria G, Grillone K, Elia L, Mignogna C, Biamonte F, Sacco R, Corcione F, Viglietto G, Malanga D, Rizzuto A. Identification of different mutational profiles in cancers arising in specific colon segments by next generation sequencing. Oncotarget 2018;9:23960-74. [PMID: 29844865 DOI: 10.18632/oncotarget.25251] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
590 Howlett AC, Abood ME. CB1 and CB2 Receptor Pharmacology. Adv Pharmacol 2017;80:169-206. [PMID: 28826534 DOI: 10.1016/bs.apha.2017.03.007] [Cited by in Crossref: 101] [Cited by in F6Publishing: 87] [Article Influence: 25.3] [Reference Citation Analysis]
591 Min KA, Maharjan P, Ham S, Shin MC. Pro-apoptotic peptides-based cancer therapies: challenges and strategies to enhance therapeutic efficacy. Arch Pharm Res 2018;41:594-616. [PMID: 29804279 DOI: 10.1007/s12272-018-1038-y] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
592 Harris AL. Mutant p53--the commonest genetic abnormality in human cancer? J Pathol. 1990;162:5-6. [PMID: 2231192 DOI: 10.1002/path.1711620103] [Cited by in Crossref: 74] [Cited by in F6Publishing: 75] [Article Influence: 2.4] [Reference Citation Analysis]
593 Tasdemir E, Maiuri MC, Galluzzi L, Vitale I, Djavaheri-Mergny M, D'Amelio M, Criollo A, Morselli E, Zhu C, Harper F, Nannmark U, Samara C, Pinton P, Vicencio JM, Carnuccio R, Moll UM, Madeo F, Paterlini-Brechot P, Rizzuto R, Szabadkai G, Pierron G, Blomgren K, Tavernarakis N, Codogno P, Cecconi F, Kroemer G. Regulation of autophagy by cytoplasmic p53. Nat Cell Biol 2008;10:676-87. [PMID: 18454141 DOI: 10.1038/ncb1730] [Cited by in Crossref: 744] [Cited by in F6Publishing: 732] [Article Influence: 57.2] [Reference Citation Analysis]
594 Schilsky RL. Colorectal Cancer. In: Vokes EE, Golomb HM, editors. Oncologic Therapies. Berlin: Springer Berlin Heidelberg; 1999. pp. 655-83. [DOI: 10.1007/978-3-642-97988-0_28] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
595 Friedman PN, Kern SE, Vogelstein B, Prives C. Wild-type, but not mutant, human p53 proteins inhibit the replication activities of simian virus 40 large tumor antigen. Proc Natl Acad Sci U S A 1990;87:9275-9. [PMID: 2174557 DOI: 10.1073/pnas.87.23.9275] [Cited by in Crossref: 63] [Cited by in F6Publishing: 65] [Article Influence: 2.1] [Reference Citation Analysis]
596 Cappell MS. From Colonic Polyps to Colon Cancer: Pathophysiology, Clinical Presentation, and Diagnosis. Clinics in Laboratory Medicine 2005;25:135-77. [DOI: 10.1016/j.cll.2004.12.010] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 1.2] [Reference Citation Analysis]
597 Choisy-rossi C, Reisdorf P, Yonish-rouach E. The p53 Tumor Suppressor Gene: Structure, Function and Mechanism of Action. In: Kumar S, editor. Apoptosis: Biology and Mechanisms. Berlin: Springer Berlin Heidelberg; 1999. pp. 145-72. [DOI: 10.1007/978-3-540-69184-6_8] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.1] [Reference Citation Analysis]
598 Robins H, Alexe G, Harris S, Levine AJ. The First Twenty-Five Years of p53 Research. In: Hainaut P, Wiman KG, editors. 25 Years of p53 Research. Dordrecht: Springer Netherlands; 2007. pp. 1-25. [DOI: 10.1007/978-1-4020-2922-6_1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
599 Walker C, Nettesheim P. Cellular oncogene expression in cell lines derived from tumors produced by transformed rat tracheal epithelial cells. Mol Carcinog 1989;2:117-20. [DOI: 10.1002/mc.2940020302] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
600 Ichikawa Y, Ishikawa T, Takahashi S, Hamaguchi Y, Morita T, Nishizuka I, Yamaguchi S, Endo I, Ike H, Togo S, Oki S, Shimada H, Kadota K, Nakamura S, Goto H, Nitanda H, Satomi S, Sakai T, Narita I, Gejyo F, Tomaru Y, Shimizu K, Hayashizaki Y, Okazaki Y. Identification of genes regulating colorectal carcinogenesis by using the algorithm for diagnosing malignant state method. Biochemical and Biophysical Research Communications 2002;296:497-506. [DOI: 10.1016/s0006-291x(02)00732-5] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
601 Worsham MJ, Van Dyke DL, Grenman SE, Grenman R, Hopkins MP, Roberts JA, Gasser KM, Schwartz DR, Carey TE. Consistent Chromosome Abnormalities in Squamous Cell Carcinoma of the Vulva. Genes Chromosom Cancer 1991;3:420-32. [DOI: 10.1002/gcc.2870030604] [Cited by in Crossref: 60] [Cited by in F6Publishing: 51] [Article Influence: 2.0] [Reference Citation Analysis]
602 Losi L, Baisse B, Bouzourene H, Benhattar J. Evolution of intratumoral genetic heterogeneity during colorectal cancer progression. Carcinogenesis 2005;26:916-22. [PMID: 15731168 DOI: 10.1093/carcin/bgi044] [Cited by in Crossref: 131] [Cited by in F6Publishing: 117] [Article Influence: 8.2] [Reference Citation Analysis]
603 Soussi T. TP53 mutations in human cancer: database reassessment and prospects for the next decade. Adv Cancer Res 2011;110:107-39. [PMID: 21704230 DOI: 10.1016/B978-0-12-386469-7.00005-0] [Cited by in Crossref: 53] [Cited by in F6Publishing: 33] [Article Influence: 5.3] [Reference Citation Analysis]
604 Soini Y, Pääkkö P, Alavaikko M, Vähäkangas K. p53 expression in lymphatic malignancies. J Clin Pathol 1992;45:1011-4. [PMID: 1452775 DOI: 10.1136/jcp.45.11.1011] [Cited by in Crossref: 27] [Cited by in F6Publishing: 28] [Article Influence: 1.0] [Reference Citation Analysis]
605 Aubrey BJ, Strasser A, Kelly GL. Tumor-Suppressor Functions of the TP53 Pathway. Cold Spring Harb Perspect Med. 2016;6. [PMID: 27141080 DOI: 10.1101/cshperspect.a026062] [Cited by in Crossref: 68] [Cited by in F6Publishing: 68] [Article Influence: 13.6] [Reference Citation Analysis]
606 Subramaniam P, Sinha SN, Wilkinson S. Immunohistochemical detection of p53 and the recurrence of rectal adenocarcinoma. Aust N Z J Surg 1995;65:740-2. [PMID: 7487716 DOI: 10.1111/j.1445-2197.1995.tb00549.x] [Reference Citation Analysis]
607 Soini Y, Vähäkangas K, Nuorva K, Kamel D, Lane DP, Pääkkö P. p53 immunohistochemistry in malignant fibrous histiocytomas and other mesenchymal tumours. J Pathol 1992;168:29-33. [PMID: 1333524 DOI: 10.1002/path.1711680106] [Cited by in Crossref: 49] [Cited by in F6Publishing: 47] [Article Influence: 1.8] [Reference Citation Analysis]
608 Myers RB, Oelschlager D, Srivastava S, Grizzle WE. Accumulation of the p53 protein occurs more frequently in metastatic than in localized prostatic adenocarcinomas. Prostate 1994;25:243-8. [DOI: 10.1002/pros.2990250504] [Cited by in Crossref: 39] [Cited by in F6Publishing: 33] [Article Influence: 1.4] [Reference Citation Analysis]
609 Cheng J, Haas M. Frequent mutations in the p53 tumor suppressor gene in human leukemia T-cell lines. Mol Cell Biol 1990;10:5502-9. [PMID: 2144611 DOI: 10.1128/mcb.10.10.5502-5509.1990] [Cited by in Crossref: 3] [Cited by in F6Publishing: 77] [Article Influence: 0.1] [Reference Citation Analysis]
610 Mercer WE, Shields MT, Lin D, Appella E, Ullrich SJ. Growth suppression induced by wild-type p53 protein is accompanied by selective down-regulation of proliferating-cell nuclear antigen expression. Proc Natl Acad Sci U S A 1991;88:1958-62. [PMID: 1705714 DOI: 10.1073/pnas.88.5.1958] [Cited by in Crossref: 146] [Cited by in F6Publishing: 155] [Article Influence: 4.9] [Reference Citation Analysis]
611 Farjami E, Clima L, Gothelf K, Ferapontova EE. "Off-on" electrochemical hairpin-DNA-based genosensor for cancer diagnostics. Anal Chem 2011;83:1594-602. [PMID: 21314139 DOI: 10.1021/ac1032929] [Cited by in Crossref: 133] [Cited by in F6Publishing: 121] [Article Influence: 13.3] [Reference Citation Analysis]
612 Bargonetti J, Prives C. Gain-of-function mutant p53: history and speculation. J Mol Cell Biol 2019;11:605-9. [PMID: 31283823 DOI: 10.1093/jmcb/mjz067] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 19.0] [Reference Citation Analysis]
613 Cai B, Liu Z, Xu Y, Wei W, Zhang S. Adenoma detection rate in 41,010 patients from Southwest China. Oncol Lett 2015;9:2073-7. [PMID: 26137015 DOI: 10.3892/ol.2015.3005] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 2.5] [Reference Citation Analysis]
614 Cornetta K, Morgan RA, Anderson WF. Safety Issues Related to Retroviral-Mediated Gene Transfer in Humans. Human Gene Therapy 1991;2:5-14. [DOI: 10.1089/hum.1991.2.1-5] [Cited by in Crossref: 156] [Cited by in F6Publishing: 134] [Article Influence: 5.2] [Reference Citation Analysis]
615 Cross S, Sanchez C, Morgan C, Schimke M, Ramel S, Idzerda R, Raskind W, Reid B. A p53-dependent mouse spindle checkpoint. Science 1995;267:1353-6. [DOI: 10.1126/science.7871434] [Cited by in Crossref: 455] [Cited by in F6Publishing: 446] [Article Influence: 17.5] [Reference Citation Analysis]
616 Console-Bram L, Marcu J, Abood ME. Cannabinoid receptors: nomenclature and pharmacological principles. Prog Neuropsychopharmacol Biol Psychiatry. 2012;38:4-15. [PMID: 22421596 DOI: 10.1016/j.pnpbp.2012.02.009.] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
617 Kerbel RS. Growth dominance of the metastatic cancer cell: cellular and molecular aspects. Adv Cancer Res 1990;55:87-132. [PMID: 2167000 DOI: 10.1016/s0065-230x(08)60469-8] [Cited by in Crossref: 125] [Cited by in F6Publishing: 46] [Article Influence: 4.0] [Reference Citation Analysis]
618 Moser AR, Dove WF, Roth KA, Gordon JI. The Min (multiple intestinal neoplasia) mutation: its effect on gut epithelial cell differentiation and interaction with a modifier system. J Cell Biol. 1992;116:1517-1526. [PMID: 1541640 DOI: 10.1083/jcb.116.6.1517] [Cited by in Crossref: 209] [Cited by in F6Publishing: 189] [Article Influence: 7.2] [Reference Citation Analysis]
619 Nicolaides NC, Sass PM, Grasso L. Advances in targeted therapeutic agents. Expert Opin Drug Discov 2010;5:1123-40. [PMID: 22827748 DOI: 10.1517/17460441.2010.521496] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 1.5] [Reference Citation Analysis]
620 Liao WT, Ye YP, Zhang NJ, Li TT, Wang SY, Cui YM, Qi L, Wu P, Jiao HL, Xie YJ, Zhang C, Wang JX, Ding YQ. MicroRNA-30b functions as a tumour suppressor in human colorectal cancer by targeting KRAS, PIK3CD and BCL2. J Pathol 2014;232:415-27. [PMID: 24293274 DOI: 10.1002/path.4309] [Cited by in Crossref: 99] [Cited by in F6Publishing: 101] [Article Influence: 14.1] [Reference Citation Analysis]
621 Hardwick RH, Shepherd NA, Moorghen M, Newcomb PV, Alderson D. Adenocarcinoma arising in Barrett's oesophagus: evidence for the participation of p53 dysfunction in the dysplasia/carcinoma sequence. Gut. 1994;35:764-768. [PMID: 8020801 DOI: 10.1136/gut.35.6.764] [Cited by in Crossref: 39] [Cited by in F6Publishing: 38] [Article Influence: 1.4] [Reference Citation Analysis]
622 Cen B, Lang JD, Du Y, Wei J, Xiong Y, Bradley N, Wang D, DuBois RN. Prostaglandin E2 Induces miR675-5p to Promote Colorectal Tumor Metastasis via Modulation of p53 Expression. Gastroenterology 2020;158:971-984.e10. [PMID: 31734182 DOI: 10.1053/j.gastro.2019.11.013] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 8.5] [Reference Citation Analysis]
623 Kaye FJ, Kratzke RA, Gerster JL, Lin PS. Recessive Oncogenes in Lung Cancer. Am Rev Respir Dis 1990;142:S44-7. [DOI: 10.1164/ajrccm/142.6_pt_2.s44] [Cited by in Crossref: 7] [Article Influence: 0.2] [Reference Citation Analysis]
624 Gimenes SNC, Lopes DS, Alves PT, Azevedo FVPV, Vecchi L, Goulart LR, Rodrigues TCS, Santos ALQ, Brites VLC, Teixeira TL, da Silva CV, Dias MH, Teixeira SC, Rodrigues RS, Yoneyama KAG, Oliveira RA, Rodrigues VM. Antitumoral effects of γCdcPLI, a PLA2 inhibitor from Crotalus durissus collilineatus via PI3K/Akt pathway on MDA-MB-231 breast cancer cell. Sci Rep 2017;7:7077. [PMID: 28765552 DOI: 10.1038/s41598-017-07082-2] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
625 el-Deiry WS, Nelkin BD, Celano P, Yen RW, Falco JP, Hamilton SR, Baylin SB. High expression of the DNA methyltransferase gene characterizes human neoplastic cells and progression stages of colon cancer. Proc Natl Acad Sci U S A 1991;88:3470-4. [PMID: 2014266 DOI: 10.1073/pnas.88.8.3470] [Cited by in Crossref: 192] [Cited by in F6Publishing: 210] [Article Influence: 6.4] [Reference Citation Analysis]
626 Patterson H, Gill S, Fisher C, Law MG, Jayatilake H, Fletcher CD, Thomas M, Grimer R, Gusterson BA, Cooper CS. Abnormalities of the p53 MDM2 and DCC genes in human leiomyosarcomas. Br J Cancer 1994;69:1052-8. [PMID: 8198970 DOI: 10.1038/bjc.1994.207] [Cited by in Crossref: 41] [Cited by in F6Publishing: 43] [Article Influence: 1.5] [Reference Citation Analysis]
627 Thompson SJ, Mellon K, Charlton RG, Marsh C, Robinson M, Neal DE. P53 and Ki-67 immunoreactivity in human prostate cancer and benign hyperplasia. Br J Urol 1992;69:609-13. [PMID: 1379102 DOI: 10.1111/j.1464-410x.1992.tb15632.x] [Cited by in Crossref: 42] [Cited by in F6Publishing: 9] [Article Influence: 1.4] [Reference Citation Analysis]
628 Morikawa T, Kuchiba A, Liao X, Imamura Y, Yamauchi M, Qian ZR, Nishihara R, Sato K, Meyerhardt JA, Fuchs CS. Tumor TP53 expression status, body mass index and prognosis in colorectal cancer. Int J Cancer. 2012;131:1169-1178. [PMID: 22038927 DOI: 10.1002/ijc.26495] [Cited by in Crossref: 44] [Cited by in F6Publishing: 47] [Article Influence: 4.4] [Reference Citation Analysis]
629 Shen J, Sheng X, Chang Z, Wu Q, Wang S, Xuan Z, Li D, Wu Y, Shang Y, Kong X, Yu L, Li L, Ruan K, Hu H, Huang Y, Hui L, Xie D, Wang F, Hu R. Iron metabolism regulates p53 signaling through direct heme-p53 interaction and modulation of p53 localization, stability, and function. Cell Rep 2014;7:180-93. [PMID: 24685134 DOI: 10.1016/j.celrep.2014.02.042] [Cited by in Crossref: 120] [Cited by in F6Publishing: 116] [Article Influence: 17.1] [Reference Citation Analysis]
630 Dieumegard B, Grandjouan S, Sabourin JC, Le Bihan ML, Lefrère I, Bellefqih JP, Rougier P, Lasser P, Bénard J, Couturier D. Extensive molecular screening for hereditary non-polyposis colorectal cancer. Br J Cancer. 2000;82:871-880. [PMID: 10732761 DOI: 10.1054/bjoc.1999.1014] [Cited by in Crossref: 53] [Cited by in F6Publishing: 53] [Article Influence: 2.5] [Reference Citation Analysis]
631 Elnatan J, Murphy D, Goh HS, Smith DR. HIT family genes: FHIT but not PKCI-1/HINT produces altered transcripts in colorectal cancer. Br J Cancer 1999;81:874-80. [PMID: 10555761 DOI: 10.1038/sj.bjc.6690779] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.1] [Reference Citation Analysis]
632 Jordão G, Tavares JN. Mathematical models in cancer therapy. Biosystems 2017;162:12-23. [DOI: 10.1016/j.biosystems.2017.08.007] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 1.8] [Reference Citation Analysis]
633 Kawano R, Takeshima Y, Inai K. Alteration of the p53 gene of lung carcinomas with sarcomatous transformation (spindle cell carcinoma): Analysis of four cases. Pathology International 1996;46:38-45. [DOI: 10.1111/j.1440-1827.1996.tb03531.x] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 0.6] [Reference Citation Analysis]
634 Lopez-Crapez E, Bibeau F, Thézenas S, Ychou M, Simony-Lafontaine J, Thirion A, Azria D, Grenier J, Senesse P. p53 status and response to radiotherapy in rectal cancer: a prospective multilevel analysis. Br J Cancer. 2005;92:2114-2121. [PMID: 15956964 DOI: 10.1038/sj.bjc.6602622] [Cited by in Crossref: 22] [Cited by in F6Publishing: 24] [Article Influence: 1.4] [Reference Citation Analysis]
635 Reihsaus E, Kraiss S, Barnekow A, Montenarh M. Cooperation of p53 and polyoma virus middle T antigen in the transformation of primary rat embryo fibroblasts. Experimental Cell Research 1992;199:10-8. [DOI: 10.1016/0014-4827(92)90456-i] [Cited by in Crossref: 1] [Article Influence: 0.0] [Reference Citation Analysis]
636 Demczuk S. Oncogenes: a review of their clinical application. Critical Reviews in Oncology/Hematology 1991;11:209-39. [DOI: 10.1016/1040-8428(91)90021-4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
637 Balazs M, Matsumura K, Moore D, Pinkel D, Gray JW, Waldman FM. Karyotypic heterogeneity and its relation to labeling index in interphase breast tumor cells. Cytometry 1995;20:62-73. [DOI: 10.1002/cyto.990200110] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 0.6] [Reference Citation Analysis]
638 Rotter V, Shaulsky G, Goldfinger N. Association of Wild-Type P53 with Cell Differentiation: Induction of Pre-b Cell Maturation in Vitro. In: Fanning E, Knippers R, Winnacker E, editors. DNA Replication and the Cell Cycle. Berlin: Springer Berlin Heidelberg; 1993. pp. 237-57. [DOI: 10.1007/978-3-642-77040-1_20] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.0] [Reference Citation Analysis]
639 Leroy B, Ballinger ML, Baran-Marszak F, Bond GL, Braithwaite A, Concin N, Donehower LA, El-Deiry WS, Fenaux P, Gaidano G, Langerød A, Hellstrom-Lindberg E, Iggo R, Lehmann-Che J, Mai PL, Malkin D, Moll UM, Myers JN, Nichols KE, Pospisilova S, Ashton-Prolla P, Rossi D, Savage SA, Strong LC, Tonin PN, Zeillinger R, Zenz T, Fraumeni JF Jr, Taschner PE, Hainaut P, Soussi T. Recommended Guidelines for Validation, Quality Control, and Reporting of TP53 Variants in Clinical Practice. Cancer Res 2017;77:1250-60. [PMID: 28254861 DOI: 10.1158/0008-5472.CAN-16-2179] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 6.3] [Reference Citation Analysis]
640 Cha YH, Kim NH, Park C, Lee I, Kim HS, Yook JI. MiRNA-34 intrinsically links p53 tumor suppressor and Wnt signaling. Cell Cycle. 2012;11:1273-1281. [PMID: 22421157 DOI: 10.4161/cc.19618] [Cited by in Crossref: 80] [Cited by in F6Publishing: 77] [Article Influence: 8.9] [Reference Citation Analysis]
641 Pino MS, Chung DC. The chromosomal instability pathway in colon cancer. Gastroenterology. 2010;138:2059-2072. [PMID: 20420946 DOI: 10.1053/j.gastro.2009.12.065s0016-5085(10)00170-8] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
642 Hidalgo Grau LA, Badia JM, Salvador CA, Monsó TS, Canaleta JF, Nogués JM, Sala JS. Gallbladder carcinoma: the role of p53 protein overexpression and Ki-67 antigen expression as prognostic markers. HPB (Oxford). 2004;6:174-180. [PMID: 18333072 DOI: 10.1080/13651820410025110] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.0] [Reference Citation Analysis]
643 Honma M, Mizusawa H, Sasaki K, Hayashi M, Ohno T, Tanaka N, Sofuni T. Demonstration by DNA fingerprint analysis of genomic instability in mouse BALB 3T3 cells during cell transformation. Mutation Research/Fundamental and Molecular Mechanisms of Mutagenesis 1994;304:167-79. [DOI: 10.1016/0027-5107(94)90208-9] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.2] [Reference Citation Analysis]
644 Gonzalez RS, Washington K, Shi C. Current applications of molecular pathology in colorectal carcinoma. Appl Cancer Res 2017;37. [DOI: 10.1186/s41241-017-0020-1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
645 Alers JC, van Dekken H. Interphase Cytogenetic Analysis of Solid Tumors by Non-Isotopic DNA in situ Hybridization. Progress in Histochemistry and Cytochemistry 1996;31:III-133. [DOI: 10.1016/s0079-6336(96)80017-9] [Cited by in Crossref: 7] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
646 Liu Y, Riley LB, Bohn SA, Boice JA, Stadler PB, Sherley JL. Comparison ofbax,waf1, and IMP dehydrogenase regulation in response to wild-type p53 expression under normal growth conditions. J Cell Physiol 1998;177:364-76. [DOI: 10.1002/(sici)1097-4652(199811)177:2<364::aid-jcp18>3.0.co;2-9] [Cited by in Crossref: 15] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
647 Sadagurski M, Nofech-mozes S, Weingarten G, White MF, Kadowaki T, Wertheimer E. Insulin receptor substrate 1 (IRS-1) plays a unique role in normal epidermal physiology. J Cell Physiol 2007;213:519-27. [DOI: 10.1002/jcp.21131] [Cited by in Crossref: 18] [Cited by in F6Publishing: 13] [Article Influence: 1.3] [Reference Citation Analysis]
648 Faulkner AD, Kaner RA, Abdallah QM, Clarkson G, Fox DJ, Gurnani P, Howson SE, Phillips RM, Roper DI, Simpson DH, Scott P. Asymmetric triplex metallohelices with high and selective activity against cancer cells. Nat Chem 2014;6:797-803. [PMID: 25143215 DOI: 10.1038/nchem.2024] [Cited by in Crossref: 92] [Cited by in F6Publishing: 77] [Article Influence: 13.1] [Reference Citation Analysis]
649 Hoffman RM. Unbalanced transmethylation and the perturbation of the differentiated state leading to cancer. Bioessays 1990;12:163-6. [DOI: 10.1002/bies.950120404] [Cited by in Crossref: 16] [Cited by in F6Publishing: 19] [Article Influence: 0.5] [Reference Citation Analysis]
650 Boag G, Lee CS, Charalambous D, Rode J. p53 Expression in laryngeal carcinoma. Pathology 1993;25:394-7. [DOI: 10.3109/00313029309090866] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.3] [Reference Citation Analysis]
651 You X, Tian J, Zhang H, Guo Y, Yang J, Zhu C, Song M, Wang P, Liu Z, Cancilla J, Lu W, Glorieux C, Wen S, Du H, Huang P, Hu Y. Loss of mitochondrial aconitase promotes colorectal cancer progression via SCD1-mediated lipid remodeling. Mol Metab 2021;48:101203. [PMID: 33676027 DOI: 10.1016/j.molmet.2021.101203] [Reference Citation Analysis]
652 Malkin D. Li–Fraumeni Syndrome. In: Hammer GD, Else T, editors. Adrenocortical Carcinoma. New York: Springer; 2011. pp. 173-91. [DOI: 10.1007/978-0-387-77236-3_11] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
653 Ramael M, Lemmens G, Eerdekens C, Buysse C, Deblier I, Jacobs W, Van Marck E. Immunoreactivity for p53 protein in malignant mesothelioma and non-neoplastic mesothelium. J Pathol 1992;168:371-5. [DOI: 10.1002/path.1711680406] [Cited by in Crossref: 50] [Cited by in F6Publishing: 41] [Article Influence: 1.7] [Reference Citation Analysis]
654 Ando M, Takemura K, Maruyama M, Endo M, Iwama T, Yuasa Y. Mutations in c-K-ras 2 gene codon 12 during colorectal tumorigenesis in familial adenomatous polyposis. Gastroenterology 1992;103:1725-31. [PMID: 1333425 DOI: 10.1016/0016-5085(92)91427-6] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 0.5] [Reference Citation Analysis]
655 Pfister NT, Prives C. Transcriptional Regulation by Wild-Type and Cancer-Related Mutant Forms of p53. Cold Spring Harb Perspect Med 2017;7:a026054. [PMID: 27836911 DOI: 10.1101/cshperspect.a026054] [Cited by in Crossref: 49] [Cited by in F6Publishing: 45] [Article Influence: 12.3] [Reference Citation Analysis]
656 Joypaul BV, Vojtesek B, Newman EL, Hopwood D, Grant A, Lane DP, Cuschieri A. Enzyme-linked immunosorbent assay for p53 in gastrointestinal malignancy: comparison with immunohistochemistry. Histopathology 1993;23:465-70. [DOI: 10.1111/j.1365-2559.1993.tb00496.x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.2] [Reference Citation Analysis]
657 Ning B, Su Z, Mei N, Hong H, Deng H, Shi L, Fuscoe JC, Tolleson WH. Toxicogenomics and cancer susceptibility: advances with next-generation sequencing. J Environ Sci Health C Environ Carcinog Ecotoxicol Rev 2014;32:121-58. [PMID: 24875441 DOI: 10.1080/10590501.2014.907460] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 4.2] [Reference Citation Analysis]
658 Wallingford JB, Seufert DW, Virta VC, Vize PD. p53 activity is essential for normal development in Xenopus. Curr Biol 1997;7:747-57. [PMID: 9368757 DOI: 10.1016/s0960-9822(06)00333-2] [Cited by in Crossref: 79] [Cited by in F6Publishing: 36] [Article Influence: 3.4] [Reference Citation Analysis]
659 Smith KJ, Barrett TL, Smith WF, Skelton HM. A Review of Tumor Suppressor Genes in Cutaneous Neoplasms With Emphasis on Cell Cycle Regulators: . The American Journal of Dermatopathology 1998;20:302-13. [DOI: 10.1097/00000372-199806000-00015] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 0.4] [Reference Citation Analysis]
660 Tanaka T. Chemoprevention of human cancer: biology and therapy. Crit Rev Oncol Hematol 1997;25:139-74. [PMID: 9177939 DOI: 10.1016/s1040-8428(97)00232-1] [Cited by in Crossref: 50] [Cited by in F6Publishing: 10] [Article Influence: 2.1] [Reference Citation Analysis]
661 Anelli A, Anelli TF, Youngson B, Rosen PP, Borgen PI. Mutations of the p53 gene in male breast cancer. Cancer 1995;75:2233-8. [PMID: 7712430 DOI: 10.1002/1097-0142(19950501)75:9<2233::aid-cncr2820750907>3.0.co;2-s] [Cited by in Crossref: 50] [Cited by in F6Publishing: 11] [Article Influence: 1.9] [Reference Citation Analysis]
662 Yew P, Cheng Kao C, Berk AJ. Dissection of functional domains in the adenovirus 2 early 1b 55k polypeptide by suppressor-linker insertional mutagenesis. Virology 1990;179:795-805. [DOI: 10.1016/0042-6822(90)90147-j] [Cited by in Crossref: 67] [Cited by in F6Publishing: 31] [Article Influence: 2.2] [Reference Citation Analysis]
663 Chari NS, Pinaire NL, Thorpe L, Medeiros LJ, Routbort MJ, McDonnell TJ. The p53 tumor suppressor network in cancer and the therapeutic modulation of cell death. Apoptosis. 2009;14:336-347. [PMID: 19229632 DOI: 10.1007/s10495-009-0327-9] [Cited by in Crossref: 38] [Cited by in F6Publishing: 35] [Article Influence: 3.2] [Reference Citation Analysis]
664 Hao Q, Cho WC. Battle against cancer: an everlasting saga of p53. Int J Mol Sci 2014;15:22109-27. [PMID: 25470027 DOI: 10.3390/ijms151222109] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 2.9] [Reference Citation Analysis]
665 Staples OD, Steele RJ, Lain S. p53 as a therapeutic target. Surgeon 2008;6:240-3. [PMID: 18697367 DOI: 10.1016/s1479-666x(08)80034-0] [Cited by in Crossref: 17] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
666 Larsson C, Friedman E. Localization and Identification of the Multiple Endocrine Neoplasia Type 1 Disease Gene. Endocrinology and Metabolism Clinics of North America 1994;23:67-79. [DOI: 10.1016/s0889-8529(18)30116-6] [Cited by in Crossref: 13] [Article Influence: 0.5] [Reference Citation Analysis]
667 Koga H, Zhang S, Kumanishi T, Washiyama K, Ichikawa T, Tanaka R, Mukawa J. Analysis of p53 gene mutations in low- and high-grade astrocytomas by polymerase chain reaction-assisted single-strand conformation polymorphism and immunohistochemistry. Acta Neuropathol 1994;87:225-32. [DOI: 10.1007/bf00296737] [Cited by in Crossref: 37] [Cited by in F6Publishing: 14] [Article Influence: 1.4] [Reference Citation Analysis]
668 Chung RY, Seizinger BR. Tumor Suppressor Genes and Cancer of the Human Nervous System. Cancer Investigation 2009;9:429-38. [DOI: 10.3109/07357909109084641] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.1] [Reference Citation Analysis]
669 Hauft SM, Kim SH, Schmidt GH, Pease S, Rees S, Harris S, Roth KA, Hansbrough JR, Cohn SM, Ahnen DJ. Expression of SV-40 T antigen in the small intestinal epithelium of transgenic mice results in proliferative changes in the crypt and reentry of villus-associated enterocytes into the cell cycle but has no apparent effect on cellular differentiation programs and does not cause neoplastic transformation. J Cell Biol 1992;117:825-39. [PMID: 1349609 DOI: 10.1083/jcb.117.4.825] [Cited by in Crossref: 49] [Cited by in F6Publishing: 54] [Article Influence: 1.7] [Reference Citation Analysis]
670 Bognar Z, Cseh AM, Fekete K, Antus C, Bognar R, Tapodi A, Ramadan FHJ, Sumegi B, Gallyas F Jr. Amiodarone's major metabolite, desethylamiodarone inhibits proliferation of B16-F10 melanoma cells and limits lung metastasis formation in an in vivo experimental model. PLoS One 2020;15:e0239088. [PMID: 32977329 DOI: 10.1371/journal.pone.0239088] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
671 Foord O, Navot N, Rotter V. Isolation and characterization of DNA sequences that are specifically bound by wild-type p53 protein. Mol Cell Biol 1993;13:1378-84. [PMID: 8441383 DOI: 10.1128/mcb.13.3.1378-1384.1993] [Cited by in Crossref: 21] [Article Influence: 0.8] [Reference Citation Analysis]
672 Sidransky D, Messing E. MOLECULAR GENETICS AND BIOCHEMICAL MECHANISMS IN BLADDER CANCER. Urologic Clinics of North America 1992;19:629-39. [DOI: 10.1016/s0094-0143(21)00435-3] [Cited by in Crossref: 27] [Article Influence: 0.9] [Reference Citation Analysis]
673 Kuerbitz SJ, Plunkett BS, Walsh WV, Kastan MB. Wild-type p53 is a cell cycle checkpoint determinant following irradiation. Proc Natl Acad Sci USA. 1992;89:7491-7495. [PMID: 1323840 DOI: 10.1073/pnas.89.16.7491] [Cited by in Crossref: 1074] [Cited by in F6Publishing: 1049] [Article Influence: 37.0] [Reference Citation Analysis]
674 Campbell FA, Redmond HP, Bouchier-Hayes D. The role of tumor rejection antigens in host antitumor defense mechanisms. Cancer 1995;75:2649-55. [PMID: 7538044 DOI: 10.1002/1097-0142(19950601)75:11<2649::aid-cncr2820751102>3.0.co;2-m] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
675 Borner C. The Bcl-2 protein family: sensors and checkpoints for life-or-death decisions. Molecular Immunology 2003;39:615-47. [DOI: 10.1016/s0161-5890(02)00252-3] [Cited by in Crossref: 486] [Cited by in F6Publishing: 150] [Article Influence: 27.0] [Reference Citation Analysis]
676 Jensen RA, Page DL. p53: The promising story continues to unfold. Human Pathology 1993;24:455-6. [DOI: 10.1016/0046-8177(93)90155-a] [Cited by in Crossref: 15] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
677 Seregard S. Cell growth and p53 expression in primary acquired melanosis and conjunctival melanoma. J Clin Pathol 1996;49:338-42. [PMID: 8655713 DOI: 10.1136/jcp.49.4.338] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.2] [Reference Citation Analysis]
678 Amemiya S, Sekizawa A, Otsuka J, Tachikawa T, Saito H, Okai T. Malignant transformation of endometriosis and genetic alterations of K-ras and microsatellite instability. Int J Gynaecol Obstet 2004;86:371-6. [PMID: 15325855 DOI: 10.1016/j.ijgo.2004.04.036] [Cited by in Crossref: 39] [Cited by in F6Publishing: 32] [Article Influence: 2.4] [Reference Citation Analysis]
679 Bischoff JR, Casso D, Beach D. Human p53 inhibits growth in Schizosaccharomyces pombe. Mol Cell Biol 1992;12:1405-11. [PMID: 1549103 DOI: 10.1128/mcb.12.4.1405-1411.1992] [Cited by in Crossref: 44] [Article Influence: 1.5] [Reference Citation Analysis]
680 Takayama H, Nonomura N, Aozasa K. Gene mutations: analysis in proliferative prostatic diseases using laser capture microdissection. Methods Enzymol 2002;356:309-22. [PMID: 12418210 DOI: 10.1016/s0076-6879(02)56945-7] [Reference Citation Analysis]
681 Nakamura Y, Wasmuth J, White R. Searching the Gene Responsible to Familial Polyposis Coli (FAP). In: Utsunomiya J, Lynch HT, editors. Hereditary Colorectal Cancer. Tokyo: Springer Japan; 1990. pp. 469-72. [DOI: 10.1007/978-4-431-68337-7_69] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.0] [Reference Citation Analysis]
682 Parkinson EK. Senescence as a modulator of oral squamous cell carcinoma development. Oral Oncology 2010;46:840-53. [DOI: 10.1016/j.oraloncology.2009.09.009] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 0.9] [Reference Citation Analysis]
683 Gangadhar T, Schilsky RL. Molecular markers to individualize adjuvant therapy for colon cancer. Nat Rev Clin Oncol. 2010;7:318-325. [PMID: 20440283 DOI: 10.1038/nrclinonc.2010.62] [Cited by in Crossref: 49] [Cited by in F6Publishing: 44] [Article Influence: 4.5] [Reference Citation Analysis]
684 Péterfia B, Kalmár A, Patai ÁV, Csabai I, Bodor A, Micsik T, Wichmann B, Egedi K, Hollósi P, Kovalszky I, Tulassay Z, Molnár B. Construction of a multiplex mutation hot spot PCR panel: the first step towards colorectal cancer genotyping on the GS Junior platform. J Cancer 2017;8:162-73. [PMID: 28243320 DOI: 10.7150/jca.16037] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
685 Kakiuchi H, Ushijima T, Ochiai M, Sugimura T, Nagao M, Imai K, Yachi A, Ito N. Rare frequency of activation of the ki-ras gene in rat colon tumors induced by heterocyclic amines: Possible alternative mechanisms of human colon carcinogenesis. Mol Carcinog 1993;8:44-8. [DOI: 10.1002/mc.2940080110] [Cited by in Crossref: 26] [Cited by in F6Publishing: 28] [Article Influence: 0.9] [Reference Citation Analysis]
686 Petersen RC. Free-radical polymer science structural cancer model: a review. Scientifica (Cairo) 2013;2013:143589. [PMID: 24278767 DOI: 10.1155/2013/143589] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.1] [Reference Citation Analysis]
687 Anbarasan T, Bourdon JC. The Emerging Landscape of p53 Isoforms in Physiology, Cancer and Degenerative Diseases. Int J Mol Sci 2019;20:E6257. [PMID: 31835844 DOI: 10.3390/ijms20246257] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 8.0] [Reference Citation Analysis]
688 Elkholi R, Chipuk JE. How do I kill thee? Let me count the ways: p53 regulates PARP-1 dependent necrosis. Bioessays 2014;36:46-51. [PMID: 24323920 DOI: 10.1002/bies.201300117] [Cited by in Crossref: 21] [Cited by in F6Publishing: 16] [Article Influence: 2.6] [Reference Citation Analysis]
689 Hicks GG, Egan SE, Greenberg AH, Mowat M. Mutant p53 tumor suppressor alleles release ras-induced cell cycle growth arrest. Mol Cell Biol 1991;11:1344-52. [PMID: 1996096 DOI: 10.1128/mcb.11.3.1344-1352.1991] [Cited by in Crossref: 34] [Article Influence: 1.1] [Reference Citation Analysis]
690 White GR, Stack M, Santibáñez-Koref M, Liscia DS, Venesio T, Wang JC, Helms C, Donis-Keller H, Betticher DC, Altermatt HJ, Hoban PR, Heighway J. High levels of loss at the 17p telomere suggest the close proximity of a tumour suppressor. Br J Cancer 1996;74:863-70. [PMID: 8826850 DOI: 10.1038/bjc.1996.449] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 0.6] [Reference Citation Analysis]
691 Li FP. Familial cancer syndromes and clusters. Curr Probl Cancer 1990;14:73-114. [PMID: 2407428 DOI: 10.1016/0147-0272(90)90008-e] [Cited by in Crossref: 25] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
692 Butler LM, Hewett PJ, Fitridge RA, Cowled PA. DEREGULATION OF APOPTOSIS IN COLORECTAL CARCINOMA: THEORETICAL AND THERAPEUTIC IMPLICATIONS. Aust N Z J Surg 2002;69:88-94. [DOI: 10.1046/j.1440-1622.1999.01498.x] [Cited by in Crossref: 32] [Cited by in F6Publishing: 30] [Article Influence: 1.7] [Reference Citation Analysis]
693 Schwab M, Brüderlein S, van der Bosch K, Weith A, Leister I, Cziepluch C, Amler L, Schlag P. Genetic Alterations in Colorectal Cancers in Correlation to Clinical Parameters. In: Utsunomiya J, Lynch HT, editors. Hereditary Colorectal Cancer. Tokyo: Springer Japan; 1990. pp. 509-16. [DOI: 10.1007/978-4-431-68337-7_75] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
694 Montesano R, Hall J, Hollstein M, Mironov N, Wild CP. Alkylation repair in human tissues. Basic Life Sci 1990;53:437-52. [PMID: 2282048 DOI: 10.1007/978-1-4613-0637-5_33] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.1] [Reference Citation Analysis]
695 Noda H, Maehara Y, Irie K, Kakeji Y, Yonemura T, Sugimachi K. Growth pattern and expressions of cell cycle regulator proteins p53 and p21WAF1/CIP1 in early gastric carcinoma. Cancer 2001;92:1828-35. [DOI: 10.1002/1097-0142(20011001)92:7<1828::aid-cncr1699>3.0.co;2-q] [Cited by in Crossref: 17] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
696 Hayashi Y, Yamashita J, Yamaguchi K. Timing and role of p53 gene mutation in the recurrence of glioma. Biochemical and Biophysical Research Communications 1991;180:1145-50. [DOI: 10.1016/s0006-291x(05)81186-6] [Cited by in Crossref: 29] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
697 Evans HJ, Prosser J. Tumor-suppressor genes: cardinal factors in inherited predisposition to human cancers. Environ Health Perspect 1992;98:25-37. [PMID: 1336726 DOI: 10.1289/ehp.929825] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 0.5] [Reference Citation Analysis]
698 Sen S, Takahashi R, Rani S, Freireich EJ, Stass SA. Expression of differentially phosphorylated Rb and mutant p53 proteins in myeloid leukemia cell lines. Leuk Res 1993;17:639-47. [PMID: 8355507 DOI: 10.1016/0145-2126(93)90068-v] [Cited by in Crossref: 16] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
699 Levine AJ, Wu MC, Chang A, Silver A, Attiyeh EF, Lin J, Epstein CB. The spectrum of mutations at the p53 locus. Evidence for tissue-specific mutagenesis, selection of mutant alleles, and a "gain of function" phenotype. Ann N Y Acad Sci 1995;768:111-28. [PMID: 8526340 DOI: 10.1111/j.1749-6632.1995.tb12115.x] [Cited by in Crossref: 73] [Cited by in F6Publishing: 69] [Article Influence: 2.9] [Reference Citation Analysis]
700 Cropp CS, Lidereau R, Campbell G, Champene MH, Callahan R. Loss of heterozygosity on chromosomes 17 and 18 in breast carcinoma: two additional regions identified. Proc Natl Acad Sci USA. 1990;87:7737-7741. [PMID: 1977164 DOI: 10.1073/pnas.87.19.7737] [Cited by in Crossref: 72] [Cited by in F6Publishing: 76] [Article Influence: 2.3] [Reference Citation Analysis]
701 Gordon JI. Understanding gastrointestinal epithelial cell biology: lessons from mice with help from worms and flies. Gastroenterology 1993;105:315-24. [PMID: 8335186 DOI: 10.1016/0016-5085(93)90703-f] [Cited by in Crossref: 41] [Cited by in F6Publishing: 14] [Article Influence: 1.5] [Reference Citation Analysis]
702 Hall M, Johnson RT. The role of DNA repair in the prevention of cancer. Mol Aspects Med 1996;17:235-83. [PMID: 8898354 DOI: 10.1016/s0098-2997(96)00001-5] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation A